253 results on '"Carlotta Sacerdote"'
Search Results
2. Risk prediction models for endometrial cancer: development and validation in an international consortium
- Author
-
Joy Shi, Peter Kraft, Bernard A Rosner, Yolanda Benavente, Amanda Black, Louise A Brinton, Chu Chen, Megan A Clarke, Linda S Cook, Laura Costas, Luigino Dal Maso, Jo L Freudenheim, Jon Frias-Gomez, Christine M Friedenreich, Montserrat Garcia-Closas, Marc T Goodman, Lisa Johnson, Carlo La Vecchia, Fabio Levi, Jolanta Lissowska, Lingeng Lu, Susan E McCann, Kirsten B Moysich, Eva Negri, Kelli O'Connell, Fabio Parazzini, Stacey Petruzella, Jerry Polesel, Jeanette Ponte, Timothy R Rebbeck, Peggy Reynolds, Fulvio Ricceri, Harvey A Risch, Carlotta Sacerdote, Veronica W Setiawan, Xiao-Ou Shu, Amanda B Spurdle, Britton Trabert, Penelope M Webb, Nicolas Wentzensen, Lynne R Wilkens, Wang Hong Xu, Hannah P Yang, Herbert Yu, Mengmeng Du, and Immaculata De Vivo
- Subjects
prediction model ,Cancer Research ,Oncology ,Settore MED/06 - Oncologia Medica ,Settore MED/42 - Igiene Generale e Applicata ,endometrial cancer ,endometrium ,cancer risk ,Settore MED/40 - Ginecologia e Ostetricia ,Settore MED/01 - Statistica Medica - Abstract
Background Endometrial cancer risk stratification may help target interventions, screening, or prophylactic hysterectomy to mitigate the rising burden of this cancer. However, existing prediction models have been developed in select cohorts and have not considered genetic factors. Methods We developed endometrial cancer risk prediction models using data on postmenopausal White women aged 45-85 years from 19 case-control studies in the Epidemiology of Endometrial Cancer Consortium (E2C2). Relative risk estimates for predictors were combined with age-specific endometrial cancer incidence rates and estimates for the underlying risk factor distribution. We externally validated the models in 3 cohorts: Nurses’ Health Study (NHS), NHS II, and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Results Area under the receiver operating characteristic curves for the epidemiologic model ranged from 0.64 (95% confidence interval [CI] = 0.62 to 0.67) to 0.69 (95% CI = 0.66 to 0.72). Improvements in discrimination from the addition of genetic factors were modest (no change in area under the receiver operating characteristic curves in NHS; PLCO = 0.64 to 0.66). The epidemiologic model was well calibrated in NHS II (overall expected-to-observed ratio [E/O] = 1.09, 95% CI = 0.98 to 1.22) and PLCO (overall E/O = 1.04, 95% CI = 0.95 to 1.13) but poorly calibrated in NHS (overall E/O = 0.55, 95% CI = 0.51 to 0.59). Conclusions Using data from the largest, most heterogeneous study population to date (to our knowledge), prediction models based on epidemiologic factors alone successfully identified women at high risk of endometrial cancer. Genetic factors offered limited improvements in discrimination. Further work is needed to refine this tool for clinical or public health practice and expand these models to multiethnic populations.
- Published
- 2023
3. Risk Factors for Heart Failure Among Pan-European Childhood Cancer Survivors: A PanCareSurFup and ProCardio Cohort and Nested Case-Control Study
- Author
-
Esmée C. de Baat, Elizabeth A.M. Feijen, Raoul C. Reulen, Rodrigue S. Allodji, Francesca Bagnasco, Edit Bardi, Fabiën N. Belle, Julianne Byrne, Elvira C. van Dalen, Ghazi Debiche, Ibrahima Diallo, Desiree Grabow, Lars Hjorth, Momcilo Jankovic, Claudia E. Kuehni, Gill Levitt, Damien Llanas, Jacqueline Loonen, Lorna Z. Zaletel, Milena M. Maule, Lucia Miligi, Helena J.H. van der Pal, Cécile M. Ronckers, Carlotta Sacerdote, Roderick Skinner, Zsuzsanna Jakab, Cristina Veres, Nadia Haddy, David L. Winter, Florent de Vathaire, Michael M. Hawkins, and Leontien C.M. Kremer
- Subjects
Heart Failure ,Cancer Research ,European People ,Antibiotics, Antineoplastic ,360 Soziale Probleme, Sozialdienste ,610 Medicine & health ,Middle Aged ,Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18] ,All institutes and research themes of the Radboud University Medical Center ,Oncology ,Cancer Survivors ,360 Social problems & social services ,Risk Factors ,Neoplasms ,Case-Control Studies ,Humans ,Anthracyclines ,610 Medizin und Gesundheit ,Child - Abstract
PURPOSE Heart failure (HF) is a potentially life-threatening complication of treatment for childhood cancer. We evaluated the risk and risk factors for HF in a large European study of long-term survivors. Little is known of the effects of low doses of treatment, which is needed to improve current treatment protocols and surveillance guidelines. METHODS This study includes the PanCareSurFup and ProCardio cohort of ≥ 5-year childhood cancer survivors diagnosed between 1940 and 2009 in seven European countries (N = 42,361). We calculated the cumulative incidence of HF and conducted a nested case-control study to evaluate detailed treatment-related risk factors. RESULTS The cumulative incidence of HF was 2% (95% CI, 1.7 to 2.2) by age 50 years. The case-control study (n = 1,000) showed that survivors who received a mean heart radiation therapy (RT) dose of 5 to < 15 Gy have an increased risk of HF (odds ratio, 5.5; 95% CI, 2.5 to 12.3), when compared with no heart RT. The risk associated with doses 5 to < 15 Gy increased with exposure of a larger heart volume. In addition, the HF risk increased in a linear fashion with higher mean heart RT doses. Regarding total cumulative anthracycline dose, survivors who received ≥ 100 mg/m2 had a substantially increased risk of HF and survivors treated with a lower dose showed no significantly increased risk of HF. The dose-response relationship appeared quadratic with higher anthracycline doses. CONCLUSION Survivors who received a mean heart RT dose of ≥ 5 Gy have an increased risk of HF. The risk associated with RT increases with larger volumes exposed. Survivors treated with < 100 mg/m2 total cumulative anthracycline dose have no significantly increased risk of HF. These new findings might have consequences for new treatment protocols for children with cancer and for cardiomyopathy surveillance guidelines.
- Published
- 2023
4. Body shape phenotypes of multiple anthropometric traits and cancer risk: a multi-national cohort study
- Author
-
Anja M. Sedlmeier, Vivian Viallon, Pietro Ferrari, Laia Peruchet-Noray, Emma Fontvieille, Amina Amadou, Nazlisadat Seyed Khoei, Andrea Weber, Hansjörg Baurecht, Alicia K. Heath, Kostas Tsilidis, Rudolf Kaaks, Verena Katzke, Elif Inan-Eroglu, Matthias B. Schulze, Kim Overvad, Catalina Bonet, Esther Ubago-Guisado, María-Dolores Chirlaque, Eva Ardanaz, Aurora Perez-Cornago, Valeria Pala, Rosario Tumino, Carlotta Sacerdote, Fabrizio Pasanisi, Kristin B. Borch, Charlotta Rylander, Elisabete Weiderpass, Marc J. Gunter, Béatrice Fervers, Michael F. Leitzmann, Heinz Freisling, [Sedlmeier, Anja M. M.] Univ Regensburg, Dept Epidemiol & Prevent Med, Regensburg, Germany, [Weber, Andrea] Univ Regensburg, Dept Epidemiol & Prevent Med, Regensburg, Germany, [Baurecht, Hansjoerg] Univ Regensburg, Dept Epidemiol & Prevent Med, Regensburg, Germany, [Leitzmann, Michael F. F.] Univ Regensburg, Dept Epidemiol & Prevent Med, Regensburg, Germany, [Viallon, Vivian] Int Agcy Res Canc IARC, Nutr & Metab Branch, Lyon, France, [Ferrari, Pietro] Int Agcy Res Canc IARC, Nutr & Metab Branch, Lyon, France, [Peruchet-Noray, Laia] Int Agcy Res Canc IARC, Nutr & Metab Branch, Lyon, France, [Fontvieille, Emma] Int Agcy Res Canc IARC, Nutr & Metab Branch, Lyon, France, [Weiderpass, Elisabete] Int Agcy Res Canc IARC, Nutr & Metab Branch, Lyon, France, [Gunter, Marc J. J.] Int Agcy Res Canc IARC, Nutr & Metab Branch, Lyon, France, [Freisling, Heinz] Int Agcy Res Canc IARC, Nutr & Metab Branch, Lyon, France, [Peruchet-Noray, Laia] Univ Barcelona, Fac Med, Dept Clin Sci, Barcelona, Spain, [Amadou, Amina] Ctr Leon Berard, Dept Prevent Canc Environm, Lyon, France, [Fervers, Beatrice] Ctr Leon Berard, Dept Prevent Canc Environm, Lyon, France, [Amadou, Amina] INSERM, UMR1296 Radiat Def, Hlth, Environm, Lyon, France, [Fervers, Beatrice] INSERM, UMR1296 Radiat Def, Hlth, Environm, Lyon, France, [Seyed Khoei, Nazlisadat] Univ Vienna, Fac Life Sci, Dept Nutr Sci, Vienna, Austria, [Heath, Alicia K. K.] Imperial Coll London, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England, [Tsilidis, Kostas] Imperial Coll London, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England, [Tsilidis, Kostas] Univ Ioannina, Dept Hyg & Epidemiol, Sch Med, Ioannina, Greece, [Kaaks, Rudolf] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany, [Katzke, Verena] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany, [Inan-Eroglu, Elif] German Inst Human Nutr Potsdam Rehbrucke, Dept Mol Epidemiol, Nuthetal, Germany, [Schulze, Matthias B. B.] German Inst Human Nutr Potsdam Rehbrucke, Dept Mol Epidemiol, Nuthetal, Germany, [Overvad, Kim] Aarhus Univ, Dept Publ Hlth, Aarhus, Denmark, [Bonet, Catalina] Catalan Inst Oncol ICO, Unit Nutr & Canc, Barcelona, Spain, [Bonet, Catalina] Bellvitge Biomed Res Inst IDIBELL, Canc Prevent & Palliat Care Program, Nutr & Canc Grp, Epidemiol,Publ Hlth, Barcelona, Spain, [Ubago-Guisado, Esther] Escuela Andaluza Salud Publ EASP, Granada, Spain, [Ubago-Guisado, Esther] Inst Invest Biosanitaria Ibs GRANADA, Granada, Spain, [Ubago-Guisado, Esther] CIBER Epidemiol & Publ Hlth CIBERESP, Madrid, Spain, [Chirlaque, Maria-Dolores] CIBER Epidemiol & Publ Hlth CIBERESP, Madrid, Spain, [Ardanaz, Eva] CIBER Epidemiol & Publ Hlth CIBERESP, Madrid, Spain, [Chirlaque, Maria-Dolores] Reg Hlth Council, Dept Epidemiol, Murcia, Spain, [Chirlaque, Maria-Dolores] Murcia Univ, IMIB Arrixaca, Murcia, Spain, [Ardanaz, Eva] IdiSNA, Navarra Publ Hlth Inst, Pamplona, Spain, [Perez-Cornago, Aurora] Univ Oxford, Nuffield Dept Populat Hlth, Canc Epidemiol Unit, Oxford, England, [Pala, Valeria] Fdn IRCCS Ist Nazl Tumori, Epidemiol & Prevent Unit, Milan, Italy, [Tumino, Rosario] AIRE ONLUS, Hyblean Assoc Epidemiol Res, Ragusa, Italy, [Sacerdote, Carlotta] Citta Salute & Sci Univ Hosp, Unit Canc Epidemiol, Turin, Italy, [Pasanisi, Fabrizio] Feder II Univ Hosp, Dept Clin Med & Surg, Clin Nutr Unit, Naples, Italy, [Borch, Kristin B. B.] UiT Arctic Univ Norway, Fac Hlth Sci, Dept Commun Med, Tromso, Norway, [Rylander, Charlotta] UiT Arctic Univ Norway, Fac Hlth Sci, Dept Commun Med, Tromso, Norway, French National Cancer Institute (l'Institut National du Cancer), International Agency for Research on Cancer (IARC), Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Danish Cancer Society (Denmark), Ligue Contre le Cancer (France), Institut Gustave Roussy (France), Mutuelle Generale de l'Education Nationale (France), Institut National de la Sante et de la Recherche Medicale (INSERM) (France), German Cancer Aid (Germany), German Cancer Research Center (DKFZ) (Germany), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE) (Germany), Federal Ministry of Education and Research (BMBF) (Germany), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy (Italy), Compagnia di San Paolo (Italy), National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS) (The Netherlands), Netherlands Cancer Registry (NKR) (The Netherlands), LK Research Funds (The Netherlands), Dutch Prevention Funds (The Netherlands), Dutch ZON (Zorg Onderzoek Nederland) (The Netherlands), World Cancer Research Fund (WCRF) (The Netherlands), Statistics Netherlands (The Netherlands), Health Research Fund (FIS)-Instituto de Salud Carlos III (ISCIII) (Spain), Regional Government of Andalucia (Spain), Regional Government of Asturias (Spain), Regional Government of Basque Country (Spain), Regional Government of Murcia (Spain), Regional Government of Navarra (Spain), Catalan Institute of Oncology-ICO (Spain), Swedish Cancer Society (Sweden), Swedish Research Council (Sweden), County Council of Skane (Sweden), County Council of Vaesterbotten (Sweden), Cancer Research UK (United Kingdom), and Medical Research Council (United Kingdom)
- Subjects
Cancer Research ,Oncology ,Height ,Fat ,Physical-activity ,Obesity ,Esophageal ,Adenocarcinoma ,Metaanalysis ,Weight ,Nutrition ,Validity - Abstract
Background Classical anthropometric traits may fail to fully represent the relationship of weight, adiposity, and height with cancer risk. We investigated the associations of body shape phenotypes with the risk of overall and site-specific cancers. Methods We derived four distinct body shape phenotypes from principal component (PC) analysis on height, weight, body mass index (BMI), waist (WC) and hip circumferences (HC), and waist-to-hip ratio (WHR). The study included 340,152 men and women from 9 European countries, aged mostly 35–65 years at recruitment (1990–2000) in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Cox proportional hazards regression was used to estimate multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). Results After a median follow-up of 15.3 years, 47,110 incident cancer cases were recorded. PC1 (overall adiposity) was positively associated with the risk of overall cancer, with a HR per 1 standard deviation (SD) increment equal to 1.07 (95% confidence interval 1.05 to 1.08). Positive associations were observed with 10 cancer types, with HRs (per 1 SD) ranging from 1.36 (1.30–1.42) for endometrial cancer to 1.08 (1.03–1.13) for rectal cancer. PC2 (tall stature with low WHR) was positively associated with the risk of overall cancer (1.03; 1.02–1.04) and five cancer types which were not associated with PC1. PC3 (tall stature with high WHR) was positively associated with the risk of overall cancer (1.04; 1.03–1.05) and 12 cancer types. PC4 (high BMI and weight with low WC and HC) was not associated with overall risk of cancer (1.00; 0.99–1.01). Conclusions In this multi-national study, distinct body shape phenotypes were positively associated with the incidence of 17 different cancers and overall cancer.
- Published
- 2022
5. Protein and amino acid intakes in relation to prostate cancer risk and mortality—A prospective study in the European Prospective Investigation into Cancer and Nutrition
- Author
-
Julie A. Schmidt, Inge Huybrechts, Kim Overvad, Anne Kirstine Eriksen, Anne Tjønneland, Rudolf Kaaks, Verena Katzke, Matthias B. Schulze, Valeria Pala, Carlotta Sacerdote, Rosario Tumino, Bas Bueno‐de‐Mesquita, Maria‐Jose Sánchez, José M. Huerta, Aurelio Barricarte, Pilar Amiano, Antonio Agudo, Anders Bjartell, Tanja Stocks, Elin Thysell, Maria Wennberg, Elisabete Weiderpass, Ruth C. Travis, Timothy J. Key, and Aurora Perez‐Cornago
- Subjects
Male ,Cancer Research ,CROSS-SECTIONAL ANALYSIS ,EGG INTAKE ,dietary protein intakes ,Risk Factors ,GROWTH-FACTOR-I ,Humans ,DIETARY QUESTIONNAIRES ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,Amino Acids ,ONE-CARBON METABOLISM ,METAANALYSIS ,Cancer och onkologi ,prostate cancer mortality ,MEAT-EATERS ,Prostatic Neoplasms ,ASSOCIATION ,dietary amino acid intakes ,Diet ,IGF-I ,Oncology ,prostate cancer incidence ,Cancer and Oncology ,tumour subtypes ,RESTRICTION - Abstract
BACKGROUND: The association between protein intake and prostate cancer risk remains unclear.AIMS: To prospectively investigate the associations of dietary intakes of total protein, protein from different dietary sources, and amino acids with prostate cancer risk and mortality.METHODS: In 131,425 men from the European Prospective Investigation into Cancer and Nutrition, protein and amino acid intakes were estimated using validated dietary questionnaires. Multivariable-adjusted Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).RESULTS: During a mean follow-up of 14.2 years, 6939 men were diagnosed with prostate cancer and 914 died of the disease. Dairy protein was positively associated with overall prostate cancer risk in the three highest fifths compared to the lowest (HR Q3 =1.14 (95% CI 1.05-1.23); HR Q 4=1.09 (1.01-1.18); HR Q5 =1.10 (1.02-1.19)); similar results were observed for yogurt protein (HR Q3 =1.14 (1.05-1.24); HR Q4 =1.09 (1.01-1.18); HR Q5 =1.12 (1.04-1.21)). For egg protein intake and prostate cancer mortality, no association was observed by fifths, but there was suggestive evidence of a positive association in the analysis per standard deviation increment. There was no strong evidence of associations with different tumour subtypes. DISCUSSION: Considering the weak associations and many tests, the results must be interpreted with caution.CONCLUSION: This study does not provide strong evidence for an association of intakes of total protein, protein from different dietary sources or amino acids with prostate cancer risk or mortality. However, our results may suggest some weak positive associations, which need to be confirmed in large-scale, pooled analyses of prospective data.
- Published
- 2022
6. Baseline and lifetime alcohol consumption and risk of skin cancer in the European Prospective Investigation into Cancer and Nutrition cohort ( <scp>EPIC</scp> )
- Author
-
Yahya Mahamat‐Saleh, Marie Al‐Rahmoun, Gianluca Severi, Reza Ghiasvand, Marit B. Veierod, Saverio Caini, Domenico Palli, Edoardo Botteri, Carlotta Sacerdote, Fulvio Ricceri, Marko Lukic, Maria J. Sánchez, Valeria Pala, Rosario Tumino, Paolo Chiodini, Pilar Amiano, Sandra Colorado‐Yohar, María‐Dolores Chirlaque, Eva Ardanaz, Catalina Bonet, Verena Katzke, Rudolf Kaaks, Matthias B. Schulze, Kim Overvad, Christina C. Dahm, Christian S. Antoniussen, Anne Tjønneland, Cecilie Kyrø, Bas Bueno‐de‐Mesquita, Jonas Manjer, Malin Jansson, Anders Esberg, Nagisa Mori, Pietro Ferrari, Elisabete Weiderpass, Marie‐Christine Boutron‐Ruault, Marina Kvaskoff, Mahamat-Saleh, Yahya, Al-Rahmoun, Marie, Severi, Gianluca, Ghiasvand, Reza, Veierod, Marit B, Caini, Saverio, Palli, Domenico, Botteri, Edoardo, Sacerdote, Carlotta, Ricceri, Fulvio, Lukic, Marko, Sánchez, Maria J, Pala, Valeria, Tumino, Rosario, Chiodini, Paolo, Amiano, Pilar, Colorado-Yohar, Sandra, Chirlaque, María-Dolore, Ardanaz, Eva, Bonet, Catalina, Katzke, Verena, Kaaks, Rudolf, Schulze, Matthias B, Overvad, Kim, Dahm, Christina C, Antoniussen, Christian S, Tjønneland, Anne, Kyrø, Cecilie, Bueno-de-Mesquita, Ba, Manjer, Jona, Jansson, Malin, Esberg, Ander, Mori, Nagisa, Ferrari, Pietro, Weiderpass, Elisabete, Boutron-Ruault, Marie-Christine, and Kvaskoff, Marina
- Subjects
Male ,Cancer och onkologi ,Cancer Research ,Skin Neoplasms ,Alcohol Drinking ,alcohol ,keratinocyte cancers ,Public Health, Global Health, Social Medicine and Epidemiology ,Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi ,cutaneous melanoma ,cohort studies ,Oncology ,Carcinoma, Basal Cell ,Risk Factors ,Cancer and Oncology ,Carcinoma, Squamous Cell ,epidemiology ,Humans ,Female ,Prospective Studies ,Melanoma ,cohort studie - Abstract
Experimental evidence suggests that alcohol induces cutaneous carcinogenesis, yet epidemiological studies on the link between alcohol intake and skin cancer have been inconsistent. The European Prospective Investigation into Cancer and Nutrition (EPIC) is a prospective cohort initiated in 1992 in 10 European countries. Alcohol intake at baseline and average lifetime alcohol intake were assessed using validated country-specific dietary and lifestyle questionnaires. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated in Cox models. A total of 14 037 skin cancer cases (melanoma: n = 2457; basal-cell carcinoma (BCC): n = 8711; squamous-cell carcinoma (SCC): n = 1928; unknown: n = 941) were identified among 450 112 participants (average follow-up: 15 years). Baseline alcohol intake was positively associated with SCC (>15 vs 0.1-4.9 g/day: HR = 1.44, 95% CI = 1.17-1.77; Ptrend = .001), BCC (HR = 1.12, 95% CI = 1.01-1.23; Ptrend = .04), and melanoma risks in men (HR = 1.17, 95% CI = 0.95-1.44; Ptrend = .17), while associations were more modest in women (SCC: HR = 1.09, 95% CI = 0.90-1.30; Ptrend = .13; BCC: HR = 1.08, 95% CI = 1.00-1.17,Ptrend = .03; melanoma: HR = 0.93, 95% CI = 0.80-1.08, Ptrend = .13). Associations were similar for lifetime alcohol intake, with an attenuated linear trend. Lifetime liquor/spirit intake was positively associated with melanoma (fourth vs first quartile: HR = 1.47, 95% CI = 1.08-1.99; Ptrend = .0009) and BCC risks in men (HR = 1.17, 95% CI = 1.04-1.31;Ptrend = .14). Baseline and lifetime intakes of wine were associated with BCC risk (HR = 1.25 in men; HR = 1.11-1.12; in women). No statistically significant associations were found between beverage types and SCC risk. Intake of beer was not associated with skin cancer risk. Our study suggests positive relationships between alcohol intake and skin cancer risk, which may have important implications for the primary prevention of skin cancer. What's new? Drinking alcohol can make the skin more sensitive to sunlight and vulnerable to skin cancer. Here, the authors conducted a large prospective cohort study to evaluate whether alcohol consumption correlates with skin cancer risk. Among the 450 112 participants, there were 2457 cases of melanoma, 8711 of basal cell carcinoma, and 1928 of squamous cell carcinoma. There was a positive association between alcohol and all three cancer types, stronger in men than in women. The association varied somewhat by beverage type.
- Published
- 2022
7. Risk Factors for Primary Bone Cancer After Childhood Cancer: A PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies Nested Case-Control Study
- Author
-
Raoul C. Reulen, David L. Winter, Ibrahim Diallo, Cristina Veres, Damien Llanas, Rodrigue S. Allodji, Francesca Bagnasco, Edit Bárdi, Elizabeth A.M. Feijen, Daniela Alessi, Miranda M. Fidler-Benaoudia, Stine Høgsholt, Jop C. Teepen, Helena Linge, Nadia Haddy, Julianne Byrne, Ghazi Debiche, Desiree Grabow, Thorgerdur Gudmundsdottir, Romain Fauchery, Wael Zrafi, Gisela Michel, Hilde Øfstaas, Peter Kaatsch, Giao Vu-Bezin, Helen Jenkinson, Melanie Kaiser, Roderick Skinner, Trevor Cole, Nicolas Waespe, Grit Sommer, Susanne Nordenfelt, Momcilo Jankovic, Tuomas Lähteenmäki Taalas, Milena M. Maule, Helena J.H. van der Pal, Cécile M. Ronckers, Flora E. van Leeuwen, Judith L. Kok, Monica Terenziani, Maria Winther Gunnes, Thomas Wiebe, Carlotta Sacerdote, Zsuzsanna Jakab, Riccardo Haupt, Päivi M. Lähteenmäki, Lorna Zadravec Zaletel, Claudia E. Kuehni, Jeanette Falck Winther, Leontien C.M. Kremer, Lars Hjorth, Florent de Vathaire, and Michael M. Hawkins
- Subjects
Cancer Research ,Oncology - Abstract
PURPOSE Radiation to the bone and exposure to alkylating agents increases the risk of bone cancer among survivors of childhood cancer, but there is uncertainty regarding the risks of bone tissue radiation doses below 10 Gy and the dose-response relationship for specific types of chemotherapy. METHODS Twelve European countries contributed 228 cases and 228 matched controls to a nested case-control study within a cohort of 69,460 5-year survivors of childhood cancer. Odds ratios (ORs) of developing bone cancer for different levels of cumulative radiation exposure and cumulative doses of specific types of chemotherapy were calculated. Excess ORs were calculated to investigate the shape and extent of any dose-response relationship. RESULTS The OR associated with bone tissue exposed to 1-4 Gy was 4.8-fold (95% CI, 1.2 to 19.6) and to 5-9 Gy was 9.6-fold (95% CI, 2.4 to 37.4) compared with unexposed bone tissue. The OR increased linearly with increasing dose of radiation ( Ptrend < .001) up to 78-fold (95% CI, 9.2 to 669.9) for doses of ≥40 Gy. For cumulative alkylating agent doses of 10,000-19,999 and ≥20,000 mg/m2, the radiation-adjusted ORs were 7.1 (95% CI, 2.2 to 22.8) and 8.3 (95% CI, 2.8 to 24.4), respectively, with independent contributions from each of procarbazine, ifosfamide, and cyclophosphamide. Other cytotoxics were not associated with bone cancer. CONCLUSION To our knowledge, we demonstrate—for the first time—that the risk of bone cancer is increased 5- to 10-fold after exposure of bone tissue to cumulative radiation doses of 1-9 Gy. Alkylating agents exceeding 10,000 mg/m2 increase the risk 7- to 8-fold, particularly following procarbazine, ifosfamide, and cyclophosphamide. These substantially elevated risks should be used to develop/update clinical follow-up guidelines and survivorship care plans.
- Published
- 2023
8. Male breast cancer after childhood cancer
- Author
-
Yuehan Wang, Raoul C. Reulen, Leontien C.M. Kremer, Florent de Vathaire, Riccardo Haupt, Lorna Zadravec Zaletel, Francesca Bagnasco, Charlotte Demoor-Goldschmidt, Willem J. van Dorp, Nadia Haddy, Lars Hjorth, Zsuzsanna Jakab, Claudia E. Kuehni, Päivi M. Lähteenmäki, Helena J.H. van der Pal, Carlotta Sacerdote, Roderick Skinner, Monica Terenziani, Finn Wesenberg, Jeanette F. Winther, Flora E. van Leeuwen, Mike M. Hawkins, Jop C. Teepen, Elvira C. van Dalen, Cécile M. Ronckers, Paediatric Oncology, CCA - Cancer Treatment and Quality of Life, and ARD - Amsterdam Reproduction and Development
- Subjects
Adult ,Male ,Cancer Research ,Data analyses ,Incidence ,Late effects ,Breast Neoplasms, Male ,Childhood cancer survivors ,Male breast cancer ,Cohort Studies ,Oncology ,Cancer Survivors ,Risk Factors ,Second cancer ,Neoplasms ,Systematic review ,Humans ,Female ,Registries ,610 Medicine & health ,Child ,Cohort study ,360 Social problems & social services - Abstract
BACKGROUND Breast cancer is a well-recognised late adverse effect in female childhood cancer survivors (CCSs), especially after chest radiotherapy; information on subsequent male breast cancer (SMBC) is limited. We summarised the existing evidence on SMBC after childhood cancer in a systematic review��and investigated the risk of SMBC among males in a Pan-European cohort. METHODS We searched Medline/PubMed for cohort studies and case reports/series that assessed SMBC after childhood cancer (���21 years). Furthermore, we analysed data on SMBC in the PanCareSurFup cohort, reporting standardised incidence ratios (SIRs), absolute excess risks (AERs), and 5- and 10-year survival rates. RESULTS The systematic review included 38 of 7080 potentially eligible articles. Cohort-specific SMBC frequencies were 0-0.40% (31 studies). SMBC occurred after a follow-up ranging from 24.0 to 42.0 years. Nine case reports/series described 11 SMBC cases, occurring 11.0-42.5 years after primary childhood cancer. In the PanCareSurFup cohort (16 SMBC/37,738 males; 0.04%), we observed a 22.3-fold increased risk of SMBC relative to the general male population (95% CI 12.7-36.2; absolute excess risk/100,000 person-years: 2.3, 95% CI 1.3-3.7). The five- and ten-year survival rates after SMBC diagnosis were 60.3% (95% CI 35.6%-85.0%) and 43.0% (95% CI 16.1%-69.9%), respectively. Clear evidence of risk factors did not emerge from these comprehensive efforts. CONCLUSIONS Compared to the general population, male CCSs have an elevated risk of developing subsequent breast cancer, although the absolute risk is low. Health care providers should be aware of this rare yet serious late effect; male CCSs with symptoms potentially related to SMBC warrant careful examination.
- Published
- 2022
9. Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study
- Author
-
Ceren Sunguc, Michael M. Hawkins, David L. Winter, Isabelle M. Dudley, Emma J. Heymer, Jop C. Teepen, Rodrigue S. Allodji, Fabiën N. Belle, Francesca Bagnasco, Julianne Byrne, Edit Bárdi, Cécile M. Ronckers, Nadia Haddy, Thorgerdur Gudmundsdottir, Stanislaw Garwicz, Momcilo Jankovic, Helena J. H. van der Pal, Maja Česen Mazić, Christina Schindera, Desiree Grabow, Milena M. Maule, Peter Kaatsch, Melanie Kaiser, Brice Fresneau, Gisela Michel, Roderick Skinner, Thomas Wiebe, Carlotta Sacerdote, Zsuzsanna Jakab, Maria Winther Gunnes, Monica Terenziani, Jeanette F. Winther, Päivi M. Lähteenmäki, Lorna Zadravec Zaletel, Claudia E. Kuehni, Leontien C. Kremer, Riccardo Haupt, Florent de Vathaire, Lars Hjorth, Raoul C. Reulen, Paediatric Oncology, Paediatric Pulmonology, CCA - Cancer Treatment and Quality of Life, and Amsterdam Reproduction & Development (AR&D)
- Subjects
Cancer Research ,Oncology ,360 Social problems & social services ,360 Soziale Probleme, Sozialdienste ,610 Medicine & health ,610 Medizin und Gesundheit - Abstract
Background: Survivors of childhood cancer are at risk of subsequent primary malignant neoplasms (SPNs), but the risk for rarer types of SPNs, such as oral cancer, is uncertain. Previous studies included few oral SPNs, hence large-scale cohorts are required to identify groups at risks. Methods: The PanCareSurFup cohort includes 69,460 5-year survivors of childhood cancer across Europe. Risks of oral SPNs were defined by standardised incidence ratios (SIRs), absolute excess risks and cumulative incidence. Results: One hundred and forty-five oral SPNs (64 salivary gland, 38 tongue, 20 pharynx, 2 lip, and 21 other) were ascertained among 143 survivors. Survivors were at 5-fold risk of an oral SPN (95% CI: 4.4–5.6). Survivors of leukaemia were at greatest risk (SIR = 19.2; 95% CI: 14.6–25.2) followed by bone sarcoma (SIR = 6.4, 95% CI: 3.7–11.0), Hodgkin lymphoma (SIR = 6.2, 95% CI: 3.9–9.9) and soft-tissue sarcoma (SIR = 5.0, 95% CI: 3.0–8.5). Survivors treated with radiotherapy were at 33-fold risk of salivary gland SPNs (95% CI: 25.3–44.5), particularly Hodgkin lymphoma (SIR = 66.2, 95% CI: 43.6–100.5) and leukaemia (SIR = 50.5, 95% CI: 36.1–70.7) survivors. Survivors treated with chemotherapy had a substantially increased risk of a tongue SPN (SIR = 15.9, 95% CI: 10.6–23.7). Conclusions: Previous radiotherapy increases the risk of salivary gland SPNs considerably, while chemotherapy increases the risk of tongue SPNs substantially. Awareness of these risks among both health-care professionals and survivors could play a crucial role in detecting oral SPNs early., + ID der Publikation: unilu_61255 + Sprache: Englisch + Letzte Aktualisierung: 2022-11-03 12:45:00
- Published
- 2023
10. Dietary patterns related to biological mechanisms and survival after breast cancer diagnosis : results from a cohort study
- Author
-
Carlota Castro-Espin, Catalina Bonet, Marta Crous-Bou, Verena Katzke, Charlotte Le Cornet, Franziska Jannasch, Matthias B. Schulze, Anja Olsen, Anne Tjønneland, Christina C. Dahm, Christian S. Antoniussen, Maria Jose Sánchez, Pilar Amiano, María Dolores Chirlaque, Marcela Guevara, Claudia Agnoli, Rosario Tumino, Carlotta Sacerdote, Maria Santucci De Magistris, Malin Sund, Stina Bodén, Torill Enget Jensen, Karina Standahl Olsen, Guri Skeie, Marc J. Gunter, Sabina Rinaldi, Esther M. Gonzalez-Gil, Elisabete Weiderpass, Sofia Christakoudi, Alicia K. Heath, Laure Dossus, and Antonio Agudo
- Subjects
Cancer Research ,Cancer och onkologi ,Nutrition and Dietetics ,Breast Neoplasms/diagnosis ,Estrogens ,Diet ,Cohort Studies ,Näringslära ,Oncology ,Risk Factors ,Cancer and Oncology ,Humans ,Female ,Prospective Studies - Abstract
BACKGROUND: Inflammatory, insulin and oestrogenic pathways have been linked to breast cancer (BC). We aimed to examine the relationship between pre-diagnostic dietary patterns related to these mechanisms and BC survival. METHODS: The diabetes risk reduction diet (DRRD), inflammatory score of diet (ISD) and oestrogen-related dietary pattern (ERDP) were calculated using dietary data from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Cox proportional hazards models were used to assess associations between dietary patterns and overall mortality and competing risk models for associations with BC-specific mortality. RESULTS: We included 13,270 BC cases with a mean follow-up after diagnosis of 8.6 years, representing 2340 total deaths, including 1475 BC deaths. Higher adherence to the DRRD score was associated with lower overall mortality (HR1–SD 0.92; 95%CI 0.87–0.96). Greater adherence to pro-inflammatory diets was borderline associated with 6% higher mortality HR1–SD 1.06; 95%CI 1.00–1.12. No significant association with the oestrogen-related dietary pattern was observed. None of the dietary patterns were associated with BC-specific mortality. CONCLUSIONS: Greater adherence to an anti-diabetic and anti-inflammatory diet prior to diagnosis is associated with lower overall mortality among BC survivors. Long-term adherence to these dietary patterns could be a means to improve the prognosis of BC survivors., Instituto de Salud Carlos III FI19/00197, European Social Fund (ESF), AECC Scientific Foundation PRYES211366AGUD, World Health Organization, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Danish Cancer Society, Ligue nationale contre le cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, Institut National de la Sante et de la Recherche Medicale (Inserm), Deutsche Krebshilfe Helmholtz Association German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE) Federal Ministry of Education & Research (BMBF), Fondazione AIRC per la ricerca sul cancro Compagnia di San Paolo Consiglio Nazionale delle Ricerche (CNR), Dutch Ministry of Public Health, Welfare and Sports (VWS) Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds Netherlands Organization for Scientific Research (NWO), World Cancer Research Fund International (WCRF), Netherlands Government, Health Research Fund (FIS)-Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra Navarra, Catalan Institute of Oncology-ICO (Spain), Swedish Cancer Society Swedish Research Council, County Councils of Skkne, Vasterbotten (Sweden), Cancer Research UK 14136 C8221/A29017, UK Research & Innovation (UKRI), Medical Research Council UK (MRC) 1000143 MR/M012190/1
- Published
- 2023
11. Are Circulating Immune Cells a Determinant of Pancreatic Cancer Risk? A Prospective Study Using Epigenetic Cell Count Measures
- Author
-
Matthias B. Schulze, Anne Tjønneland, Laure Dossus, Sofia Christakoudi, Kim Overvad, Verena Katzke, Roel Vermeulen, Giovanna Masala, Pilar Amiano, Elisabete Weiderpass, José María Huerta, Anja Olsen, Federico Canzian, Valeria Pala, Theron Johnson, Oskar Franklin, Charlotte Le Cornet, Marie-Christine Boutron-Ruault, Salvatore Panico, Eva Ardanaz, Rosario Tumino, Esther Molina-Montes, Bas Bueno-de-Mesquita, Marta Crous-Bou, Sven Olek, Rayaan Mahfouz, Rudolf Kaaks, Aurora Perez-Cornago, Bianca Brauer, Gianluca Severi, Carlotta Sacerdote, Vinciane Rebours, and Malin Sund
- Subjects
Adult ,Male ,Neutrophils ,Epidemiology ,Lymphocyte ,pancreatic cancer ,T-Lymphocytes, Regulatory ,Epigenesis, Genetic ,Immune system ,neutrophils ,Pancreatic cancer ,Biomarkers, Tumor ,Humans ,T-lymphocyte subsets ,Cytotoxic T cell ,Medicine ,Lymphocyte Count ,Prospective Studies ,Prospective cohort study ,Aged ,Aged, 80 and over ,business.industry ,FOXP3 ,Middle Aged ,medicine.disease ,European Prospective Investigation into Cancer and Nutrition ,Causality ,Pancreatic Neoplasms ,EPIC study ,immune system ,medicine.anatomical_structure ,Oncology ,Case-Control Studies ,Immunology ,Female ,business ,CD8 - Abstract
Background: Evidence is accumulating that immune cells play a prominent role in pancreatic cancer etiology but prospective investigations are missing. Methods: We conducted a nested case–control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) study with 502 pairs of incident pancreatic cancer cases and matched controls. Relative counts of circulating immune cells (neutrophils and lymphocyte sublineages: total CD3+, CD8+, CD4+, and FOXP3+ regulatory T cells (Tregs) relative to nucleated cells, (white blood cells) were measured by qRT-PCR. ORs with 95% confidence intervals were estimated using logistic regressions, modeling relative counts of immune cells on a continuous scale. Results: Neither relative counts of immune cell types taken individually, nor mutually adjusted for each other were associated with pancreatic cancer risks. However, in subgroup analyses by strata of lag-time, higher relative counts of Tregs and lower relative counts of CD8+ were significantly associated with an increased pancreatic cancer risks in participants diagnosed within the first 5 years of follow-up. Conclusions: These results might reflect reverse causation, due to higher relative counts of Tregs and lower counts of CD8+ cells among individuals with more advanced stages of latent pancreatic cancer, who are closer to the point of developing clinical manifest disease. Impact: We have shown, for the first time, that increased relative counts of regulatory T cells and lower relative counts of CD8+, cytotoxic T cells may be associated with pancreatic cancer risk or relatively late-stage tumor development. See related commentary by Michaud and Kelsey, p. 2176
- Published
- 2021
12. Blood cell DNA methylation biomarkers in preclinical malignant pleural mesothelioma: The EPIC prospective cohort
- Author
-
Alessandra Allione, Clara Viberti, Ilaria Cotellessa, Chiara Catalano, Elisabetta Casalone, Giovanni Cugliari, Alessia Russo, Simonetta Guarrera, Dario Mirabelli, Carlotta Sacerdote, Marco Gentile, Fabian Eichelmann, Matthias B. Schulze, Sophia Harlid, Anne Kirstine Eriksen, Anne Tjønneland, Martin Andersson, Martijn E.T. Dollé, Heleen Van Puyvelde, Elisabete Weiderpass, Miguel Rodriguez‐Barranco, Antonio Agudo, Alicia K. Heath, María‐Dolores Chirlaque, Thérèse Truong, Dzevka Dragic, Gianluca Severi, Sabina Sieri, Torkjel M. Sandanger, Eva Ardanaz, Paolo Vineis, and Giuseppe Matullo
- Subjects
Cancer Research ,DNA methylation ,Oncology ,cancer biomarkers ,mesothelioma ,prospective nested case-control study - Abstract
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer mainly caused by asbestos exposure. Specific and sensitive non-invasive biomarkers may facilitate and enhance screening programs for the early detection of cancer. We investigated DNA methylation (DNAm) profiles in MPM pre-diagnostic blood samples in a case-control study nested in the European Prospective Investigation into Cancer and nutrition (EPIC) cohort, aiming to characterise DNAm biomarkers associated with MPM. From the EPIC cohort, we included samples from 135 participants who developed MPM during 20 years of follow up and from 135 matched, cancer-free, controls. For the discovery phase we selected EPIC participants who developed MPM within five years from enrolment (n=36) with matched controls. We identified nine differentially methylated CpGs, selected by 10-fold cross-validation and correlation analyses: cg25755428 (MRI1), cg20389709 (KLF11), cg23870316, cg13862711 (LHX6), cg06417478 (HOOK2), cg00667948, cg01879420 (AMD1), cg25317025 (RPL17) and cg06205333 (RAP1A). Receiver operating characteristic (ROC) analysis showed that the model including baseline characteristics (age, sex, PC1wbc) along with the nine MPM-related CpGs has a better predictive value for MPM occurrence than the baseline model alone, maintaining some performance also at more than five years before diagnosis [AUC (area under the curve) 10 years=0.75; baseline AUC range=0.63-0.67)]. DNAm changes as non-invasive biomarkers in pre-diagnostic blood samples of MPM cases were investigated for the first time. Their application can improve the identification of asbestos-exposed individuals at higher MPM risk in order to possibly adopt more intensive monitoring for early disease identification.
- Published
- 2022
13. Diet-wide association study of 92 foods and nutrients and lung cancer risk in the European Prospective Investigation into Cancer and Nutrition study and the Netherlands Cohort Study
- Author
-
Alicia K. Heath, David C. Muller, Piet A. van den Brandt, Elena Critselis, Marc Gunter, Paolo Vineis, Elisabete Weiderpass, Heiner Boeing, Pietro Ferrari, Melissa A. Merritt, Agnetha L. Rostgaard‐Hansen, Anne Tjønneland, Kim Overvad, Verena Katzke, Bernard Srour, Giovanna Masala, Carlotta Sacerdote, Fulvio Ricceri, Fabrizio Pasanisi, Bas Bueno‐de‐Mesquita, George S. Downward, Guri Skeie, Torkjel M. Sandanger, Marta Crous‐Bou, Miguel Rodríguez‐Barranco, Pilar Amiano, José María Huerta, Eva Ardanaz, Isabel Drake, Mikael Johansson, Ingegerd Johansson, Tim Key, Nikos Papadimitriou, Elio Riboli, Ioanna Tzoulaki, Konstantinos K. Tsilidis, Epidemiologie, RS: GROW - R1 - Prevention, RS: CAPHRI - R5 - Optimising Patient Care, IRAS OH Epidemiology Chemical Agents, Heath, Alicia K, Muller, David C, van den Brandt, Piet A, Critselis, Elena, Gunter, Marc, Vineis, Paolo, Weiderpass, Elisabete, Boeing, Heiner, Ferrari, Pietro, Merritt, Melissa A, Rostgaard-Hansen, Agnetha L, Tjønneland, Anne, Overvad, Kim, Katzke, Verena, Srour, Bernard, Masala, Giovanna, Sacerdote, Carlotta, Ricceri, Fulvio, Pasanisi, Fabrizio, Bueno-de-Mesquita, Ba, Downward, George S, Skeie, Guri, Sandanger, Torkjel M, Crous-Bou, Marta, Rodríguez-Barranco, Miguel, Amiano, Pilar, Huerta, José María, Ardanaz, Eva, Drake, Isabel, Johansson, Mikael, Johansson, Ingegerd, Key, Tim, Papadimitriou, Niko, Riboli, Elio, Tzoulaki, Ioanna, and Tsilidis, Konstantinos K
- Subjects
Cancer Research ,Lung Neoplasms ,ALCOHOL-CONSUMPTION ,QUESTIONNAIRE ,Netherlands/epidemiology ,Lung Neoplasms/epidemiology ,Ascorbic Acid ,Europe/epidemiology ,Cohort Studies ,foods ,Diet/adverse effects ,nutrients ,Risk Factors ,cohort study ,Humans ,Prospective Studies ,Vitamin A ,Netherlands ,Cancer och onkologi ,food ,BETA-CAROTENE ,SCALE PROSPECTIVE COHORT ,Nutrients ,diet ,lung cancer ,Diet ,Europe ,Oncology ,RED MEAT ,Cancer and Oncology ,DOSE-RESPONSE METAANALYSIS ,SMOKERS - Abstract
It is unclear whether diet, and in particular certain foods or nutrients, are associated with lung cancer risk. We assessed associations of 92 dietary factors with lung cancer risk in 327,790 participants in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cox regression yielded adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) per standard deviation (SD) higher intake/day of each food/nutrient. Correction for multiple comparisons was performed using the false discovery rate and identified associations were evaluated in the Netherlands Cohort Study (NLCS). In EPIC, 2,420 incident lung cancer cases were identified during a median of 15 years of follow-up. Higher intakes of fibre (HR per 1 SD higher intake/day=0.91, 95%CI 0.87-0.96), fruit (HR=0.91, 95%CI 0.86-0.96), and vitamin C (HR=0.91, 95%CI 0.86-0.96) were associated with a lower risk of lung cancer, whereas offal (HR=1.08, 95%CI 1.03-1.14), retinol (HR=1.06, 95%CI 1.03-1.10), and beer/cider (HR=1.04, 95%CI 1.02-1.07) intakes were positively associated with lung cancer risk. Associations did not differ by sex and there was less evidence for associations among never smokers. None of the six associations with overall lung cancer risk identified in EPIC were replicated in the NLCS (2,861 cases), however in analyses of histological subtypes, inverse associations of fruit and vitamin C with squamous cell carcinoma were replicated in the NLCS. Overall, there is little evidence that intakes of specific foods and nutrients play a major role in primary lung cancer risk, but fruit and vitamin C intakes seem to be inversely associated with squamous cell lung cancer. This article is protected by copyright. All rights reserved.
- Published
- 2022
14. Pregnancy outcomes and risk of endometrial cancer
- Author
-
Lauren A. Wise, Jennifer A. Doherty, Harvey A. Risch, Sara H. Olson, Louise A. Brinton, Lynne R. Wilkens, Mengmeng Du, Piet A. van den Brandt, Herbert Yu, Diego Serraino, Carlotta Sacerdote, Malcolm C. Pike, Kirsten B. Moysich, Kristin E. Anderson, Fulvio Ricceri, Timothy R. Rebbeck, Stacey Petruzella, Leo J. Schouten, Elisabete Weiderpass, Amanda B. Spurdle, Renhua Na, Rachael Z. Stolzenberg-Solomon, Fabio Levi, Susan J. Jordan, Christine M. Friedenreich, Fabio Parazzini, Anna E. Prizment, Xiao-Ou Shu, Chu Chen, Lingeng Lu, Todd R. Sponholtz, Thomas E. Rohan, Veronica Wendy Setiawan, Anthony B. Miller, Peggy Reynolds, Penelope M. Webb, Britton Trabert, Vittorio Krogh, Julie R. Palmer, Eva Negri, Wanghong Xu, Gretchen L. Gierach, Marc T. Goodman, Susan E. McCann, Immaculata De Vivo, Hans-Olov Adami, Carlo La Vecchia, Anne Zeleniuch-Jacquotte, Nicolas Wentzensen, Linda S. Cook, J. S. Jordan, R. Na, E. Weiderpa, H. O. Adami, K. E. Anderson, P. A. van den Brandt, L. A. Brinton, C. Chen, L. S. Cook, J. A. Doherty, M. Du, C. M. Friedenreich, G. L. Gierach, M. T. Goodman, V. Krogh, F. Levi, L. Lu, A. B. Miller, S. E. McCann, B. K. Moysich, E. Negri, S. H. Olson, S. Petruzella, J. R. Palmer, F. Parazzini, M. C. Pike, A. E. Prizment, T. R. Rebbeck, P. Reynold, F. Ricceri, H. A. Risch, T. E. Rohan, C. Sacerdote, L. J. Schouten, D. Serraino, V. W. Setiawan, X. -O. Shu, T. R. Sponholtz, A. B. Spurdle, R. Z. Stolzenberg-Solomon, B. Trabert, N. Wentzensen, L. R. Wilken, L. A. Wise, H. Yu, C. La Vecchia, I. De Vivo, W. Xu, A. Zeleniuch-Jacquotte, P. M. Webb, Epidemiologie, and RS: GROW - R1 - Prevention
- Subjects
Cancer Research ,medicine.medical_specialty ,miscarriage ,induced abortion ,Article ,Miscarriage ,03 medical and health sciences ,0302 clinical medicine ,AGE ,Pregnancy ,Risk Factors ,Epidemiology ,medicine ,Humans ,HORMONE-BINDING GLOBULIN ,REPRODUCTIVE FACTORS ,sex of offspring ,business.industry ,Obstetrics ,Endometrial cancer ,Pregnancy Outcome ,endometrial cancer ,parity ,WOMEN ,Odds ratio ,PROGESTERONE ,medicine.disease ,Confidence interval ,Endometrial Neoplasms ,3. Good health ,ESTROGEN ,Pooled analysis ,Oncology ,Case-Control Studies ,030220 oncology & carcinogenesis ,Cohort ,Female ,SEX ,business - Abstract
A full-term pregnancy is associated with reduced endometrial cancer risk; however, whether the effect of additional pregnancies is independent of age at last pregnancy is unknown. The associations between other pregnancy-related factors and endometrial cancer risk are less clear. We pooled individual participant data from 11 cohort and 19 case-control studies participating in the Epidemiology of Endometrial Cancer Consortium (E2C2) including 16 986 women with endometrial cancer and 39 538 control women. We used one- and two-stage meta-analytic approaches to estimate pooled odds ratios (ORs) for the association between exposures and endometrial cancer risk. Ever having a full-term pregnancy was associated with a 41% reduction in risk of endometrial cancer compared to never having a full-term pregnancy (OR = 0.59, 95% confidence interval [CI] 0.56-0.63). The risk reduction appeared the greatest for the first full-term pregnancy (OR = 0.78, 95% CI 0.72-0.84), with a further similar to 15% reduction per pregnancy up to eight pregnancies (OR = 0.20, 95% CI 0.14-0.28) that was independent of age at last full-term pregnancy. Incomplete pregnancy was also associated with decreased endometrial cancer risk (7%-9% reduction per pregnancy). Twin births appeared to have the same effect as singleton pregnancies. Our pooled analysis shows that, while the magnitude of the risk reduction is greater for a full-term pregnancy than an incomplete pregnancy, each additional pregnancy is associated with further reduction in endometrial cancer risk, independent of age at last full-term pregnancy. These results suggest that the very high progesterone level in the last trimester of pregnancy is not the sole explanation for the protective effect of pregnancy.
- Published
- 2021
15. Biomarkers of the transsulfuration pathway and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC) study
- Author
-
Joanna L. Clasen, Alicia K. Heath, Heleen Van Puyvelde, Inge Huybrechts, Jin Young Park, Pietro Ferrari, Ghislaine Scelo, Arve Ulvik, Øivind Midttun, Per Magne Ueland, Kim Overvad, Anne Kirstine Eriksen, Anne Tjønneland, Rudolf Kaaks, Verena Katzke, Matthias B. Schulze, Domenico Palli, Claudia Agnoli, Paolo Chiodini, Rosario Tumino, Carlotta Sacerdote, Raul Zamora‐Ros, Miguel Rodriguez‐Barranco, Carmen Santiuste, Eva Ardanaz, Pilar Amiano, Julie A. Schmidt, Elisabete Weiderpass, Marc Gunter, Elio Riboli, Amanda J. Cross, Mattias Johansson, David C. Muller, Clasen, J. L., Heath, A. K., Van Puyvelde, H., Huybrechts, I., Park, J. Y., Ferrari, P., Scelo, G., Ulvik, A., Midttun, O., Ueland, P. M., Overvad, K., Eriksen, A. K., Tjonneland, A., Kaaks, R., Katzke, V., Schulze, M. B., Palli, D., Agnoli, C., Chiodini, P., Tumino, R., Sacerdote, C., Zamora-Ros, R., Rodriguez-Barranco, M., Santiuste, C., Ardanaz, E., Amiano, P., Schmidt, J. A., Weiderpass, E., Gunter, M., Riboli, E., Cross, A. J., Johansson, M., Muller, D. C., and Cancer Research UK
- Subjects
Cancer Research ,dietary biomarkers ,transsulfuration ,dietary biomarker ,HOMOCYSTEINE ,METABOLISM ,urologic and male genital diseases ,vitamin B6 ,SERUM ,INFLAMMATION ,Humans ,1112 Oncology and Carcinogenesis ,ASSAY ,AMINO-ACIDS ,Oncology & Carcinogenesis ,Cysteine ,Prospective Studies ,Carcinoma, Renal Cell ,Homocysteine ,Carcinoma, Renal Cell/epidemiology ,Science & Technology ,Kidney Neoplasms/epidemiology ,PLASMA ,kidney cancer ,Bayes Theorem ,Kidney Neoplasms ,Vitamin B 6 ,Oncology ,VITAMIN-B-12 ,Case-Control Studies ,Pyridoxal Phosphate ,CYSTEINE ,Life Sciences & Biomedicine ,Biomarkers ,FOLATE - Abstract
Previous studies have suggested that components of one-carbon metabolism, particularly circulating vitamin B6, have an etiological role in renal cell carcinoma (RCC). Vitamin B6 is a cofactor in the transsulfuration pathway. We sought to holistically investigate the role of the transsulfuration pathway in RCC risk. We conducted a nested case-control study (455 RCC cases and 455 matched controls) within the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Plasma samples from the baseline visit were analyzed for metabolites of the transsulfuration pathway, including pyridoxal 5'-phosphate (PLP, the biologically active form of vitamin B6), homocysteine, serine, cystathionine, and cysteine, in addition to folate. Bayesian conditional logistic regression was used to estimate associations of metabolites with RCC risk as well as interactions with established RCC risk factors. Circulating PLP and cysteine were inversely associated with RCC risk, and these associations were not attenuated after adjustment for other transsulfuration metabolites (odds ratio (OR) and 90% credible interval (CrI) per 1 SD increase in log concentration: 0.76 [0.66, 0.87]; 0.81 [0.66, 0.96], respectively). A comparison of joint metabolite profiles suggested substantially greater RCC risk for the profile representative of low overall transsulfuration function compared to high function (OR 2.70 [90% CrI 1.26, 5.70]). We found some statistical evidence of interactions of cysteine with body mass index, and PLP and homocysteine with smoking status, on their associations with RCC risk. In conclusion, we found evidence suggesting that the transsulfuration pathway may play a role in metabolic dysregulation leading to RCC development. ispartof: INTERNATIONAL JOURNAL OF CANCER vol:151 issue:5 pages:708-716 ispartof: location:United States status: published
- Published
- 2022
16. Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study
- Author
-
Laura Botta, Gemma Gatta, Riccardo Capocaccia, Charles Stiller, Adela Cañete, Luigino Dal Maso, Kaire Innos, Ana Mihor, Friederike Erdmann, Claudia Spix, Brigitte Lacour, Rafael Marcos-Gragera, Deirdre Murray, Silvia Rossi, Monika Hackl, Elizabeth Van Eycken, Nancy Van Damme, Zdravka Valerianova, Mario Sekerija, Vasos Scoutellas, Anna Demetriou, Ladislav Dušek, Denisa Krejci, Hans Storm, Margit Mägi, Keiu Paapsi, Nea Malila, Janne Pitkäniemi, Valerie Jooste, Jacqueline Clavel, Claire Poulalhon, Emmanuel Desandes, Alain Monnereau, Alexander Katalinic, Eleni Petridou, Georgios Markozannes, Miklos Garami, Helgi Birgisson, Paul M Walsh, Guido Mazzoleni, Fabio Vittadello, Francesco Cuccaro, Rocco Galasso, Giuseppe Sampietro, Stefano Rosso, Cinzia Gasparotto, Giovanni Maifredi, Margherita Ferrante, Antonina Torrisi, Antonella Sutera Sardo, Maria Letizia Gambino, Monica Lanzoni, Paola Ballotari, Erica Giacomazzi, Stefano Ferretti, Adele Caldarella, Gianfranco Manneschi, Milena Sant, Paolo Baili, Franco Berrino, Annalisa Trama, Roberto Lillini, Alice Bernasconi, Simone Bonfarnuzzo, Claudia Vener, Fabio Didonè, Paolo Lasalvia, Giulia Del Monego, Lucia Buratti, Diego Serraino, Martina Taborelli, Roberta De Angelis, Elena Demuru, Corrado Di Benedetto, Mariano Santaquilani, Serenella Venanzi, Marco Tallon, Luca Boni, Silvia Iacovacci, Antonio Giampiero Russo, Federico Gervasi, Gianbattista Spagnoli, Luca Cavalieri d'Oro, Mario Fusco, Maria Francesca Vitale, Mario Usala, Francesco Vitale, Maria Michiara, Giorgio Chiranda, Carlotta Sacerdote, Milena Maule, Giuseppe Cascone, Eugenia Spata, Lucia Mangone, Fabio Falcini, Rossella Cavallo, Daniela Piras, Ylenia Dinaro, Marine Castaing, Anna Clara Fanetti, Sante Minerba, Giuseppina Candela, Tiziana Scuderi, Roberto Vito Rizzello, Fabrizio Stracci, Giovanna Tagliabue, Massimo Rugge, Angelita Brustolin, Santa Pildava, Giedre Smailyte, Miriam Azzopardi, Tom Børge Johannesen, Joanna Didkowska, Urszula Wojciechowska, Magdalena Bielska-Lasota, Ana Pais, Ana Maria Ferreira, Maria José Bento, Ana Miranda, Chakameh Safaei Diba, Vesna Zadnik, Tina Zagar, Carmen Sánchez-Contador Escudero, Paula Franch Sureda, Arantza Lopez de Munain, Marta De-La-Cruz, Marìa Dolores Rojas, Araceli Aleman, Ana Vizcaino, Fernando Almela, Arantza Sanvisens, Maria Josè Sanchez, Maria Dolores Chirlaque, Antonia Sanchez-Gil, Marcela Guevara, Eva Ardanaz, Adela Cañete-Nieto, Rafael Peris-Bonet, Jaume Galceran, Maria Carulla, Claudia Kuehni, Shelagh Redmond, Otto Visser, Henrike Karim-Kos, Sarah Stevens, Anna Gavin, David Morrison, Dyfed Wyn Huws, Botta, L, Gatta, G, Capocaccia, R, Stiller, C, Canete, A, Dal Maso, L, Innos, K, Mihor, A, Erdmann, F, Spix, C, Lacour, B, Marcos-Gragera, R, Murray, D, Rossi, S, Hackl, M, Van Eycken, E, Van Damme, N, Valerianova, Z, Sekerija, M, Scoutellas, V, Demetriou, A, Dusek, L, Krejci, D, Storm, H, Magi, M, Paapsi, K, Malila, N, Pitkaniemi, J, Jooste, V, Clavel, J, Poulalhon, C, Desandes, E, Monnereau, A, Katalinic, A, Petridou, E, Markozannes, G, Garami, M, Birgisson, H, Walsh, P, Mazzoleni, G, Vittadello, F, Cuccaro, F, Galasso, R, Sampietro, G, Rosso, S, Gasparotto, C, Maifredi, G, Ferrante, M, Torrisi, A, Sutera Sardo, A, Gambino, M, Lanzoni, M, Ballotari, P, Giacomazzi, E, Ferretti, S, Caldarella, A, Manneschi, G, Sant, M, Baili, P, Berrino, F, Trama, A, Lillini, R, Bernasconi, A, Bonfarnuzzo, S, Vener, C, Didone, F, Lasalvia, P, Del Monego, G, Buratti, L, Serraino, D, Taborelli, M, De Angelis, R, Demuru, E, Di Benedetto, C, Santaquilani, M, Venanzi, S, Tallon, M, Boni, L, Iacovacci, S, Russo, A, Gervasi, F, Spagnoli, G, Cavalieri d'Oro, L, Fusco, M, Vitale, M, Usala, M, Vitale, F, Michiara, M, Chiranda, G, Sacerdote, C, Maule, M, Cascone, G, Spata, E, Mangone, L, Falcini, F, Cavallo, R, Piras, D, Dinaro, Y, Castaing, M, Fanetti, A, Minerba, S, Candela, G, Scuderi, T, Rizzello, R, Stracci, F, Tagliabue, G, Rugge, M, Brustolin, A, Pildava, S, Smailyte, G, Azzopardi, M, Johannesen, T, Didkowska, J, Wojciechowska, U, Bielska-Lasota, M, Pais, A, Ferreira, A, Bento, M, Miranda, A, Safaei Diba, C, Zadnik, V, Zagar, T, Sanchez-Contador Escudero, C, Franch Sureda, P, Lopez de Munain, A, De-La-Cruz, M, Rojas, M, Aleman, A, Vizcaino, A, Almela, F, Sanvisens, A, Sanchez, M, Chirlaque, M, Sanchez-Gil, A, Guevara, M, Ardanaz, E, Canete-Nieto, A, Peris-Bonet, R, Galceran, J, Carulla, M, Kuehni, C, Redmond, S, Visser, O, Karim-Kos, H, Stevens, S, Gavin, A, Morrison, D, and Huws, D
- Subjects
Retinal Neoplasms ,Retinoblastoma ,Bone Neoplasms ,Sarcoma, Ewing ,EUROCARE-6 ,survival ,Burkitt Lymphoma ,population-based cancer registrie ,Europe ,Oncology ,Humans ,cure fraction, childhood cancer, EUROCARE ,Child ,chidlhood cancer - Abstract
Background: The EUROCARE-5 study revealed disparities in childhood cancer survival among European countries, giving rise to important initiatives across Europe to reduce the gap. Extending its representativeness through increased coverage of eastern European countries, the EUROCARE-6 study aimed to update survival progress across countries and years of diagnosis and provide new analytical perspectives on estimates of long-term survival and the cured fraction of patients with childhood cancer. Methods: In this population-based study, we analysed 135 847 children (aged 0–14 years) diagnosed during 2000–13 and followed up to the end of 2014, recruited from 80 population-based cancer registries in 31 European countries. We calculated age-adjusted 5-year survival differences by country and over time using period analysis, for all cancers combined and for major cancer types. We applied a variant of standard mixture cure models for survival data to estimate the cure fraction of patients by childhood cancer and to estimate projected 15-year survival. Findings: 5-year survival for all childhood cancer combined in Europe in 2010–14 was 81% (95% CI 81–82), showing an increase of three percentage points compared with 2004–06. Significant progress over time was observed for almost all cancers. Survival remained stable for osteosarcomas, Ewing sarcoma, Burkitt lymphoma, non-Hodgkin lymphomas, and rhabdomyoscarcomas. For all cancers combined, inequalities still persisted among European countries (with age-adjusted 5-year survival ranging from 71% [95% CI 60–79] to 87% [77–93]). The 15-year survival projection for all patients with childhood cancer diagnosed in 2010–13 was 78%. We estimated the yearly long-term mortality rate due to causes other than the diagnosed cancer to be around 2 per 1000 patients for all childhood cancer combined, but to approach zero for retinoblastoma. The cure fraction for patients with childhood cancer increased over time from 74% (95% CI 73–75) in 1998–2001 to 80% (79–81) in 2010–13. In the latter cohort, the cure fraction rate ranged from 99% (95% CI 74–100) for retinoblastoma to 60% (58–63) for CNS tumours and reached 90% (95% CI 87–93) for lymphoid leukaemia and 70% (67–73) for acute myeloid leukaemia. Interpretation: Childhood cancer survival is increasing over time in Europe but there are still some differences among countries. Regular monitoring of childhood cancer survival and estimation of the cure fraction through population-based registry data are crucial for evaluating advances in paediatric cancer care. Funding: European Commission.
- Published
- 2022
17. The 8q24 region hosts miRNAs altered in biospecimens of colorectal and bladder cancer patients
- Author
-
Amedeo Gagliardi, Giulia Francescato, Giulio Ferrero, Giovanni Birolo, Sonia Tarallo, Antonio Francavilla, Giulia Piaggeschi, Carla Di Battista, Gaetano Gallo, Alberto Realis Luc, Carlotta Sacerdote, Giuseppe Matullo, Paolo Vineis, Alessio Naccarati, and Barbara Pardini
- Subjects
Cancer Research ,Oncology ,8q24 genomic region ,bladder cancer ,Radiology, Nuclear Medicine and imaging ,colorectal cancer ,microRNAs ,stool ,urine - Abstract
The 8q24 locus is enriched in cancer-associated polymorphisms and, despite containing relatively few protein-coding genes, it hosts the MYC oncogene and other genetic elements connected to tumorigenesis, including microRNAs (miRNAs). Research on miRNAs may provide insights into the transcriptomic regulation of this multiple cancer-associated region.We profiled all miRNAs located in the 8q24 region in 120 colorectal cancer (CRC) patients and 80 controls. miRNA profiling was performed on cancer/non-malignant adjacent mucosa, stool, and plasma extracellular vesicles (EVs), and the results validated with The Cancer Genome Atlas (TCGA) data. To verify if the 8q24-annotated miRNAs altered in CRC were dysregulated in other cancers and biofluids, we evaluated their levels in bladder cancer (BC) cases from the TCGA dataset and in urine and plasma EVs from a set of BC cases and healthy controls.Among the detected mature miRNAs in the region, 12 were altered between CRC and adjacent mucosa (adj. p 0.05). Five and four miRNAs were confirmed as dysregulated in the CRC and BC TCGA dataset, respectively. A co-expression analysis of tumor/adjacent tissue data from the CRC group revealed a correlation between the dysregulated miRNAs and CRC-related genes (PVT1 and MYC) annotated in 8q24 region. miR-30d-5p and miR-151a-3p, altered in CRC tissue, were also dysregulated in stool of CRC patients and urine of BC cases, respectively. Functional enrichment of dysregulated miRNA target genes highlighted terms related to TP53-mediated cell cycle control.Altered expression of 8q24-annotated miRNAs may be relevant for the initiation and/or progression of cancer.
- Published
- 2022
18. Mediating role of lifestyle behaviors in the association between education and cancer: results from the European Prospective Investigation into Cancer and Nutrition
- Author
-
Alessandra Macciotta, Alberto Catalano, Maria Teresa Giraudo, Elisabete Weiderpass, Pietro Ferrari, Heinz Freisling, Sandra M. Colorado-Yohar, Carmen Santiuste, Pilar Amiano, Alicia K. Heath, Heather A. Ward, Sofia Christakoudi, Paolo Vineis, Deependra Singh, Salvatore Vaccarella, Matthias B. Schulze, Anouk E. Hiensch, Evelyn M. Monninkhof, Verena Katzke, Rudolf Kaaks, Rosario Tumino, Fulvio Lazzarato, Lorenzo Milani, Antonio Agudo, Christina C. Dahm, Laura Baglietto, Vittorio Perduca, Gianluca Severi, Sara Grioni, Salvatore Panico, Eva Ardanaz, Kristin B. Borch, Faith O. Benebo, Tonje Braaten, Maria-Jose Sánchez, Claudia Giachino, Carlotta Sacerdote, and Fulvio Ricceri
- Subjects
Male ,Cohort Studies ,Oncology ,Epidemiology ,Risk Factors ,Incidence ,Humans ,Educational Status ,Female ,Breast Neoplasms ,Prospective Studies ,Life Style ,Europe/epidemiology - Abstract
Background: Many studies have shown that socioeconomic position (SEP) is associated with the incidence of malignant tumors at different sites. This study aims to estimate the association between educational level (as proxy for SEP) and cancer incidence and to understand whether the observed associations might be partially explained by lifestyle behaviors. Methods: The analyses were performed on data from the European Prospective Investigation into Cancer and Nutrition (EPIC) study, globally and by sex. We used Cox proportional hazards models together with mediation analysis to disentangle the total effect (TE) of educational level [measured through the Relative Index of Inequality (RII)] on cancer incidence into pure direct (PDE) and total indirect (TIE) effect, unexplained and explained by mediators, respectively. PDE and TIE were then combined to compute the proportions mediated (PM). Results: After an average of 14 years of follow-up, 52,422 malignant tumors were ascertained. Low educated participants showed higher risk of developing stomach, lung, kidney (in women), and bladder (in men) cancers, and, conversely, lower risk of melanoma and breast cancer (in post-menopausal women), when compared with more educated participants. Mediation analyses showed that portions of the TE of RII on cancer could be explained by site-specific related lifestyle behaviors for stomach, lung, and breast (in women). Conclusions: Cancer incidence in Europe is determined at least in part by a socioeconomically stratified distribution of risk factors. Impact: These observational findings support policies to reduce cancer occurrence by altering mediators, such as lifestyle behaviors, particularly focusing on underprivileged strata of the population.
- Published
- 2022
19. A blood DNA methylation biomarker for predicting short-term risk of cardiovascular events
- Author
-
Andrea Cappozzo, Cathal McCrory, Oliver Robinson, Anna Freni Sterrantino, Carlotta Sacerdote, Vittorio Krogh, Salvatore Panico, Rosario Tumino, Licia Iacoviello, Fulvio Ricceri, Sabina Sieri, Paolo Chiodini, Gareth J. McKay, Amy Jayne McKnight, Frank Kee, Ian S. Young, Bernadette McGuinness, Eileen M. Crimmins, Thalida Em Arpawong, Rose Anne Kenny, Aisling O’Halloran, Silvia Polidoro, Giuliana Solinas, Paolo Vineis, Francesca Ieva, Giovanni Fiorito, Cappozzo, Andrea, Mccrory, Cathal, Robinson, Oliver, Freni Sterrantino, Anna, Sacerdote, Carlotta, Krogh, Vittorio, Panico, Salvatore, Tumino, Rosario, Iacoviello, Licia, Ricceri, Fulvio, Sieri, Sabina, Chiodini, Paolo, Mckay, Gareth J, Mcknight, Amy Jayne, Kee, Frank, Young, Ian S, Mcguinness, Bernadette, Crimmins, Eileen M, Arpawong, Thalida Em, Kenny, Rose Anne, O'Halloran, Aisling, Polidoro, Silvia, Solinas, Giuliana, Vineis, Paolo, Ieva, Francesca, Fiorito, Giovanni, and Medical Research Council (MRC)
- Subjects
SELECTION ,Genetic Markers ,MODELS ,Insulins ,PHENOTYPES ,PROFILE ,Epigenesis, Genetic ,SDG 3 - Good Health and Well-being ,Cardiovascular risk ,DNA methylation ,Epigenetics ,Molecular epidemiology ,Risk scores ,Surrogate biomarkers ,Genetics ,Humans ,Noncommunicable Diseases ,Molecular Biology ,Genetics (clinical) ,Triglycerides ,Genetics & Heredity ,0604 Genetics ,Science & Technology ,Epigenetic ,1103 Clinical Sciences ,Glucose ,Oncology ,DNA methylation, Molecular epidemiology, Risk scores, Surrogate biomarkers, Cardiovascular risk, Epigenetics ,Cardiovascular Diseases ,1114 Paediatrics and Reproductive Medicine ,Risk score ,SHRINKAGE ,HEALTH ,Life Sciences & Biomedicine ,SOCIOECONOMIC POSITION ,Developmental Biology - Abstract
Background Recent evidence highlights the epidemiological value of blood DNA methylation (DNAm) as surrogate biomarker for exposure to risk factors for non-communicable diseases (NCD). DNAm surrogate of exposures predicts diseases and longevity better than self-reported or measured exposures in many cases. Consequently, disease prediction models based on blood DNAm surrogates may outperform current state-of-the-art prediction models. This study aims to develop novel DNAm surrogates for cardiovascular diseases (CVD) risk factors and develop a composite biomarker predictive of CVD risk. We compared the prediction performance of our newly developed risk score with the state-of-the-art DNAm risk scores for cardiovascular diseases, the ‘next-generation’ epigenetic clock DNAmGrimAge, and the prediction model based on traditional risk factors SCORE2. Results Using data from the EPIC Italy cohort, we derived novel DNAm surrogates for BMI, blood pressure, fasting glucose and insulin, cholesterol, triglycerides, and coagulation biomarkers. We validated them in four independent data sets from Europe and the USA. Further, we derived a DNAmCVDscore predictive of the time-to-CVD event as a combination of several DNAm surrogates. ROC curve analyses show that DNAmCVDscore outperforms previously developed DNAm scores for CVD risk and SCORE2 for short-term CVD risk. Interestingly, the performance of DNAmGrimAge and DNAmCVDscore was comparable (slightly lower for DNAmGrimAge, although the differences were not statistically significant). Conclusions We described novel DNAm surrogates for CVD risk factors useful for future molecular epidemiology research, and we described a blood DNAm-based composite biomarker, DNAmCVDscore, predictive of short-term cardiovascular events. Our results highlight the usefulness of DNAm surrogate biomarkers of risk factors in epigenetic epidemiology to identify high-risk populations. In addition, we provide further evidence on the effectiveness of prediction models based on DNAm surrogates and discuss methodological aspects for further improvements. Finally, our results encourage testing this approach for other NCD diseases by training and developing DNAm surrogates for disease-specific risk factors and exposures.
- Published
- 2022
20. Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer
- Author
-
Trasias Mukama, Renée Turzanski Fortner, Verena Katzke, Lucas Cory Hynes, Agnese Petrera, Stefanie M. Hauck, Theron Johnson, Matthias Schulze, Catarina Schiborn, Agnetha Linn Rostgaard-Hansen, Anne Tjønneland, Kim Overvad, María José Sánchez Pérez, Marta Crous-Bou, María-Dolores Chirlaque, Pilar Amiano, Eva Ardanaz, Eleanor L. Watts, Ruth C. Travis, Carlotta Sacerdote, Sara Grioni, Giovanna Masala, Simona Signoriello, Rosario Tumino, Inger T. Gram, Torkjel M. Sandanger, Hanna Sartor, Eva Lundin, Annika Idahl, Alicia K. Heath, Laure Dossus, Elisabete Weiderpass, Rudolf Kaaks, Mukama, T., Fortner, R. T., Katzke, V., Hynes, L. C., Petrera, A., Hauck, S. M., Johnson, T., Schulze, M., Schiborn, C., Rostgaard-Hansen, A. L., Tjonneland, A., Overvad, K., Perez, M. J. S., Crous-Bou, M., Chirlaque, M. -D., Amiano, P., Ardanaz, E., Watts, E. L., Travis, R. C., Sacerdote, C., Grioni, S., Masala, G., Signoriello, S., Tumino, R., Gram, I. T., Sandanger, T. M., Sartor, H., Lundin, E., Idahl, A., Heath, A. K., Dossus, L., Weiderpass, E., and Kaaks, R.
- Subjects
Ovarian Neoplasms ,Cancer Research ,Cancer och onkologi ,Science & Technology ,endocrine system diseases ,Membrane Proteins ,Blood Proteins ,Carcinoma, Ovarian Epithelial ,female genital diseases and pregnancy complications ,1117 Public Health and Health Services ,ADAM Proteins ,Oncology ,ROC Curve ,CA-125 Antigen ,Case-Control Studies ,Cancer and Oncology ,Biomarkers, Tumor ,Humans ,TRIAL ,Female ,Folate Receptor 1 ,1112 Oncology and Carcinogenesis ,Oncology & Carcinogenesis ,Life Sciences & Biomedicine ,Early Detection of Cancer - Abstract
The coordination of EPIC is financially supported by International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London-, which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, Institut National de la Sante et de la Recherche Medicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS)-Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra,-and the Catalan Institute of OncologyICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skane and Vasterbotten (Sweden); Cancer Research UK (C864/A14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (MR/N003284/1, MC-UU 12015/1 and MC UU_00006/1to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford). (United Kingdom). Open Access funding enabled and organized by Projekt DEAL., BACKGROUND: CA125 is the best available yet insufficiently sensitive biomarker for early detection of ovarian cancer. There is a need to identify novel biomarkers, which individually or in combination with CA125 can achieve adequate sensitivity and specificity for the detection of earlier-stage ovarian cancer. METHODS: In the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, we measured serum levels of 92 preselected proteins for 91 women who had blood sampled ≤18 months prior to ovarian cancer diagnosis, and 182 matched controls. We evaluated the discriminatory performance of the proteins as potential early diagnostic biomarkers of ovarian cancer. RESULTS: Nine of the 92 markers; CA125, HE4, FOLR1, KLK11, WISP1, MDK, CXCL13, MSLN and ADAM8 showed an area under the ROC curve (AUC) of ≥0.70 for discriminating between women diagnosed with ovarian cancer and women who remained cancerfree. All, except ADAM8, had shown at least equal discrimination in previous case-control comparisons. The discrimination of the biomarkers, however, was low for the lag-time of >9–18 months and paired combinations of CA125 with any of the 8 markers did not improve discrimination compared to CA125 alone. CONCLUSION: Using pre-diagnostic serum samples, this study identified markers with good discrimination for the lag-time of 0–9 months. However, the discrimination was low in blood samples collected more than 9 months prior to diagnosis, and none of the markers showed major improvement in discrimination when added to CA125., World Health Organization, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Danish Cancer Society, Ligue Contre le Cancer (France), Institut Gustave Roussy (France), Mutuelle Generale de l'Education Nationale (France), Institut National de la Sante et de la Recherche Medicale (Inserm), Deutsche Krebshilfe, German Cancer Research Center (DKFZ) (Germany), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE) (Germany), Federal Ministry of Education & Research (BMBF), Fondazione AIRC per la ricerca sul cancro, Compagnia di San Paolo, Consiglio Nazionale delle Ricerche (CNR), Netherlands Government, World Cancer Research Fund International (WCRF), Health Research Fund (FIS)-Instituto de Salud Carlos III (ISCIII) (Spain), Junta de Andalucia, Regional Government of Asturias (Spain), Regional Government of Basque Country (Spain), Regional Government of Murcia (Spain), Regional Government of Navarra (Spain), Catalan Institute of OncologyICO (Spain), Swedish Cancer Society, Swedish Research Council, County Council of Skane (Sweden), County Council of Vasterbotten (Sweden), Cancer Research UK C864/A14136 C8221/A29017, UK Research & Innovation (UKRI), Medical Research Council UK (MRC) MR/N003284/1 MC-UU 12015/1 MC UU_00006/1 MR/M012190/1, Projekt DEAL
- Published
- 2022
21. Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition
- Author
-
Salma Butt, Rudolf Kaaks, Agnès Fournier, Marina Kvaskoff, Elisabete Weiderpass, Karolin Isaksson, Matthias B. Schulze, Susana Merino, Reza Ghiasvand, Gianluca Severi, Eva Ardanaz, Ingrid Ljuslinder, Yahya Mahamat-Saleh, Bas Bueno-de-Mesquita, Renée T. Fortner, Sandra Colorado-Yohar, Marie Al Rahmoun, Salvatore Panico, Clio Dessinioti, Sabina Sieri, Carlotta Sacerdote, Antonia Trichopoulou, Katerina Niforou, Anne Tjønneland, Laure Dossus, Ruth C. Travis, Saverio Caini, Leire Gil Majuelo, Kay-Tee Khaw, Maria J. Sánchez, Marit B. Veierød, Anja Olsen, Sabina Rinaldi, Torkjel M. Sandanger, Iris Cervenka, Malin Jansson, Marie-Christine Boutron-Ruault, Rosario Tumino, Edoardo Botteri, Domenico Palli, and Leila Lujan-Barroso
- Subjects
Oncology ,Cancer Research ,Skin Neoplasms ,Time Factors ,Dones ,hormonal treatments ,030207 dermatology & venereal diseases ,0302 clinical medicine ,cohort studies ,Risk Factors ,Surveys and Questionnaires ,Epidemiology ,Skin cancer ,Medicine ,Prospective Studies ,Prospective cohort study ,Melanoma ,oral contraceptives ,Incidence ,Estrogen Replacement Therapy ,Confounding ,Hazard ratio ,Confounding Factors, Epidemiologic ,Middle Aged ,European Prospective Investigation into Cancer and Nutrition ,Europe ,Postmenopause ,030220 oncology & carcinogenesis ,epidemiology ,Female ,Cohort study ,Adult ,medicine.medical_specialty ,menopausal hormone therapy ,Contraceptives, Oral, Hormonal ,cutaneous melanoma ,03 medical and health sciences ,Breast cancer ,Internal medicine ,Humans ,VDP::Medisinske Fag: 700 ,Women ,Nutrició ,Càncer de pell ,Aged ,Proportional Hazards Models ,Nutrition ,business.industry ,medicine.disease ,VDP::Medical disciplines: 700 ,Premenopause ,Cutaneous melanoma ,business - Abstract
This is the peer reviewed version of the following article: Cervenka, I., Al Rahmoun, M., Mahamat-Saleh, Y., Fournier, A., Boutron-Ruault, M.-C., Severi, G. ... Kvaskoff, M. (2019). Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, which has been published in final form at https://doi.org/10.1002/ijc.32674. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Evidence suggests an influence of sex hormones on cutaneous melanoma risk, but epidemiologic findings are conflicting. We examined the associations between use of oral contraceptives (OCs) and menopausal hormone therapy (MHT) and melanoma risk in women participating in the European Prospective Investigation into Cancer and Nutrition (EPIC). EPIC is a prospective cohort study initiated in 1992 in 10 European countries. Information on exogenous hormone use at baseline was derived from country‐specific self‐administered questionnaires. We used Cox proportional hazards regression models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Over 1992–2015, 1,696 melanoma cases were identified among 334,483 women, whereof 770 cases among 134,758 postmenopausal women. There was a positive, borderline‐significant association between OC use and melanoma risk (HR = 1.12, 95% CI = 1.00–1.26), with no detected heterogeneity across countries (phomogeneity = 0.42). This risk increased linearly with duration of use (ptrend = 0.01). Among postmenopausal women, ever use of MHT was associated with a nonsignificant increase in melanoma risk overall (HR = 1.14, 95% CI = 0.97–1.43), which was heterogeneous across countries (phomogeneity = 0.05). Our findings do not support a strong and direct association between exogenous hormone use and melanoma risk. In order to better understand these relations, further research should be performed using prospectively collected data including detailed information on types of hormone, and on sun exposure, which may act as an important confounder or effect modifier on these relations.
- Published
- 2019
22. Prediagnosis Leisure-Time Physical Activity and Lung Cancer Survival: A Pooled Analysis of 11 Cohorts
- Author
-
Jae Jeong Yang, Danxia Yu, Emily White, Dong Hoon Lee, William Blot, Kim Robien, Rashmi Sinha, Yikyung Park, Yumie Takata, Yu-Tang Gao, Karl Smith-Byrne, Evelyn M Monninkhof, Rudolf Kaaks, Arnulf Langhammer, Kristin Benjaminsen Borch, Laila Al-Shaar, Qing Lan, Elin Pettersen Sørgjerd, Xuehong Zhang, Clair Zhu, María Dolores Chirlaque, Gianluca Severi, Kim Overvad, Carlotta Sacerdote, Dagfinn Aune, Mattias Johansson, Stephanie A Smith-Warner, Wei Zheng, and Xiao-Ou Shu
- Subjects
Cancer Research ,Lung Neoplasms ,Science & Technology ,Lung Neoplasms/diagnosis ,MORTALITY ,SEDENTARY BEHAVIOR ,QUESTIONNAIRE ,WOMENS HEALTH ,EXERCISE ,Motor Activity ,United States/epidemiology ,OBSTRUCTIVE PULMONARY-DISEASE ,PREVENTION ,United States ,Leisure Activities ,Oncology ,REPRODUCIBILITY ,Humans ,Prospective Studies ,VALIDITY ,CARDIORESPIRATORY FITNESS ,Life Sciences & Biomedicine - Abstract
BackgroundLittle is known about the association between physical activity before cancer diagnosis and survival among lung cancer patients. In this pooled analysis of 11 prospective cohorts, we investigated associations of prediagnosis leisure-time physical activity (LTPA) with all-cause and lung cancer–specific mortality among incident lung cancer patients.MethodsUsing self-reported data on regular engagement in exercise and sports activities collected at study enrollment, we assessed metabolic equivalent hours (MET-h) of prediagnosis LTPA per week. According to the Physical Activity Guidelines for Americans, prediagnosis LTPA was classified into inactivity, less than 8.3 and at least 8.3 MET-h per week (the minimum recommended range). Cox regression was used to estimate hazard ratios (HRs) and 95% confidence interval (CIs) for all-cause and lung cancer–specific mortality after adjustment for major prognostic factors and lifetime smoking history.ResultsOf 20 494 incident lung cancer patients, 16 864 died, including 13 596 deaths from lung cancer (overall 5-year relative survival rate = 20.9%, 95% CI = 20.3% to 21.5%). Compared with inactivity, prediagnosis LTPA of more than 8.3 MET-h per week was associated with a lower hazard of all-cause mortality (multivariable-adjusted HR = 0.93, 95% CI = 0.88 to 0.99), but not with lung cancer–specific mortality (multivariable-adjusted HR = 0.99, 95% CI = 0.95 to 1.04), among the overall population. Additive interaction was found by tumor stage (Pinteraction = .008 for all-cause mortality and .003 for lung cancer–specific mortality). When restricted to localized cancer, prediagnosis LTPA of at least 8.3 MET-h per week linked to 20% lower mortality: multivariable-adjusted HRs were 0.80 (95% CI = 0.67 to 0.97) for all-cause mortality and 0.80 (95% CI = 0.65 to 0.99) for lung cancer–specific mortality.ConclusionsRegular participation in LTPA that met or exceeded the minimum Physical Activity Guidelines was associated with reduced hazards of mortality among lung cancer patients, especially those with early stage cancer.
- Published
- 2021
23. Pre-diagnostic alterations in circulating bile acid profiles in the development of hepatocellular carcinoma
- Author
-
Heinz Freisling, Susana Merino, Aurelio Barricarte, Augustin Scalbert, Domenico Palli, Eleni Peppa, Hanna Nyström, Klas Sjöberg, Magdalena Stepien, Antonia Trichopoulou, Aurora Perez-Cornago, Marina Lopez-Nogueroles, Gianluca Severi, Carlotta Sacerdote, Dragos Ciocan, Tilman Kühn, Elisabete Weiderpass, Cosmin Sebastian Voican, Manuela M. Bergmann, Gabriel Perlemuter, Eugene Jansen, Rudolf Kaaks, Michael F. Leitzmann, Julie A. Schmidt, Catherine Dong, Anna Karakatsani, María José Sánchez, Rosario Tumino, Bodil Ohlsson, H. Bas Bueno-de-Mesquita, Marc J. Gunter, Raul Zamora Ros, Guri Skeie, José Mª Huerta, Heiner Boeing, Agustín Lahoz, Vittorio Krogh, Pilar Amiano, Francesca Mancini, Anne Tjønneland, Marie-Christine Boutron-Ruault, Salvatore Panico, Mazda Jenab, Sofia Christakoudi, Vivian Viallon, Renée T. Fortner, Mårten Werner, Faculté de Médecine Paris-Saclay, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)-Université Paris-Saclay, Department of Radiology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Kræftens Bekæmpelse, DCS, Deutsches Krebsforschungszentrum, DKFZ, Centre International de Recherche sur le Cancer, CIRC, National Research Council, NRC, University of Maryland School of Public Health, SPH, Medical Research Council, MRC: 1000143, MR/M012190/1, Cancer Research UK, CRUK: 14136, C8221/A29017, World Cancer Research Fund, WCRF, University of Cambridge, Imperial College London, Institut National de la Santé et de la Recherche Médicale, Inserm, Bundesministerium für Bildung und Forschung, BMBF, Cancerfonden, Ministerie van Volksgezondheid, Welzijn en Sport, VWS, Ligue Contre le Cancer, Vetenskapsrådet, VR, Instituto de Salud Carlos III, ISCIII, Deutsche Krebshilfe, Institut National Du Cancer, INCa: 2009‐139, 2014‐1‐RT‐02‐CIRC‐1, Institut Gustave-Roussy, Mutuelle Générale de l'Education Nationale, MGEN, NIHR Imperial Biomedical Research Centre, BRC, This work was supported in part by the French National Cancer Institute (L'Institut National du Cancer, INCa, grant numbers 2009‐139 and 2014‐1‐RT‐02‐CIRC‐1, PI: M. Jenab) and by internal funds of the IARC. The coordination of EPIC is financially supported by the International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France), German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam‐Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany), Associazione Italiana per la Ricerca sul Cancro‐AIRC‐Italy, Compagnia di SanPaolo and National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands), Health Research Fund (FIS)—Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra and the Catalan Institute of Oncology—ICO (Spain), Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden), Cancer Research UK (14136 to EPIC‐Norfolk, C8221/A29017 to EPIC‐Oxford), Medical Research Council (1000143 to EPIC‐Norfolk, MR/M012190/1 to EPIC‐Oxford) (United Kingdom). The funding sources had no influence on the design of the study, the collection, analysis and interpretation of data, the writing of the report, or the decision to submit the article for publication. Funding information, and We would like to acknowledge Dr Krasimira Aleksandrova for input on the present manuscript, along with the National Institute for Public Health and the Environment (Bilthoven, The Netherlands), the Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands, Department of Public Health Aarhus University (Aarhus, Denmark), University of Cambridge (Cambridge, United Kingdom), for their contributions and ongoing support to the EPIC Study.
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,obesity ,Carcinoma, Hepatocellular ,medicine.drug_class ,education ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Gastroenterology ,Bile Acids and Salts ,Cohort Studies ,chemistry.chemical_compound ,Internal medicine ,medicine ,Biomarkers, Tumor ,Choline ,Humans ,Prospective cohort study ,Carcinogen ,Aged ,Cancer prevention ,Bile acid ,cancer prevention ,business.industry ,Confounding ,Liver Neoplasms ,bile acid metabolism ,biomarkers ,hepatocellular carcinoma ,Middle Aged ,medicine.disease ,Obesity ,Oncology ,chemistry ,Hepatocellular carcinoma ,Case-Control Studies ,Female ,business - Abstract
This is the peer reviewed version of the following article: Stepien et.al (2021). Prediagnostic alterations in circulating bile acid profiles in the development of hepatocellular carcinoma. International Journal of Cancer, which has been published in final form at https://doi.org/10.1002/ijc.33885. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited. Bile acids (BAs) play different roles in cancer development. Some are carcinogenic and BA signaling is also involved in various metabolic, inflammatory and immune-related processes. The liver is the primary site of BA synthesis. Liver dysfunction and microbiome compositional changes, such as during hepatocellular carcinoma (HCC) development, may modulate BA metabolism increasing concentration of carcinogenic BAs. Observations from prospective cohorts are sparse. We conducted a study (233 HCC case-control pairs) nested within a large observational prospective cohort with blood samples taken at recruitment when healthy with follow-up over time for later cancer development. A targeted metabolomics method was used to quantify 17 BAs (primary/secondary/tertiary; conjugated/unconjugated) in prediagnostic plasma. Odd ratios (OR) for HCC risk associations were calculated by multivariable conditional logistic regression models. Positive HCC risk associations were observed for the molar sum of all BAs (ORdoubling = 2.30, 95% confidence intervals [CI]: 1.76-3.00), and choline- and taurine-conjugated BAs. Relative concentrations of BAs showed positive HCC risk associations for glycoholic acid and most taurine-conjugated BAs. We observe an association between increased HCC risk and higher levels of major circulating BAs, from several years prior to tumor diagnosis and after multivariable adjustment for confounders and liver functionality. Increase in BA concentration is accompanied by a shift in BA profile toward higher proportions of taurine-conjugated BAs, indicating early alterations of BA metabolism with HCC development. Future studies are needed to assess BA profiles for improved stratification of patients at high HCC risk and to determine whether supplementation with certain BAs may ameliorate liver dysfunction.
- Published
- 2021
24. Serum Extracellular Vesicle-Derived microRNAs as Potential Biomarkers for Pleural Mesothelioma in a European Prospective Study
- Author
-
Elisabetta Casalone, Giovanni Birolo, Barbara Pardini, Alessandra Allione, Alessia Russo, Chiara Catalano, Manlio Mencoboni, Daniela Ferrante, Corrado Magnani, Marika Sculco, Irma Dianzani, Federica Grosso, Dario Mirabelli, Rosa Angela Filiberti, Ottavio Rena, Carlotta Sacerdote, Miguel Rodriguez-Barranco, Karl Smith-Byrne, Salvatore Panico, Claudia Agnoli, Theron Johnson, Rudolf Kaaks, Rosario Tumino, José María Huerta, Elio Riboli, Alicia K Heath, Camino Trobajo-Sanmartín, Matthias B. Schulze, Calogero Saieva, Pilar Amiano, Antonio Agudo, Elisabete Weiderpass, Paolo Vineis, and Giuseppe Matullo
- Subjects
Malalties de la pleura ,Mesothelioma ,Pleural disease ,next generation sequencing ,early changes ,malignant pleural mesothelioma ,biomarkers ,microRNAs ,Cancer Research ,Biochemical markers ,Mesotelioma ,Oncology ,Marcadors bioquímics - Abstract
Simple Summary Malignant pleural mesothelioma (MPM) is an aggressive and still incurable cancer. There is an urgent need to identify effective and reliable tools for detecting and diagnosing the early onset of MPM. In our study, we investigated the whole miRNAs expression profile from serum extracellular vesicles to identify early changes related to MPM development. miR-11400, miR-148a-3p, and miR-409-3p levels were increased in pre-clinical MPM patients up to five years before their diagnosis. The three-miRNA pattern showed a good discrimination capacity to distinguish pre-clinical MPM from cancer-free controls. The three miRNAs also displayed high diagnostic capabilities for differentiating between MPM patients and controls. This study identified a potential EV miRNA signature in preclinical MPM up to five years before diagnosis and raises the possibility of early intervention. Malignant pleural mesothelioma (MPM) is an aggressive cancer with a dismal prognosis. Early therapeutic interventions could improve patient outcomes. We aimed to identify a pattern of microRNAs (miRNAs) as potential early non-invasive markers of MPM. In a case-control study nested in the European Prospective Investigation into Cancer and Nutrition cohort, we screened the whole miRNome in serum extracellular vesicles (EVs) of preclinical MPM cases. In a subgroup of 20 preclinical samples collected five years prior MPM diagnosis, we observed an upregulation of miR-11400 (fold change (FC) = 2.6, adjusted p-value = 0.01), miR-148a-3p (FC = 1.5, p-value = 0.001), and miR-409-3p (FC = 1.5, p-value = 0.04) relative to matched controls. The 3-miRNA panel showed a good classification capacity with an area under the receiver operating characteristic curve (AUC) of 0.81 (specificity = 0.75, sensitivity = 0.70). The diagnostic ability of the model was also evaluated in an independent retrospective cohort, yielding a higher predictive power (AUC = 0.86). A signature of EV miRNA can be detected up to five years before MPM; moreover, the identified miRNAs could provide functional insights into the molecular changes related to the late carcinogenic process, preceding MPM development.
- Published
- 2022
25. Endogenous Circulating Sex Hormone Concentrations and Colon Cancer Risk in Postmenopausal Women: a Prospective Study and Meta-Analysis
- Author
-
Matthias B. Schulze, Ruth C. Travis, Rosario Tumino, Rudolf Kaaks, Agnès Fournier, Niki Dimou, Pekka Keski-Rahkonen, Amanda J. Cross, Salvatore Panico, Marina Kvaskoff, Renée T. Fortner, María José Sánchez, Gianluca Severi, Dagfinn Aune, Carlotta Sacerdote, Marc J. Gunter, Konstantinos K. Tsilidis, Bas Bueno-de-Mesquita, Inger T. Gram, Eva Ardanaz, Sandra Colorado-Yohar, Marit Waaseth, Audrey Gicquiau, Vittorio Krogh, Paula Jakszyn, Sabina Rinaldi, Nagisa Mori, Justin Harbs, Neil Murphy, Sophia Harlid, Giovanna Masala, Eleanor L. Watts, and Bethany Van Guelpen
- Subjects
Cancer Research ,Colorectal cancer ,Physiology ,chemistry.chemical_compound ,Sex hormone-binding globulin ,Sex Hormone-Binding Globulin ,Odds Ratio ,Testosterone ,Prospective Studies ,Prospective cohort study ,Gonadal Steroid Hormones ,Progesterone ,biology ,Estradiol ,VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801 ,Dehydroepiandrosterone Sulfate ,Middle Aged ,Europe ,Postmenopause ,Oncology ,Colonic Neoplasms ,Female ,Menopause ,AcademicSubjects/MED00010 ,Menopausa ,Estrone ,Dehydroepiandrosterone ,Article ,Càncer colorectal ,medicine ,Confidence Intervals ,Humans ,Androstenedione ,Cancer och onkologi ,business.industry ,Rectal Neoplasms ,Estrogens ,Odds ratio ,medicine.disease ,Logistic Models ,chemistry ,Cancer and Oncology ,Case-Control Studies ,biology.protein ,VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801 ,business - Abstract
This work was supported by the French National Cancer Institute (INCa SHSESP17, grant No. 2017-127 to N. Murphy). The coordination of EPIC is financially supported by International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, Institut National de la Sante et de la Recherche Medicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition PotsdamRehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (the Netherlands); Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology-ICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Ska degrees ne and V_asterbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford) (United Kingdom)., Background: Observational studies have consistently reported that postmenopausal hormone therapy use is associated with lower colon cancer risk, but epidemiologic studies examining the associations between circulating concentrations of endogenous estrogens and colorectal cancer have reported inconsistent results. Methods: We investigated the associations between circulating concentrations of estrone, estradiol, free estradiol, testosterone, free testosterone, androstenedione, dehydroepiandrosterone (DHEA), progesterone, and sex hormone–binding globulin (SHBG) with colon cancer risk in a nested case-control study of 1028 postmenopausal European women (512 colon cancer cases, 516 matched controls) who were noncurrent users of exogenous hormones at blood collection. Multivariable conditional logistic regression models were used to compute odds ratios and 95% confidence intervals to evaluate the association between circulating sex hormones and colon cancer risk. We also conducted a dose-response meta-analysis of prospective studies of circulating estrone and estradiol with colorectal, colon, and rectal cancer risk in postmenopausal women. All statistical tests were 2-sided. Results: In the multivariable model, a nonstatistically significantly positive relationship was found between circulating estrone and colon cancer risk (odds ratio per log2 1-unit increment¼1.17 [95% confidence interval¼1.00 to 1.38]; odds ratioquartile4-quartile1¼1.33 [95% confidence interval¼0.89 to 1.97], Ptrend¼.20). Circulating concentrations of estradiol, free estradiol, testosterone, free testosterone, androstenedione, DHEA, progesterone, and SHBG were not associated with colon cancer risk. In the doseresponse meta-analysis, no clear evidence of associations were found between circulating estradiol and estrone concentrations with colorectal, colon, and rectal cancer risk. Conclusion: Our observational and meta-analysis results do not support an association between circulating concentrations of endogenous sex hormones and colon or rectal cancer in postmenopausal women., French National Cancer Institute (INCa SHSESP17) 2017-127, World Health Organization, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Danish Cancer Society, Ligue Contre le Cancer (France), Institut Gustave Roussy (France), Mutuelle Generale de l'Education Nationale (France), Institut National de la Sante et de la Recherche Medicale (Inserm), Deutsche Krebshilfe German Cancer Research Center (DKFZ) (Germany) German Institute of Human Nutrition Potsdam Rehbruecke (DIfE) (Germany), Federal Ministry of Education & Research (BMBF), Fondazione AIRC per la ricerca sul cancro, Compagnia di San Paolo Consiglio Nazionale delle Ricerche (CNR), Netherlands Government, World Cancer Research Fund International (WCRF), Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII) (Spain) Junta de Andalucia Regional Government of Asturias (Spain) Regional Government of Basque Country (Spain) Regional Government of Murcia (Spain) Regional Government of Navarra (Spain) Catalan Institute of Oncology-ICO (Spain), Swedish Cancer Society Swedish Research Council County Council of Skane (Sweden) County Council of Vasterbotten (Sweden), Cancer Research UK 14136 C8221/A29017 UK Research & Innovation (UKRI) Medical Research Council UK (MRC) 1000143 MR/M012190/1
- Published
- 2021
26. No association between polymorphisms in CYP2E1, GSTM1, NAT1, NAT2 and the risk of gastric adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition
- Author
-
Salvatore Panico, Nadia García, H. B. Bueno-De-Mesquita, Kim Overvad, Hendriek C. Boshuizen, Timothy J. Key, M. E. Numans, Antonio Berenguer, Rosario Tumino, Khaw K-T., Gabriele Nagel, Carmen Navarro, Boutron-Ruault M-C., Domenico Palli, Elio Riboli, J. Linseisen, Anne Tjønneland, Aurelio Barricarte, A. Olsen, Eiliv Lund, Françoise Clavel-Chapelon, Calogero Saieva, Teresa Norat, G. Del Giudice, Sheila Bingham, Guillem Pera, Henrik Simán, Antonia Trichopoulou, Mazda Jenab, Carlos A. González, Hendrik Bläker, J. R. Quirós, Carlos Martinez, Antonio Agudo, Roger Stenling, P. H. M. Peeters, Carlotta Sacerdote, Pilar Amiano, Pamela Ferrari, Naomi E. Allen, Göran Berglund, Fátima Carneiro, Gabriel Capellá, Franco Berrino, Heiner Boeing, Núria Sala, and Göran Hallmans
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Pathology ,Genotype ,Arylamine N-Acetyltransferase ,Epidemiology ,Adenocarcinoma ,Biology ,Glutathione transferase ,Gastric adenocarcinoma ,Stomach Neoplasms ,Internal medicine ,medicine ,Humans ,Stomach cancer ,neoplasms ,Glutathione Transferase ,Polymorphism, Genetic ,integumentary system ,Cytochrome P-450 CYP2E1 ,Middle Aged ,medicine.disease ,digestive system diseases ,European Prospective Investigation into Cancer and Nutrition ,Europe ,Logistic Models ,Case-Control Studies ,Female ,Stomach Adenocarcinoma - Abstract
No association between polymorphisms in CYP2E1, GSTM1, NAT1, NAT2 and the risk of gastric adenocarcinoma in the European prospective investigation into cancer and nutrition.
- Published
- 2021
27. Coffee and tea consumption and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition
- Author
-
Aurelio Barricarte, Tilman Kühn, Nikos Papadimitriou, Rosario Tumino, Elio Riboli, Lena Maria Nilsson, Dimitrios Trichopoulos, Dagfinn Aune, Bas Bueno-de-Mesquita, Kim Overvad, Ruth C. Travis, Nerea Larrañaga, Bodil Hammer Bech, Peter Wallström, Antonia Trichopoulou, Christina Bamia, Maria Luisa Redondo, Heiner Boeing, Valerie Cayssials, Rudolf Kaaks, Carlotta Sacerdote, Anne Tjønneland, Ioanna Tzoulaki, Neil Murphy, Anna Karakatsani, Aurora Perez-Cornago, Rikard Landberg, Anastasia Kotanidou, Cecilie Kyrø, Sara Grioni, Pagona Lagiou, Saverio Caini, David S. Lopez, Heinz Freisling, Maria Dolores Chirlaque, Amanda J. Cross, Kay-Tee Khaw, Isabel Drake, Timothy J. Key, Konstantinos K. Tsilidis, Domenico Palli, Marc J. Gunter, David C. Muller, Abhijit Sen, Malene Outzen, Manuela M. Bergmann, and María José Sánchez
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,Proportional hazards model ,Incidence (epidemiology) ,Hazard ratio ,Cancer ,medicine.disease ,European Prospective Investigation into Cancer and Nutrition ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Internal medicine ,Epidemiology ,medicine ,business ,Cohort study - Abstract
The epidemiological evidence regarding the association of coffee and tea consumption with prostate cancer risk is inconclusive, and few cohort studies have assessed these associations by disease stage and grade. We examined the associations of coffee (total, caffeinated and decaffeinated) and tea intake with prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition. Among 142,196 men, 7,036 incident prostate cancer cases were diagnosed over 14 years of follow-up. Data on coffee and tea consumption were collected through validated country-specific food questionnaires at baseline. We used Cox proportional hazards regression models to compute hazard ratios (HRs) and 95% confidence intervals (CI). Models were stratified by center and age, and adjusted for anthropometric, lifestyle and dietary factors. Median coffee and tea intake were 375 and 106 mL/day, respectively, but large variations existed by country. Comparing the highest (median of 855 mL/day) versus lowest (median of 103 mL/day) consumers of coffee and tea (450 vs. 12 mL/day) the HRs were 1.02 (95% CI, 0.94–1.09) and 0.98 (95% CI, 0.90–1.07) for risk of total prostate cancer and 0.97 (95% CI, 0.79–1.21) and 0.89 (95% CI, 0.70–1.13) for risk of fatal disease, respectively. No evidence of association was seen for consumption of total, caffeinated or decaffeinated coffee or tea and risk of total prostate cancer or cancer by stage, grade or fatality in this large cohort. Further investigations are needed to clarify whether an association exists by different preparations or by concentrations and constituents of these beverages.
- Published
- 2018
28. Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer
- Author
-
Timothy H.T. Cheng, V. Wendy Setiawan, Jolanta Lissowska, Kamila Czene, Zhaoming Wang, Linda S. Cook, Shirley Hodgson, Mitul Shah, Matthias W. Beckmann, Douglas F. Easton, Annika Lindblom, Daniel D. Buchanan, Wei Zheng, Constance Turman, Gloria E. Sarto, Susan E. Hankinson, Chu Chen, Joe Dennis, Christine M. Friedenreich, Dylan M. Glubb, Peter Hillemanns, Tracy A. O'Mara, Camilla Krakstad, Yong-Bing Xiang, Arif B. Ekici, Maxine M. Chen, Marta Crous-Bous, Montserrat Garcia-Closas, David Van Den Berg, Amanda Black, Immaculata De Vivo, Roger L. Milne, Geoffrey Otton, Frédéric Amant, Timothy R. Rebbeck, Carlotta Sacerdote, Erling A. Hoivik, Xiao-Ou Shu, Melissa C. Southey, Paul L. Auer, Brooke L. Fridley, Thilo Dörk, Elizabeth G. Holliday, Fredrick R. Schumacher, Loreall Pooler, Daniela Annibali, Mia M. Gaudet, Maggie Gorman, Peter A. Fasching, Matthias Rübner, Hannah P. Yang, Graham G. Giles, Stefan P. Renner, Jirong Long, Ellen L. Goode, Katie A. Ashton, Claire Palles, Emma Tham, Diether Lambrechts, Xin Sheng, Rodney J. Scott, Angela M. Jones, Alexander Hein, Amanda B. Spurdle, Nicolas Wentzensen, David J. Hunter, Rami Nassir, Peter Kraft, Lynn Martin, Christopher A. Haiman, Alison M. Dunning, Stephen J. Chanock, Jone Trovik, Loic Le Marchand, Harvey A. Risch, Tony Proietto, Matthias Dürst, Sean C. Dowdy, Lucy Xia, Miriam Mints, Anthony M. Magliocco, Pik Fang Kho, Herbert Yu, Lingeng Lu, Mark McEvoy, Xiaolin Liang, Louise A. Brinton, Per Hall, Jonathan Tyrer, Ingo B. Runnebaum, Penelope M. Webb, John Attia, Ian Tomlinson, Deborah J. Thompson, Buchanan, Daniel D [0000-0003-2225-6675], Chen, Chu [0000-0003-2267-8050], De Vivo, Immaculata [0000-0002-7185-7402], Dörk, Thilo [0000-0002-9458-0282], Fasching, Peter A [0000-0003-4885-8471], Friedenreich, Christine M [0000-0002-4783-1966], Gaudet, Mia M [0000-0002-6429-4007], Goode, Ellen L [0000-0002-9094-8326], Lu, Lingeng [0000-0001-9871-0809], Sacerdote, Carlotta [0000-0002-8008-5096], Shu, Xiao-Ou [0000-0002-0711-8314], Wang, Zhaoming [0000-0001-7556-3869], Wentzensen, Nicolas [0000-0003-1251-0836], Xiang, Yong-Bing [0000-0002-3840-9915], Yu, Herbert [0000-0003-3950-4815], Spurdle, Amanda B [0000-0003-1337-7897], O'Mara, Tracy A [0000-0002-5436-3232], Apollo - University of Cambridge Repository, ARD - Amsterdam Reproduction and Development, Obstetrics and Gynaecology, and CCA - Imaging and biomarkers
- Subjects
Oncology ,Cancer Research ,Colorectal cancer ,Blood lipids ,chemistry.chemical_compound ,0302 clinical medicine ,HDL cholesterol ,Medicine ,triglycerides ,METABOLIC SYNDROME ,2. Zero hunger ,Mendelian Randomization Analysis ,ASSOCIATION ,3. Good health ,030220 oncology & carcinogenesis ,LDL cholesterol ,SERUM-LIPIDS ,Female ,lipids (amino acids, peptides, and proteins) ,Life Sciences & Biomedicine ,Risk ,medicine.medical_specialty ,endometrial cancer risk ,Article ,03 medical and health sciences ,INFLAMMATION ,Internal medicine ,Mendelian randomization ,CAUSAL ,Humans ,Science & Technology ,Cholesterol ,business.industry ,Endometrial cancer ,Cholesterol, HDL ,Case-control study ,Cholesterol, LDL ,medicine.disease ,Endometrial Neoplasms ,BODY-MASS INDEX ,LIPOPROTEIN ,chemistry ,Case-Control Studies ,RISK-FACTORS ,Metabolic syndrome ,business ,Genome-Wide Association Study - Abstract
Blood lipids have been associated with the development of a range of cancers, including breast, lung and colorectal cancer. For endometrial cancer, observational studies have reported inconsistent associations between blood lipids and cancer risk. To reduce biases from unmeasured confounding, we performed a bidirectional, two-sample Mendelian randomization analysis to investigate the relationship between levels of three blood lipids (low-density lipoprotein [LDL] and high-density lipoprotein [HDL] cholesterol, and triglycerides) and endometrial cancer risk. Genetic variants associated with each of these blood lipid levels (P
- Published
- 2021
29. Dietary intake and plasma phospholipid concentrations of saturated, monounsaturated and trans fatty acids and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort
- Author
-
Joseph A. Rothwell, Giovanna Masala, José María Huerta, Aurora Perez-Cornago, Elisabete Weiderpass, Anja Olsen, Magritt Brustad, Claudia Agnoli, Corinne Casagrande, Guri Skeie, Ulrika Ericson, Verena Katzke, Mazda Jenab, Christina C. Dahm, Anne Tjønneland, Geneviève Nicolas, Rudolf Kaaks, Inge Huybrechts, Veronika Fedirko, Carlotta Sacerdote, Neil Murphy, Maria Wennberg, Veronique Chajes, Jeroen W.G. Derksen, Matthias B. Schulze, Elom K. Aglago, Bas Bueno-de-Mesquita, Alicia K Heath, Pilar Amiano, Salvatore Panico, Paula Jakszyn, Rosario Tumino, Marc J. Gunter, Inger T. Gram, María José Sánchez, Centre International de Recherche contre le Cancer - International Agency for Research on Cancer (CIRC - IARC), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, 1000143, MR/M012190/1, Kræftens Bekæmpelse, DCS, Deutsches Krebsforschungszentrum, DKFZ, Centre International de Recherche sur le Cancer, CIRC, National Research Council, NRC, University of Maryland School of Public Health, SPH, Cancer Research UK, CRUK: 14136, C8221/A29017, World Cancer Research Fund, WCRF, Imperial College London, Institut National de la Santé et de la Recherche Médicale, Inserm, Bundesministerium für Bildung und Forschung, BMBF, Cancerfonden, Ministerie van Volksgezondheid, Welzijn en Sport, VWS, Ligue Contre le Cancer, Vetenskapsrådet, VR, Instituto de Salud Carlos III, ISCIII, Associazione Italiana per la Ricerca sul Cancro, AIRC, Deutsche Krebshilfe, Rijksinstituut voor Volksgezondheid en Milieu, RIVM, Institut Gustave-Roussy, Mutuelle Générale de l'Education Nationale, MGEN, NIHR Imperial Biomedical Research Centre, BRC, World Cancer Research Fund, Grant/Award Number: WCRF 2013/1002 Funding information trans, The authors would like to thank the EPIC study participants and staff for their valuable contribution to this research. The authors would also like to thank Ms Beatrice Vozar, Mr Bertrand Hemon and Ms Carine Biessy for the analysis of plasma samples, and the preparation of the databases. The coordination of EPIC is financially supported by International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France), German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition PotsdamRehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany), Associazione Italiana per la Ricerca sul Cancro‐AIRC‐Italy, Compagnia di SanPaolo and National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands), Health Research Fund (FIS)—Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology—ICO (Spain), Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden), Cancer Research UK (14136 to EPIC‐Norfolk, C8221/A29017 to EPIC‐Oxford), MedicalResearch Council (1000143 to EPIC‐Norfolk, MR/M012190/1 to EPIC‐Oxford). (United Kingdom), the National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands. The EPIC‐Norfolk study (DOI 10.22025/2019.10.105.00004) has received funding from the Medical Research Council (MR/N003284/1, MC‐PC_13048 and MC‐UU_12015/1). We are grateful to all the participants who have been part of the project and to the many members of the study teams at the University of Cambridge who have enabled this research. The authors would like to acknowledge the use of data and samples from EPIC centres in Cambridge, France, Asturias, and Navarro. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the article. Our study was funded by a grant from the World Cancer Research Fund to Marc Gunter (Grant number: WCRF 2013/1002)., Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle G?n?rale de l'Education Nationale, Institut National de la Sant? et de la Recherche M?dicale (INSERM) (France), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy), Health Research Fund (FIS)?Instituto de Salud Carlos III (ISCIII), Regional Governments of Andaluc?a, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology?ICO (Spain), Swedish Cancer Society, Swedish Research Council and County Councils of Sk?ne and V?sterbotten (Sweden), Cancer Research UK (14136 to EPIC-Norfolk, C8221/A29017 to EPIC-Oxford), MedicalResearch Council (1000143 to EPIC-Norfolk, and MR/M012190/1 to EPIC-Oxford). (United Kingdom), the National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands. The EPIC-Norfolk study (DOI 10.22025/2019.10.105.00004) has received funding from the Medical Research Council (MR/N003284/1, MC-PC_13048 and MC-UU_12015/1). We are grateful to all the participants who have been part of the project and to the many members of the study teams at the University of Cambridge who have enabled this research. The authors would like to acknowledge the use of data and samples from EPIC centres in Cambridge, France, Asturias, and Navarro. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the article. Our study was funded by a grant from the World Cancer Research Fund to Marc Gunter (Grant number: WCRF 2013/1002).
- Subjects
Cancer Research ,medicine.medical_specialty ,Colorectal cancer ,Myristic acid ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,colorectal cancer ,Gastroenterology ,fatty acids ,DISEASE ,Palmitic acid ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,COLON ,medicine ,2 SIDES ,2. Zero hunger ,chemistry.chemical_classification ,business.industry ,Fatty acid ,Odds ratio ,ASSOCIATION ,medicine.disease ,Elaidic acid ,3. Good health ,European Prospective Investigation into Cancer and Nutrition ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,biomarker ,Stearic acid ,business ,dietary intake ,LIPIDS - Abstract
International audience; Epidemiologic studies examining the association between specific fatty acids and colorectal cancer (CRC) risk are inconclusive. We investigated the association between dietary estimates and plasma levels of individual and total saturated (SFA), monounsaturated (MUFA), industrial-processed trans (iTFA), and ruminant-sourced trans (rTFA) fatty acids, and CRC risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Baseline fatty acid intakes were estimated in 450 112 participants (6162 developed CRC, median follow-up = 15 years). In a nested case-control study, plasma phospholipid fatty acids were determined by gas chromatography in 433 colon cancer cases and 433 matched controls. Multivariable-adjusted hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were computed using Cox and conditional logistic regression, respectively. Dietary total SFA (highest vs lowest quintile, HRQ5vsQ1 = 0.80; 95%CI:0.69-0.92), myristic acid (HRQ5vsQ1 = 0.83, 95%CI:0.74-0.93) and palmitic acid (HRQ5vsQ1 = 0.81, 95%CI:0.70-0.93) were inversely associated with CRC risk. Plasma myristic acid was also inversely associated with colon cancer risk (highest vs lowest quartile, ORQ4vsQ1 = 0.51; 95%CI:0.32-0.83), whereas a borderline positive association was found for plasma stearic acid (ORQ4vsQ1 = 1.63; 95%CI:1.00-2.64). Dietary total MUFA was inversely associated with colon cancer (per 1-SD increment, HR1-SD = 0.92, 95%CI: 0.85-0.98), but not rectal cancer (HR1-SD = 1.04, 95%CI:0.95-1.15, Pheterogeneity = 0.027). Dietary iTFA, and particularly elaidic acid, was positively associated with rectal cancer (HR1-SD = 1.07, 95%CI:1.02-1.13). Our results suggest that total and individual saturated fatty acids and fatty acids of industrial origin may be relevant to the aetiology of CRC. Both dietary and plasma myristic acid levels were inversely associated with colon cancer risk, which warrants further investigation.
- Published
- 2021
30. Prospective Identification of Elevated Circulating CDCP1 in Patients Years before Onset of Lung Cancer
- Author
-
Matthew Whitaker, Matthias B. Schulze, Barbara Bodinier, Torkjel M. Sandanger, Rosario Tumino, Carlotta Sacerdote, Mattias Johansson, Roel Vermeulen, Sonia Dagnino, Paolo Vineis, Karl Smith-Byrne, Claudia Agnoli, Dusan Petrovic, Salvatore Panico, Therese Haugdahl Nøst, Florence Guida, Marc Chadeau-Hyam, Domenico Palli, Mikael Johansson, Pekka Keski-Rahkonen, Augustin Scalbert, Cancer Research UK, Research Council of Norway, and Commission of the European Communities
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,Lung Neoplasms ,INVASION ,PROTEIN ,medicine.disease_cause ,0302 clinical medicine ,Prospective Studies ,Early Detection of Cancer ,RISK ,Confounding ,Wnt signaling pathway ,Prognosis ,3. Good health ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,CDCP1 ,Adenocarcinoma ,HEALTH ,medicine.symptom ,Life Sciences & Biomedicine ,PROJECT ,medicine.medical_specialty ,MODELS ,Inflammation ,Adenocarcinoma of Lung ,Article ,03 medical and health sciences ,INFLAMMATION ,Antigens, CD ,Antigens, Neoplasm ,Internal medicine ,PANTHER ,medicine ,Biomarkers, Tumor ,Humans ,COHORT ,1112 Oncology and Carcinogenesis ,QUANTITATIVE PROTEOMICS ,Oncology & Carcinogenesis ,Lung cancer ,Science & Technology ,Lung ,business.industry ,medicine.disease ,030104 developmental biology ,Case-Control Studies ,Carcinogenesis ,business ,Cell Adhesion Molecules ,Follow-Up Studies - Abstract
Increasing evidence points to a role for inflammation in lung carcinogenesis. A small number of circulating inflammatory proteins have been identified as showing elevated levels prior to lung cancer diagnosis, indicating the potential for prospective circulating protein concentration as a marker of early carcinogenesis. To identify novel markers of lung cancer risk, we measured a panel of 92 circulating inflammatory proteins in 648 prediagnostic blood samples from two prospective cohorts in Italy and Norway (women only). To preserve the comparability of results and protect against confounding factors, the main statistical analyses were conducted in women from both studies, with replication sought in men (Italian participants). Univariate and penalized regression models revealed for the first time higher blood levels of CDCP1 protein in cases that went on to develop lung cancer compared with controls, irrespective of time to diagnosis, smoking habits, and gender. This association was validated in an additional 450 samples. Associations were stronger for future cases of adenocarcinoma where CDCP1 showed better explanatory performance. Integrative analyses combining gene expression and protein levels of CDCP1 measured in the same individuals suggested a link between CDCP1 and the expression of transcripts of LRRN3 and SEM1. Enrichment analyses indicated a potential role for CDCP1 in pathways related to cell adhesion and mobility, such as the WNT/β-catenin pathway. Overall, this study identifies lung cancer–related dysregulation of CDCP1 expression years before diagnosis. Significance: Prospective proteomics analyses reveal an association between increased levels of circulating CDCP1 and lung carcinogenesis irrespective of smoking and years before diagnosis, and integrating gene expression indicates potential underlying mechanisms. See related commentary by Itzstein et al., p. 3441.
- Published
- 2021
- Full Text
- View/download PDF
31. Impact of Rhabdomyosarcoma Treatment Modalities by Age in a Population-Based Setting
- Author
-
Rosa Filiberti, Marine Castaing, Maria Francesca Vitale, Gemma Gatta, Annalisa Trama, Patrizia Gasparini, Laura Botta, Maria Michiara, Fabio Falcini, Andrea C. Ferrari, Claudia Cirilli, Anita Andreano, Massimo Rugge, Stefano Chiaravalli, Luca Bergamaschi, Gianni Bisogno, Fabrizio Stracci, Giovanna Tagliabue, Carlotta Sacerdote, Michela Casanova, Alice Bernasconi, Alessandro Barchielli, Giuseppe Milano, and Rosario Tumino
- Subjects
musculoskeletal diseases ,Adult ,Pediatrics ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Population based ,chemotherapy ,Medical Oncology ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Epidemiology ,Antineoplastic Combined Chemotherapy Protocols ,Rhabdomyosarcoma ,medicine ,Humans ,030212 general & internal medicine ,Young adult ,Child ,neoplasms ,Retrospective Studies ,Chemotherapy ,business.industry ,registries ,epidemiology ,prognosis ,rhabdomyosarcoma ,Middle Aged ,medicine.disease ,Prognosis ,Combined Modality Therapy ,Treatment Outcome ,Oncology ,Treatment modality ,030220 oncology & carcinogenesis ,Pediatrics, Perinatology and Child Health ,business - Abstract
Purpose: Rhabdomyosarcoma (RMS) has a worse prognosis in adults than in children, but there is evidence of a better outcome in the former if treated using a pediatric-like approach. This study desc...
- Published
- 2021
32. A comparison of complementary measures of vitamin B6 status, function, and metabolism in the European Prospective Investigation into Cancer and Nutrition (EPIC) study
- Author
-
Amanda J. Cross, Leila Lujan-Barroso, Matthias B. Schulze, Theron Johnson, Björn Gylling, Christina C. Dahm, José María Huerta, David C. Muller, Øivind Midttun, Giovanna Masala, Carlotta Sacerdote, Pilar Amiano, Joanna L Clasen, Mattias Johansson, Elio Riboli, Julie A. Schmidt, Ghislaine Scelo, Verena Katzke, Ulrika Ericson, Jin Young Park, Elisabete Weiderpass, Francesco Segrado, Marga C. Ocké, Arve Ulvik, Jonas Manjer, Pietro Ferrari, Ana Ching-López, Inge Huybrechts, Jytte Halkjær, Heleen Van Puyvelde, Alicia K Heath, Eva Ardanaz, Maria Santucci de Magistris, Anja Olsen, Ingegerd Johansson, Per Magne Ueland, and Cancer Research UK
- Subjects
0301 basic medicine ,Oncology ,Male ,Vitamines ,dietary biomarkers ,Medicine (miscellaneous) ,HOMOCYSTEINE ,Transsulfuration pathway ,Status function ,PLASMA PYRIDOXAL 5'-PHOSPHATE ,vitamin B6 ,09 Engineering ,SERUM ,AcademicSubjects/MED00160 ,chemistry.chemical_compound ,0302 clinical medicine ,Vitamins, Minerals, and Phytochemicals ,Neoplasms ,DIETARY-INTAKE ,Medicine and Health Sciences ,Medicine ,AMINO-ACIDS ,Càncer ,ONE-CARBON METABOLISM ,11 Medical and Health Sciences ,Cancer ,Nutrition and Dietetics ,SOLUBLE VITAMINS ,Factors de risc en les malalties ,Biochemical markers ,Vitamins ,Middle Aged ,European Prospective Investigation into Cancer and Nutrition ,Europe ,Original Research Communications ,MICROBIOLOGICAL ASSAY ,030220 oncology & carcinogenesis ,Marcadors bioquímics ,Epic study ,Female ,Vitamin B 6 Deficiency ,Life Sciences & Biomedicine ,kynurenine pathway ,medicine.medical_specialty ,Risk factors in diseases ,Vitamin B 6/blood ,BIOMARKERS ,Nutritional Status ,PLP ,03 medical and health sciences ,AcademicSubjects/MED00060 ,Internal medicine ,Humans ,transsulfuration pathway ,Pyridoxal ,Aged ,Cancer och onkologi ,Science & Technology ,030109 nutrition & dietetics ,Nutrition & Dietetics ,business.industry ,Metabolism ,medicine.disease ,Vitamin B 6 ,chemistry ,Case-Control Studies ,Cancer and Oncology ,Linear Models ,B-VITAMINS ,Vitamin b6 ,business ,Neoplasms/epidemiology - Abstract
BACKGROUND: Vitamin B6 insufficiency has been linked to increased risk of cancer and other chronic diseases. The circulating concentration of pyridoxal 5'-phosphate (PLP) is a commonly used measure of vitamin B6 status. Ratios of substrates indicating PLP coenzymatic function and metabolism may be useful complementary measures to further explore the role of vitamin B6 in health. OBJECTIVES: We explored the sensitivity of 5 outcomes, namely PLP concentration, homocysteine:cysteine (Hcy:Cys), cystathionine:cysteine (Cysta:Cys), the 3´-hydroxykynurenine ratio (HKr), and the 4-pyridoxic acid ratio (PAr) to vitamin B6 intake as well as personal and lifestyle characteristics. MEDTHODS: Dietary intake and biomarker data were collected from participants from 3 nested case-control studies within the European Prospective Investigation into Cancer and Nutrition (EPIC). Bayesian regression models assessed the associations of the 5 biomarker outcomes with vitamin B6 intake and personal and lifestyle covariates. Analogous models examined the relations of Hcy:Cys, Cysta:Cys, and HKr with PLP. RESULTS: In total, 4608 participants were included in the analyses. Vitamin B6 intake was most strongly associated with PLP, moderately associated with Hcy:Cys, Cysta:Cys, and HKr, and not associated with PAr (fold change in marker given a doubling of vitamin B6 intake: PLP 1.60 [95% credible interval (CrI): 1.50, 1.71]; Hcy:Cys 0.87 [95% CrI: 0.84, 0.90]; Cysta:Cys 0.89 [95% CrI: 0.84, 0.94]; HKr 0.88 [95% CrI: 0.85, 0.91]; PAr 1.00 [95% CrI: 0.95, 1.05]). PAr was most sensitive to age, and HKr was least sensitive to BMI and alcohol intake. Sex and menopause status were strongly associated with all 5 markers. CONCLUSIONS: We found that 5 different markers, capturing different aspects of vitamin B6-related biological processes, varied in their associations with vitamin B6 intake and personal and lifestyle predictors. ispartof: AMERICAN JOURNAL OF CLINICAL NUTRITION vol:114 issue:1 pages:338-347 ispartof: location:United States status: published
- Published
- 2021
33. Weight change in middle adulthood and risk of cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort
- Author
-
Amanda J. Cross, Kristin Benjaminsen Borch, Renée T. Fortner, Vittorio Simeon, Paul Brennan, Guri Skeie, Elio Riboli, Rosario Tumino, Elisabete Weiderpass, Gianluca Severi, Carlotta Sacerdote, Kim Overvad, Manuela M. Bergmann, Isabel Drake, Sara Grioni, Panagiota Pagoni, Giovanna Masala, Pietro Ferrari, Heinz Freisling, Matthias B. Schulze, Maria Dolores Chirlaque, Pilar Amiano, Mattias Johansson, Ioanna Tzoulaki, Konstantinos K. Tsilidis, Timothy J. Key, J. Ramón Quirós, Eva Ardanaz, Antonio Agudo, Neil Murphy, Marie-Christine Boutron-Ruault, Christel Häggström, Sofia Christakoudi, Rudolf Kaaks, Merete Ellingjord-Dale, Sophia Harlid, Charlotta Rylander, Tanja Stocks, Anne Tjønneland, Fanny Artaud, Laure Dossus, Jytte Halkjær, Miguel Rodríguez-Barranco, Aurora Perez-Cornago, David C. Muller, Centre International de Recherche contre le Cancer - International Agency for Research on Cancer (CIRC - IARC), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Kræftens Bekæmpelse, DCS German Cancer Research Center, DKFZ Centre International de Recherche sur le Cancer, CIRC National Research Council, NRC Medical Research Council, MRC: MC_UU_00011/6, MR/M012190/1 Cancer Research UK, CRUK: C570/A16491, C8221/A19170 World Cancer Research Fund, WCRF European Commission, EC Institut National de la Santé et de la Recherche Médicale, Inserm Bundesministerium für Bildung und Forschung, BMBF Cancerfonden Ministerie van Volksgezondheid, Welzijn en Sport, VWS Ligue Contre le Cancer Vetenskapsrådet, VR Associazione Italiana per la Ricerca sul Cancro, AIRC Deutsche Krebshilfe Rijksinstituut voor Volksgezondheid en Milieu, RIVM Institut Gustave-Roussy Mutuelle Générale de l'Education Nationale, MGEN NIHR Imperial Biomedical Research Centre, BRC Fondation Gustave Roussy, The authors thank the National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands, for their contribution and ongoing support to the EPIC study. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Kr?ftens Bek?mpelse) (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle G?n?rale de l'Education Nationale, Institut National de la Sant? et de la Recherche M?dicale (INSERM) (France), German Cancer Aid (Deutsche Krebshilfe), German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), Federal Ministry of Education and Research (Bundesministerium f?r Bildung und Forschung, BMBF) (Germany), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands), Health Research Fund (FIS-ISCIII), Regional Governments of Andaluc?a, Asturias, Basque Country, Murcia, Navarra, and the Catalan Institute of Oncology (Barcelona) (Spain), Swedish Cancer Society (Cancerfonden), Swedish Research Council (Vetenskapsr?det), County Councils of Sk?ne and V?sterbotten (Sweden), Cancer Research UK (C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (MR/M012190/1 to EPIC-Oxford) (United Kingdom). Panagiota Pagoni is funded by Medical Research Council (grant reference MC_UU_00011/6). Infrastructure support for the Department of Epidemiology and Biostatistics at Imperial College London (UK) was provided by the NIHR Imperial Biomedical Research Centre (BRC). The funders had no role in the design and conduct of the study, the collection, analysis and interpretation of the data, or the preparation, review and approval of the manuscript, or in the decision to submit the manuscript for publication., The authors thank the National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands, for their contribution and ongoing support to the EPIC study. The coordination of EPIC is financially supported by the European Commission (DG‐SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Kræftens Bekæmpelse) (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France), German Cancer Aid (Deutsche Krebshilfe), German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) (Germany), Associazione Italiana per la Ricerca sul Cancro‐AIRC‐Italy and National Research Council (Italy), Health Research Fund (FIS‐ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia, Navarra, and the Catalan Institute of Oncology (Barcelona) (Spain), Swedish Cancer Society (Cancerfonden), Swedish Research Council (Vetenskapsrådet), County Councils of Skåne and Västerbotten (Sweden), Cancer Research UK (C570/A16491 and C8221/A19170 to EPIC‐Oxford), Medical Research Council (MR/M012190/1 to EPIC‐Oxford) (United Kingdom). Panagiota Pagoni is funded by Medical Research Council (grant reference MC_UU_00011/6). Infrastructure support for the Department of Epidemiology and Biostatistics at Imperial College London (UK) was provided by the NIHR Imperial Biomedical Research Centre (BRC). The funders had no role in the design and conduct of the study, the collection, analysis and interpretation of the data, or the preparation, review and approval of the manuscript, or in the decision to submit the manuscript for publication., Associazione Italiana per la Ricerca sul Cancro, Bundesministerium für Bildung und Forschung, Cancer Research UK, Grant/Award Numbers: C570/A16491, C8221/A19170, Cancerfonden, Catalan Institute of Oncology Barcelona, Centre International de Recherche sur le Cancer, County Council of Skåne Sweden, County Council of Västerbotten Sweden, Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, Directorate‐General for Health and Consumers, Dutch Ministry of Public Health, Welfare and Sports (VWS), Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), Health Research Fund (FIS‐ISCIII) Spain, Institut Gustave‐Roussy, Institut National de la Santé et de la Recherche Médicale, Kræftens Bekæmpelse, Ligue Contre le Cancer, LK Research Funds, Medical Research Council, Grant/Award Numbers: MC_UU_00011/6, MR/M012190/1, Mutuelle Générale de l'Education Nationale, National Research Council Italy, Netherlands Cancer Registry, Regional Government of Andalucía, Regional Government of Asturias, Regional Government of Basque Country, Regional Government of Murcia, Regional Government of Navarra, Statistics Netherlands, Vetenskapsrådet, World Cancer Research Fund (WCRF), Institut Gustave Roussy, International Agency for Research on Cancer, European Commission (DG‐SANCO) Funding information, Christakoudi, S., Pagoni, P., Ferrari, P., Cross, A. J., Tzoulaki, I., Muller, D. C., Weiderpass, E., Freisling, H., Murphy, N., Dossus, L., Turzanski Fortner, R., Agudo, A., Overvad, K., Perez-Cornago, A., Key, T. J., Brennan, P., Johansson, M., Tjonneland, A., Halkjaer, J., Boutron-Ruault, M. -C., Artaud, F., Severi, G., Kaaks, R., Schulze, M. B., Bergmann, M. M., Masala, G., Grioni, S., Simeon, V., Tumino, R., Sacerdote, C., Skeie, G., Rylander, C., Borch, K. B., Quiros, J. R., Rodriguez-Barranco, M., Chirlaque, M. -D., Ardanaz, E., Amiano, P., Drake, I., Stocks, T., Haggstrom, C., Harlid, S., Ellingjord-Dale, M., Riboli, E., Tsilidis, K. K., and Cancer Research UK
- Subjects
Male ,Cancer Research ,middle adulthood ,Overweight ,Body Mass Index ,Cohort Studies ,0302 clinical medicine ,Weight loss ,Risk Factors ,Neoplasms ,Prospective Studies ,Correlation of Data ,2. Zero hunger ,Ovarian Neoplasms ,Obstetrics ,Hazard ratio ,PROLIFERATION ,WOMEN ,weight gain ,Middle Aged ,Kidney Neoplasms ,3. Good health ,European Prospective Investigation into Cancer and Nutrition ,BMI change ,Europe ,Oncology ,030220 oncology & carcinogenesis ,ddc:540 ,Female ,SQUAMOUS-CELL CARCINOMA ,medicine.symptom ,Life Sciences & Biomedicine ,EXPRESSION ,medicine.medical_specialty ,Breast Neoplasms ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,03 medical and health sciences ,LEPTIN ,FATNESS ,medicine ,Humans ,cancer ,1112 Oncology and Carcinogenesis ,Oncology & Carcinogenesis ,Obesity ,Risk factor ,Proportional Hazards Models ,Cancer och onkologi ,Science & Technology ,business.industry ,Weight change ,Endometrial Neoplasms ,BODY-MASS INDEX ,ESTROGEN-RECEPTORS ,Pancreatic Neoplasms ,Nutrition Assessment ,Cancer and Oncology ,Institut für Ernährungswissenschaft ,GAIN ,weight loss ,business ,Weight gain ,Body mass index - Abstract
International audience; Obesity is a risk factor for several major cancers. Associations of weight change in middle adulthood with cancer risk, however, are less clear. We examined the association of change in weight and body mass index (BMI) category during middle adulthood with 42 cancers, using multivariable Cox proportional hazards models in the European Prospective Investigation into Cancer and Nutrition cohort. Of 241 323 participants (31% men), 20% lost and 32% gained weight (>0.4 to 5.0 kg/year) during 6.9 years (average). During 8.0 years of follow-up after the second weight assessment, 20 960 incident cancers were ascertained. Independent of baseline BMI, weight gain (per one kg/year increment) was positively associated with cancer of the corpus uteri (hazard ratio [HR] = 1.14; 95% confidence interval: 1.05-1.23). Compared to stable weight (±0.4 kg/year), weight gain (>0.4 to 5.0 kg/year) was positively associated with cancers of the gallbladder and bile ducts (HR = 1.41; 1.01-1.96), postmenopausal breast (HR = 1.08; 1.00-1.16) and thyroid (HR = 1.40; 1.04-1.90). Compared to maintaining normal weight, maintaining overweight or obese BMI (World Health Organisation categories) was positively associated with most obesity-related cancers. Compared to maintaining the baseline BMI category, weight gain to a higher BMI category was positively associated with cancers of the postmenopausal breast (HR = 1.19; 1.06-1.33), ovary (HR = 1.40; 1.04-1.91), corpus uteri (HR = 1.42; 1.06-1.91), kidney (HR = 1.80; 1.20-2.68) and pancreas in men (HR = 1.81; 1.11-2.95). Losing weight to a lower BMI category, however, was inversely associated with cancers of the corpus uteri (HR = 0.40; 0.23-0.69) and colon (HR = 0.69; 0.52-0.92). Our findings support avoiding weight gain and encouraging weight loss in middle adulthood.
- Published
- 2021
34. Food biodiversity and total and cause-specific mortality in 9 European countries:An analysis of a prospective cohort study
- Author
-
Kris A. Murray, Stina Ramne, Carl Lachat, Jytte Halkjær, Giovanna Masala, H. Bas Bueno-de-Mesquita, Stina Bodén, Torkjel M. Sandanger, Christina C. Dahm, Matthias B. Schulze, Pietro Ferrari, Heinz Freisling, Marc J. Gunter, Paula Jakszyn, Paolo Vineis, Franziska Jannasch, Miguel Rodríguez-Barranco, Yvonne T. van der Schouw, Eva Ardanaz, Andrew D. Jones, Inge Huybrechts, Verena Katzke, Gina Kennedy, Konstantinos K. Tsilidis, Salvatore Panico, Mathilde Touvier, Lluís Cirera, Ingegerd Johansson, Anne Tjønneland, Roseline Remans, Christopher Millett, Elisabete Weiderpass, Elio Riboli, Rosario Tumino, Giles Hanley-Cook, Geneviève Nicolas, Carine Biessy, Mélanie Deschasaux-Tanguy, Carlotta Sacerdote, Alemayehu Argaw, Bernard Srour, Guri Skeie, Emmanuelle Kesse-Guyot, Corinne Casagrande, Daniel B Ibsen, and Giuliana Gargano
- Subjects
Male ,Mediterranean diet ,DIVERSITY ,Comorbidity ,GUIDELINES ,Geographical Locations ,Cause of Death ,Medicine and Health Sciences ,Medicine ,Prospective Studies ,Prospective cohort study ,11 Medical and Health Sciences ,RISK ,Nutrition and Dietetics ,Ecology ,Mortality rate ,Hazard ratio ,General Medicine ,Biodiversity ,Middle Aged ,Micronutrient ,CANCER ,European Prospective Investigation into Cancer and Nutrition ,Näringslära ,MEDITERRANEAN DIET ,Europe ,Oncology ,Cohort ,Marital status ,Female ,HEALTH ,Life Sciences & Biomedicine ,Research Article ,Adult ,Ecological Metrics ,Death Rates ,ENVIRONMENTAL IMPACTS ,Beverages ,Medicine, General & Internal ,Comorbiditat ,Population Metrics ,General & Internal Medicine ,Humans ,CORONARY-HEART-DISEASE ,Mortality ,Nutrició ,Proportional Hazards Models ,Nutrition ,Science & Technology ,Population Biology ,business.industry ,Ecology and Environmental Sciences ,Biology and Life Sciences ,Cancers and Neoplasms ,CONSUMPTION ,Species Diversity ,Biodiversitat ,Diet ,Food ,Multivariate Analysis ,People and Places ,business ,Demography - Abstract
Background Food biodiversity, encompassing the variety of plants, animals, and other organisms consumed as food and drink, has intrinsic potential to underpin diverse, nutritious diets and improve Earth system resilience. Dietary species richness (DSR), which is recommended as a crosscutting measure of food biodiversity, has been positively associated with the micronutrient adequacy of diets in women and young children in low- and middle-income countries (LMICs). However, the relationships between DSR and major health outcomes have yet to be assessed in any population. Methods and findings We examined the associations between DSR and subsequent total and cause-specific mortality among 451,390 adults enrolled in the European Prospective Investigation into Cancer and Nutrition (EPIC) study (1992 to 2014, median follow-up: 17 years), free of cancer, diabetes, heart attack, or stroke at baseline. Usual dietary intakes were assessed at recruitment with country-specific dietary questionnaires (DQs). DSR of an individual’s yearly diet was calculated based on the absolute number of unique biological species in each (composite) food and drink. Associations were assessed by fitting multivariable-adjusted Cox proportional hazards regression models. In the EPIC cohort, 2 crops (common wheat and potato) and 2 animal species (cow and pig) accounted for approximately 45% of self-reported total dietary energy intake [median (P10–P90): 68 (40 to 83) species consumed per year]. Overall, higher DSR was inversely associated with all-cause mortality rate. Hazard ratios (HRs) and 95% confidence intervals (CIs) comparing total mortality in the second, third, fourth, and fifth (highest) quintiles (Qs) of DSR to the first (lowest) Q indicate significant inverse associations, after stratification by sex, age, and study center and adjustment for smoking status, educational level, marital status, physical activity, alcohol intake, and total energy intake, Mediterranean diet score, red and processed meat intake, and fiber intake [HR (95% CI): 0.91 (0.88 to 0.94), 0.80 (0.76 to 0.83), 0.69 (0.66 to 0.72), and 0.63 (0.59 to 0.66), respectively; PWald < 0.001 for trend]. Absolute death rates among participants in the highest and lowest fifth of DSR were 65.4 and 69.3 cases/10,000 person-years, respectively. Significant inverse associations were also observed between DSR and deaths due to cancer, heart disease, digestive disease, and respiratory disease. An important study limitation is that our findings were based on an observational cohort using self-reported dietary data obtained through single baseline food frequency questionnaires (FFQs); thus, exposure misclassification and residual confounding cannot be ruled out. Conclusions In this large Pan-European cohort, higher DSR was inversely associated with total and cause-specific mortality, independent of sociodemographic, lifestyle, and other known dietary risk factors. Our findings support the potential of food (species) biodiversity as a guiding principle of sustainable dietary recommendations and food-based dietary guidelines., Dr. Giles T. Hanley-Cook and colleagues, analyzed data from a prospective cohort study to investigate the association between food biodiversity, and total and cause-specific mortality in nine European countries., Author summary Why was this study done? Facilitating populations to transition to diets that are both nutritious and sustainable is a key challenge for human and environmental health. Dietary (between food group) diversity is increasingly advocated within the framework of dietary recommendations and food-based dietary guidelines. Food biodiversity, defined as the variety of plants, animals, and other organisms that are consumed between and within food groups globally, is a potential lever for improved public and planetary health. Nevertheless, scientific evidence is a prerequisite to understand the associations between metrics of food biodiversity and major health outcomes. Thus far, evidence regarding the positive association between dietary species richness (DSR), i.e., the absolute number of unique species consumed by an individual, and micronutrient adequacy of diets is limited to low- and middle-income countries (LMICs). What did the researchers do and find? This study assessed the relationships between DSR and all-cause and cause-specific mortality in the large and diverse European population that constitutes the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, including 451,390 adults from 9 European countries with 46,627 recorded deaths between 1992 and 2014. In addition, this study provides a picture of the usual consumption of food and beverage species across 9 European countries. Higher DSR was inversely associated with total mortality rate and cause-specific deaths due to cancer, heart disease, respiratory disease, and digestive disease, independent of other established components of diet quality. Overall, self-reported total energy intake was derived from a narrow range of species. What do these findings mean? Our findings add to the evidence base on the relevance of food biodiversity, both between and within food groups, as a basis for public health strategies championing dietary (species) diversity in European countries. These findings will play a key role in communications about the merits of biodiversity stewardship, in the context of ongoing European/global debate on nutritious and sustainable diets for a stable Earth system.
- Published
- 2021
35. Association between anthropometry and lifestyle factors and risk of B cell lymphoma: an exposome wide analysis
- Author
-
Anne Tjønneland, Claudia Agnoli, Pietro Ferrari, Pilar Amiano, Bas Bueno-de-Mesquita, Miguel Rodríguez-Barranco, Alexandra Nieters, Aurelio Barricarte, Roel Vermeulen, Elisabete Weiderpass, Giovanna Masala, José María Huerta, Marta Solans, Delphine Casabonne, Federico Canzian, Caroline Besson, Florentin Späth, Gianluca Severi, Carlotta Sacerdote, James McKay, Catalina Bonet, Sabine Naudin, Fatemeh Saberi Hosnijeh, Sofia Christakoudi, Heinz Freisling, Rosario Tumino, Kristin Benjaminsen Borch, Rudolf Kaaks, Matthias B. Schulze, Yolanda Benavente, Anja Olsen, Charlotta Rylander, Anika Knuppel, Marie Christine Boutron Ruault, Mats Jerkeman, Immunology, Centre international de Recherche sur le Cancer (CIRC), Institut Gustave Roussy (IGR), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Mode de vie, génétique et santé : études intégratives et transgénérationnelles (U1018 (Équipe 9)), Institut Gustave Roussy (IGR)-Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), 179 2017SGR1085 Kræftens Bekæmpelse, DCS German Cancer Research Center, DKFZ Centre International de Recherche sur le Cancer, CIRC Wellcome Trust, WT: 205212/Z/16/Z National Research Council, NRC Medical Research Council, MRC: MR/M012190/1 Cancer Research UK, CRUK: 14136, C570/A11692, C570/A16491 World Cancer Research Fund, WCRF European Commission, EC Institut National de la Santé et de la Recherche Médicale, Inserm Bundesministerium für Bildung und Forschung, BMBF: 01EO1303 Cancerfonden Ministerie van Volksgezondheid, Welzijn en Sport, VWS Agència de Gestió d'Ajuts Universitaris i de Recerca, AGAUR Ligue Contre le Cancer Vetenskapsrådet, VR NordForsk Associazione Italiana per la Ricerca sul Cancro, AIRC Deutsche Krebshilfe Institut Gustave-Roussy Mutuelle Générale de l'Education Nationale, MGEN European Regional Development Fund, ERDF: ERC2009‐AdG 232997, PI13/00061, PI13/01162, PI14/01219, PI17/01280 Hellenic Health Foundation, HHF, Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), CERCA Programme/Generalitat de Catalunya for institutional support, Grant/Award Number: 2017SGR1085, Associazione Italiana per la Ricerca sul Cancro‐AIRC‐Italy and National Research Council (Italy), Cancer Research UK, Grant/Award Numbers: 14136 (to EPIC‐Norfolk), C570/A11692, C570/A16491, Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), (Spain), Danish Cancer Society (Denmark), TRANSCAN/Dutch Cancer Society, Grant/Award Number: 179, NOVEL consortium, Dutch Ministry of Public Health, Welfare and Sports (VWS), Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), European Commission (DG‐SANCO), Federal Ministry of Education and Research (BMBF), German Cancer Aid, German Cancer Research Center (DKFZ), German Federal Ministry of Education and Research, Grant/Award Number: BMBF 01EO1303, German Institute of Human Nutrition Potsdam‐Rehbruecke, Nuthetal (Germany), Institut Gustave Roussy, Institut National de la Sante et de la Recherche Medicale (France), International Agency for Research on Cancer, Ligue Natinale Contre le Cancer, LK Research Funds, Medical Research Council, Grant/Award Numbers: 1000143 (to EPIC‐Norfolk), MR/M012190/1 (to EPIC‐Oxford), Mutuelle Generale de l'Education Nationale, Netherlands Cancer Registry (NKR), Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway), Spanish Ministry of Economy and Competitiveness ‐ Carlos III Institute of Health cofunded by FEDER funds/European Regional Develpment Fund (ERDF) ‐ a way to build Europe, Grant/Award Numbers: PI13/00061 (to Granada), PI13/01162 (to EPIC‐Murcia), PI17/01280, PI14/01219 (to Barcelona), Statistics Netherlands (The Netherlands), Grant/Award Number: Grant number: ERC2009‐AdG 232997, Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Vasterbotten (Sweden), the Hellenic Health Foundation (Greece), Wellcome Trust, Grant/Award Number: 205212/Z/16/Z, and World Cancer Research Fund (WCRF) Funding information
- Subjects
Oncology ,Male ,Limfomes ,Cancer Research ,Lymphoma ,Follicular lymphoma ,Cohort Studies ,0302 clinical medicine ,Risk Factors ,Prospective Studies ,Càncer ,Prospective cohort study ,B-cell lymphoma ,Cancer ,2. Zero hunger ,wide association study ,VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801 ,Anthropometry ,exposome wide association study ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,Plasma cell neoplasm ,Middle Aged ,exposome‐ ,CANCER ,3. Good health ,European Prospective Investigation into Cancer and Nutrition ,exposome‐ ,MEDITERRANEAN DIET ,030220 oncology & carcinogenesis ,OBESITY ,Lymphomas ,Female ,SMOKING ,NON-HODGKIN-LYMPHOMA ,Life Sciences & Biomedicine ,Cancer Epidemiology ,prospective study ,NATIONAL-HEALTH ,medicine.medical_specialty ,Inverse Association ,lifestyle ,Lymphoma, B-Cell ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,lymphoma ,exposome‐wide association study ,exposome ,DIETARY-FAT ,03 medical and health sciences ,SDG 3 - Good Health and Well-being ,Internal medicine ,medicine ,Humans ,1112 Oncology and Carcinogenesis ,Oncology & Carcinogenesis ,VALIDITY ,Life Style ,Cancer och onkologi ,Science & Technology ,Proportional hazards model ,business.industry ,medicine.disease ,exposome-wide association study ,PHYSICAL-ACTIVITY ,PROSPECTIVE COHORT ,Cancer and Oncology ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801 ,business - Abstract
To better understand the role of individual and lifestyle factors in human disease, an exposome‐wide association study was performed to investigate within a single‐study anthropometry measures and lifestyle factors previously associated with B‐cell lymphoma (BCL). Within the European Prospective Investigation into Cancer and nutrition study, 2402 incident BCL cases were diagnosed from 475 426 participants that were followed‐up on average 14 years. Standard and penalized Cox regression models as well as principal component analysis (PCA) were used to evaluate 84 exposures in relation to BCL risk. Standard and penalized Cox regression models showed a positive association between anthropometric measures and BCL and multiple myeloma/plasma cell neoplasm (MM). The penalized Cox models additionally showed the association between several exposures from categories of physical activity, smoking status, medical history, socioeconomic position, diet and BCL and/or the subtypes. PCAs confirmed the individual associations but also showed additional observations. The PC5 including anthropometry, was positively associated with BCL, diffuse large B‐cell lymphoma (DLBCL) and MM. There was a significant positive association between consumption of sugar and confectionary (PC11) and follicular lymphoma risk, and an inverse association between fish and shellfish and Vitamin D (PC15) and DLBCL risk. The PC1 including features of the Mediterranean diet and diet with lower inflammatory score showed an inverse association with BCL risk, while the PC7, including dairy, was positively associated with BCL and DLBCL risk. Physical activity (PC10) was positively associated with DLBCL risk among women. This study provided informative insights on the etiology of BCL., What's new? The “exposome” includes all non‐genetic exposures (e.g. diet, viral, environmental, etc.), with the goal of understanding how those exposures may affect an individual's health. In this study, the authors used a technique called “EWAS” (exposome‐wide association study) to identify multiple factors that are associated with B‐cell lymphoma (BCL) risk. Their results confirm both previously reported risk factors and protective factors. In addition, they identify several previously unknown associations. These new insights, gained via the analysis of multiple exposures, suggest that traditional single‐factor approaches may be suboptimal compared with an EWAS approach.
- Published
- 2020
36. Stochastic Epigenetic Mutations Are Associated with Risk of Breast Cancer, Lung Cancer, and Mature B-cell Neoplasms
- Author
-
Graham G. Giles, Salvatore Panico, Rosario Tumino, Giovanni Fiorito, Torkjel M. Sandanger, Sonia Tarallo, Vittorio Krogh, Melissa C. Southey, Domenico Palli, Pierre Antoine Dugué, Gianluca Severi, Amedeo Gagliardi, Daniel F. Schmidt, Paolo Vineis, Silvia Polidoro, Therese Haugdahl Nøst, Nicole Wong Doo, Dallas R. English, Roger L. Milne, Carlotta Sacerdote, Laura Baglietto, Allison M. Hodge, Daniel D. Buchanan, Luigia Pace, Barbara Pardini, Eiliv Lund, Enes Makalic, Alessio Naccarati, and John L. Hopper
- Subjects
0301 basic medicine ,Oncology ,Male ,medicine.medical_specialty ,Lung Neoplasms ,Lymphoma ,Epidemiology ,Breast Neoplasms ,Epigenesis, Genetic ,Female ,Humans ,Lymphoma, Large B-Cell, Diffuse ,Middle Aged ,Mutation ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Genetic ,Internal medicine ,medicine ,Large B-Cell ,Neoplasm ,Epigenetics ,Lung cancer ,business.industry ,VDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762 ,Cancer ,medicine.disease ,Diffuse ,3. Good health ,VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762 ,030104 developmental biology ,CpG site ,030220 oncology & carcinogenesis ,DNA methylation ,Biomarker (medicine) ,business ,Epigenesis - Abstract
Background: Age-related epigenetic dysregulations are associated with several diseases, including cancer. The number of stochastic epigenetic mutations (SEM) has been suggested as a biomarker of life-course accumulation of exposure-related DNA damage; however, the predictive role of SEMs in cancer has seldom been investigated. Methods: A SEM, at a given CpG site, was defined as an extreme outlier of DNA methylation value distribution across individuals. We investigated the association of the total number of SEMs with the risk of eight cancers in 4,497 case–control pairs nested in three prospective cohorts. Furthermore, we investigated whether SEMs were randomly distributed across the genome or enriched in functional genomic regions. Results: In the three-study meta-analysis, the estimated ORs per one-unit increase in log(SEM) from logistic regression models adjusted for age and cancer risk factors were 1.25; 95% confidence interval (CI), 1.11–1.41 for breast cancer, and 1.23; 95% CI, 1.07–1.42 for lung cancer. In the Melbourne Collaborative Cohort Study, the OR for mature B-cell neoplasm was 1.46; 95% CI, 1.25–1.71. Enrichment analyses indicated that SEMs frequently occur in silenced genomic regions and in transcription factor binding sites regulated by EZH2 and SUZ12 (P < 0.0001 and P = 0.0005, respectively): two components of the polycomb repressive complex 2 (PCR2). Finally, we showed that PCR2-specific SEMs are generally more stable over time compared with SEMs occurring in the whole genome. Conclusions: The number of SEMs is associated with a higher risk of different cancers in prediagnostic blood samples. Impact: We identified a candidate biomarker for cancer early detection, and we described a carcinogenesis mechanism involving PCR2 complex proteins worthy of further investigations.
- Published
- 2020
37. Small Non-Coding RNA Profiling in Plasma Extracellular Vesicles of Bladder Cancer Patients by Next-Generation Sequencing: Expression Levels of miR-126-3p and piR-5936 Increase with Higher Histologic Grades
- Author
-
Giovanni Birolo, Alessio Naccarati, Paolo Vineis, Serena Aneli, Marco Oderda, Mihnea P. Dragomir, Barbara Pardini, Giuseppe Matullo, Marco Allasia, Paolo Gontero, Alexandru A Sabo, Carlotta Sacerdote, and Alessandra Allione
- Subjects
0301 basic medicine ,Cancer Research ,small non-coding RNA profiling ,non-invasive biomarkers ,Urinary system ,Urine ,lcsh:RC254-282 ,DNA sequencing ,Article ,Andrology ,03 medical and health sciences ,0302 clinical medicine ,microRNA ,Medicine ,Liquid biopsy ,Bladder cancer ,Extracellular vesicles ,MicroRNAs ,Next-generation sequencing ,Non-invasive biomarkers ,PiRNAs ,Small non-coding RNA profiling ,liquid biopsy ,business.industry ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Non-coding RNA ,medicine.disease ,Cystoscopies ,microRNAs ,030104 developmental biology ,Oncology ,piRNAs ,030220 oncology & carcinogenesis ,bladder cancer ,next-generation sequencing ,business ,extracellular vesicles - Abstract
Bladder cancer (BC) is the tenth most frequent cancer worldwide. Due to the need for recurrent cystoscopies and the lack of non-invasive biomarkers, BC is associated with a high management burden. In this respect, small non-coding RNAs (sncRNAs) have been investigated in urine as possible biomarkers for BC, but in plasma their potential has not yet been defined. The expression levels of sncRNAs contained in plasma extracellular vesicles (EVs) from 47 men with BC and 46 healthy controls were assessed by next-generation sequencing. The sncRNA profiles were compared with urinary profiles from the same subjects. miR-4508 resulted downregulated in plasma EVs of muscle-invasive BC patients, compared to controls (adj-p = 0.04). In World Health Organization (WHO) grade 3 (G3) BC, miR-126-3p was upregulated both in plasma EVs and urine, when compared to controls (for both, adj-p <, 0.05). Interestingly, two sncRNAs were associated with the risk class: miR-4508 with a downward trend going from controls to high risk BC, and piR-hsa-5936 with an upward trend (adj-p = 0.04 and adj-p = 0.05, respectively). Additionally, BC cases with low expression of miR-185-5p and miR-106a-5p or high expression of miR-10b-5p showed shorter survival (adj-p = 0.0013, adj-p = 0.039 and adj-p = 0.047, respectively). SncRNAs from plasma EVs could be diagnostic biomarkers for BC, especially in advanced grade.
- Published
- 2020
38. An application of the Toronto Childhood Cancer Stage Guidelines in three population‐based cancer registries: The case of central nervous tumors
- Author
-
Sabrina Fabiano, Gemma Gatta, Daniela Alessi, Milena Maule, Fabio Savoia, Giovanna Tagliabue, Anna D’Agostino, Francesco Vetrano, Carlotta Sacerdote, Franco Merletti, Patrizia Piga, Marcella Sessa, and Maria Luisa Mosso
- Subjects
Adult ,Male ,Ependymoma ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Population ,Disease ,Central Nervous System Neoplasms ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,staging system ,cancer registry ,childhood cancer ,Humans ,Medicine ,Registries ,Stage (cooking) ,Young adult ,Preschool ,Child ,education ,Survival rate ,Data Management ,Neoplasm Staging ,education.field_of_study ,business.industry ,Infant, Newborn ,Infant ,Cancer ,Hematology ,central nervous cancers ,Newborn ,Prognosis ,medicine.disease ,Cancer registry ,Survival Rate ,Oncology ,Child, Preschool ,030220 oncology & carcinogenesis ,Female ,Follow-Up Studies ,Practice Guidelines as Topic ,SEER Program ,Pediatrics, Perinatology and Child Health ,business ,030215 immunology - Abstract
Background Cancer stage is a determinant of survival of childhood central nervous system (CNS) cancers and could help the interpretation of survival variability among countries. Consensus guidelines to stage childhood malignancies in population cancer registries ("Toronto Childhood Cancer Stage Guidelines") have been recently proposed with the goal of data comparability. Indeed, stage is not systematically recorded in all registries and, when it is, different classification systems are used. We applied the Toronto Childhood Cancer Stage Guidelines to CNS cancer cases of three population-based cancer registries with the aim of evaluating the feasibility of staging this type of cancer and the critical points in the classification of CNS tumors. Procedures The Toronto Childhood Cancer Stage Guidelines were applied to 175 CNS patients, diagnosed from January 1, 2002 to December 31, 2014 in three cancer registries in Italy, and the percentage of cases that could be staged was assessed. Results One hundred eight of 126 (86%) medulloblastomas and other embryonal CNS cancers and 22 of 49 (45%) ependymomas were staged. Using these guidelines, survival of children with localized tumors could be discriminated from that of children with metastatic disease. Conclusions The use of the Toronto Childhood Cancer Stage Guidelines is feasible for staging medulloblastoma in Italian population-based cancer registries, whereas it is more difficult for ependymomas. In Italy, cerebrospinal fluid examination, one of the decisive tests to stage CNS tumors, is not routinely performed as a first-line diagnosis procedure in ependymoma pediatric patients. A similar exercise by a larger number of cancer registries in different countries could suggest improvements in the childhood cancer staging system.
- Published
- 2020
39. Serum levels of hsa‐miR‐16‐5p , hsa‐miR‐29a‐3p , hsa‐miR‐150‐5p , hsa‐miR‐155‐5p and hsa‐miR ‐ 223‐3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study
- Author
-
Heiner Boeing, María Arestin, Aurelio Barricarte, Delphine Casabonne, Elio Riboli, Roel Vermeulen, Carlo La Vecchia, Alexandra Nieters, Federico Canzian, Julie A. Schmidt, Matthias B. Schulze, María Armesto, Rosario Tumino, Yolanda Benavente, Rudolf Kaaks, Salvatore Panico, María José Sánchez, Anna Karakatsani, Pilar Amiano, Caroline Besson, Marc J. Gunter, Giovanna Masala, Carlotta Sacerdote, María Dolores Chirlaque, Silvia de Sanjosé, Valeria Pala, Anne Tjønneland, Charles H. Lawrie, Antonia Trichopoulou, Elisabete Weiderpass, Eric J. Duell, Fatemeh Saberi Hosnijeh, Anja Olsen, Vittorio Perduca, Julia Seifert, Francesca Mancini, Laura Costas, CIBER de Epidemiología y Salud Pública (CIBERESP), Catalan Institute of Oncology (ICO-IDIBELL), Facultat de Medicina [Barcelona], Centre Hospitalier de Versailles André Mignot (CHV), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut Gustave Roussy (IGR), Épidémiologie des radiations, épidémiologie clinique des cancers et survie (U1018 (Équipe 3) ), Institut Gustave Roussy (IGR)-Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Unit of Nutrition, Environment, and Cancer, Catalan Institute of Oncology, Department of Community Medicine, Faculty of Health Sciences, The Arctic University of Norway (UiT), Cancer Risk Factors and LifeStyle Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Division of Cancer Epidemiology, German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Department of Cancer Epidemiology, Mathématiques Appliquées Paris 5 (MAP5 - UMR 8145), Université Paris Descartes - Paris 5 (UPD5)-Institut National des Sciences Mathématiques et de leurs Interactions (INSMI)-Centre National de la Recherche Scientifique (CNRS), Mode de vie, génétique et santé : études intégratives et transgénérationnelles (U1018 (Équipe 9)), Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale Tumori - National Cancer Institute [Milan], WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Dept of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School [Athens]-University of Athens Medical School [Athens], Hellenic Health Foundation, Department of Clinical Sciences and Community Health [Milan, Italy], Università degli Studi di Milano [Milano] (UNIMI), Civile - M.P.Arezzo Hospital, Nutrition and Metabolism Section, International Agency for Research on Cancer, Department of Clinical and Experimental Medicine, Università degli studi di Napoli Federico II, CPO Piemonte, Department of Epidemiology, German Institute of Human Nutrition (DIfE), German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), School of Public Health [London, UK] (Faculty of Medicine), Imperial College London, Danish Cancer Society Research Center, Danish Cancer Society, Division of Environmental Epidemiology, Utrecht University [Utrecht]-Institute of Risk Assessment Sciences, Center for Chronic Immunodeficiency (CCI), University Medical Center Freiburg, Freiburg, Germany, IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, and Immunology
- Subjects
Oncology ,Male ,DOWN-REGULATION ,Cancer Research ,PROGNOSIS ,Chronic lymphocytic leukemia ,ACTIVATION ,0302 clinical medicine ,mir-223 ,Odds Ratio ,Prospective Studies ,Prospective cohort study ,ComputingMilieux_MISCELLANEOUS ,Area under the curve ,Middle Aged ,MIR-155 ,3. Good health ,European Prospective Investigation into Cancer and Nutrition ,Up-Regulation ,Europe ,DIFFERENTIATION ,INFECTIONS ,030220 oncology & carcinogenesis ,embryonic structures ,Monoclonal B-cell lymphocytosis ,Female ,B-CELL LYMPHOCYTOSIS ,Life Sciences & Biomedicine ,prospective study ,EXPRESSION ,medicine.medical_specialty ,MICRORNA SIGNATURE ,miR-155 ,03 medical and health sciences ,Predictive Value of Tests ,Internal medicine ,medicine ,Biomarkers, Tumor ,Humans ,1112 Oncology and Carcinogenesis ,Oncology & Carcinogenesis ,Liquid biopsy ,Science & Technology ,business.industry ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,body regions ,circulating miRNA ,MicroRNAs ,Case-Control Studies ,chronic lymphocytic leukemia ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business ,serum ,CLL - Abstract
Chronic lymphocytic leukemia (CLL) is an incurable disease accounting for almost one-third of leukemias in the Western world. Aberrant expression of microRNAs (miRNAs) is a well-established characteristic of CLL, and the robust nature of miRNAs makes them eminently suitable liquid biopsy biomarkers. Using a nested case–control study within the European Prospective Investigation into Cancer and Nutrition (EPIC), the predictive values of five promising human miRNAs (hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p), identified in a pilot study, were examined in serum of 224 CLL cases (diagnosed 3 months to 18 years after enrollment) and 224 matched controls using Taqman based assays. Conditional logistic regressions were applied to adjust for potential confounders. The median time from blood collection to CLL diagnosis was 10 years (p25–p75: 7–13 years). Overall, the upregulation of hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-29a-3p was associated with subsequent risk of CLL [OR1∆Ct-unit increase (95%CI) = 1.42 (1.18–1.72), 1.64 (1.31–2.04) and 1.75 (1.31–2.34) for hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-29a-3p, respectively] and the strongest associations were observed within 10 years of diagnosis. However, the predictive performance of these miRNAs was modest (area under the curve
- Published
- 2020
40. Adult weight change and premenopausal breast cancer risk: a prospective pooled analysis of data from 628,463 women
- Author
-
Graham G. Giles, A. Heather Eliassen, Marie-Christine Boutron-Ruault, Kala Visvanathan, Kimberly A. Bertrand, Susan E. Hankinson, Yu Chen, Timothy J. Key, Minouk J. Schoemaker, Thomas E. Rohan, Walter C. Willett, Kotaro Ozasa, Antonia Trichopoulou, Laura Baglietto, Anne Zeleniuch-Jacquotte, Inger T. Gram, Atsuko Sadakane, Giske Ursin, Huiyan Ma, Laure Dossus, Dale P. Sandler, Elisabete Weiderpass, Victoria A. Kirsh, Malin Sund, Martha S. Linet, Hans-Olov Adami, Julie R. Palmer, Roger L. Milne, Rudolf Kaaks, Susanna C. Larsson, Lauren B. Wright, Avonne E. Connor, Carlotta Sacerdote, Hazel B. Nichols, Cari M. Kitahara, Anthony J. Swerdlow, Katie M. O'Brien, Mark N. Brook, Michael Jones, Leslie Bernstein, Alicja Wolk, Rulla M. Tamimi, and Elio Riboli
- Subjects
Adult ,Risk ,Oncology ,Cancer Research ,medicine.medical_specialty ,Adolescent ,premenopause ,Body size ,Weight Gain ,Affect (psychology) ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,cohort studies ,Internal medicine ,breast neoplasms ,medicine ,Humans ,body weight changes ,risk factors ,skin and connective tissue diseases ,Cancer och onkologi ,VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801 ,business.industry ,Body Weight ,Weight change ,Age Factors ,Middle Aged ,3. Good health ,Pooled analysis ,Receptors, Estrogen ,Cancer and Oncology ,030220 oncology & carcinogenesis ,Premenopausal breast cancer ,Female ,sense organs ,VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801 ,business ,Cancer Epidemiology ,Cohort study - Abstract
Early‐adulthood body size is strongly inversely associated with risk of premenopausal breast cancer. It is unclear whether subsequent changes in weight affect risk. We pooled individual‐level data from 17 prospective studies to investigate the association of weight change with premenopausal breast cancer risk, considering strata of initial weight, timing of weight change, other breast cancer risk factors and breast cancer subtype. Hazard ratios (HR) and 95% confidence intervals (CI) were obtained using Cox regression. Among 628,463 women, 10,886 were diagnosed with breast cancer before menopause. Models adjusted for initial weight at ages 18–24 years and other breast cancer risk factors showed that weight gain from ages 18–24 to 35–44 or to 45–54 years was inversely associated with breast cancer overall (e.g., HR per 5 kg to ages 45–54: 0.96, 95% CI: 0.95–0.98) and with oestrogen‐receptor(ER)‐positive breast cancer (HR per 5 kg to ages 45–54: 0.96, 95% CI: 0.94–0.98). Weight gain from ages 25–34 was inversely associated with ER‐positive breast cancer only and weight gain from ages 35–44 was not associated with risk. None of these weight gains were associated with ER‐negative breast cancer. Weight loss was not consistently associated with overall or ER‐specific risk after adjusting for initial weight. Weight increase from early‐adulthood to ages 45–54 years is associated with a reduced premenopausal breast cancer risk independently of early‐adulthood weight. Biological explanations are needed to account for these two separate factors., What's new? Body weight in childhood and early adulthood plays a key role in determining premenopausal breast cancer risk but little is conclusively known about how subsequent weight changes affect this risk. Here the authors pooled results from existing studies on weight changes and breast cancer risk including more than 600,000 premenopausal women. The results show that weight gain >10–15 kg from early adulthood on lowers the risk of developing premenopausal breast cancer, providing further evidence of body weight as an important determinant of breast cancer risk.
- Published
- 2020
41. Citrus intake and risk of skin cancer in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC)
- Author
-
Christina Lasheras, Kim Overvad, Verena Katzke, Domenico Palli, Marina Kvaskoff, Saverio Caini, Pilar Amiano, Emily Sonestedt, Sara Grioni, Aurora Perez-Cornago, Anja Olsen, Augustin Scalbert, Anne Tjønneland, Christina C. Dahm, Elisabete Weiderpass, Guri Skeie, Tilman Kühn, Eleni Peppa, Matthias B. Schulze, Marie Al-Rahmoun, Marit B. Veierød, Carlotta Sacerdote, Reza Ghiasvand, Paula Jakszyn, Francesca Mancini, Antonia Trichopoulou, Marie-Christine Boutron-Ruault, Miguel Rodríguez-Barranco, Salvatore Panico, Iris Cervenka, Fulvio Ricceri, Ana Ezponda, Rosario Tumino, Edoardo Botteri, Gianluca Severi, Carlo La Vecchia, Yahya Mahamat-Saleh, and Sandra Colorado-Yohar
- Subjects
Oncology ,Adult ,Keratinocytes ,Male ,medicine.medical_specialty ,Citrus ,Skin Neoplasms ,Epidemiology ,Nutritional Status ,030204 cardiovascular system & hematology ,Risk Assessment ,VDP::Medical disciplines: 700::Health sciences: 800::Nutrition: 811 ,VDP::Medisinske Fag: 700::Helsefag: 800::Ernæring: 811 ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Basal cell carcinoma ,030212 general & internal medicine ,Prospective cohort study ,Melanoma ,Aged ,business.industry ,VDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762 ,Hazard ratio ,Middle Aged ,Keratinocyte cancers ,medicine.disease ,European Prospective Investigation into Cancer and Nutrition ,VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762 ,Europe ,Cohort studies ,Cutaneous melanoma ,Female ,Cohort ,Skin cancer ,business ,Cohort study - Abstract
Citrus intake has been suggested to increase the risk of skin cancer. Although this relation is highly plausible biologically, epidemiologic evidence is lacking. We aimed to examine the potential association between citrus intake and skin cancer risk. EPIC is an ongoing multi-center prospective cohort initiated in 1992 and involving ~ 520,000 participants who have been followed-up in 23 centers from 10 European countries. Dietary data were collected at baseline using validated country-specific dietary questionnaires. We used Cox proportional hazards regression models to compute hazard ratios (HR) and 95% confidence intervals (CI). During a mean follow-up of 13.7 years, 8448 skin cancer cases were identified among 270,112 participants. We observed a positive linear dose–response relationship between total citrus intake and skin cancer risk (HR = 1.10, 95% CI 1.03–1.18 in the highest vs. lowest quartile; Ptrend = 0.001), particularly with basal cell carcinoma (BCC) (HR = 1.11, 95% CI 1.02–1.20, Ptrend = 0.007) and squamous cell carcinoma (SCC) (HR = 1.23, 95% CI 1.04–1.47, Ptrend = 0.01). Citrus fruit intake was positively associated with skin cancer risk (HR = 1.08, 95% CI 1.01–1.16, Ptrend = 0.01), particularly with melanoma (HR = 1.23, 95% CI 1.02–1.48; Ptrend = 0.01), although with no heterogeneity across skin cancer types (Phomogeneity = 0.21). Citrus juice was positively associated with skin cancer risk (Ptrend = 0.004), particularly with BCC (Ptrend = 0.008) and SCC (Ptrend = 0.004), but not with melanoma (Phomogeneity = 0.02). Our study suggests moderate positive linear dose–response relationships between citrus intake and skin cancer risk. Studies with available biomarker data and the ability to examine sun exposure behaviors are warranted to clarify these associations and examine the phototoxicity mechanisms of furocoumarin-rich foods.
- Published
- 2020
42. Antibody Responses to Helicobacter pylori and Risk of Developing Colorectal Cancer in a European Cohort
- Author
-
Kristin Benjaminsen Borch, Catherine Dong, Elisabete Weiderpass, Elio Riboli, Antonia Trichopoulou, Rudolf Kaaks, Claudia Agnoli, Michael Pawlita, Franck Carbonnel, Roel Vermeulen, Heiner Boeing, David J. Hughes, Amanda J. Cross, Julia Butt, Bethany Van Guelpen, Liher Imaz, Marc J. Gunter, Semi Zouiouich, José Ramón Quirós, Cecilie Kyrø, Mazda Jenab, Inger T. Gram, Aurora Perez-Cornago, Matthias B. Schulze, Alicia K Heath, Carlotta Sacerdote, Rosario Tumino, Eva Ardanaz, Jin Young Park, Carmen Santiuste, Anna Karakatsani, Domenico Palli, Tim Waterboer, Bas Bueno-de-Mesquita, Anne Tjønneland, Miguel Rodríguez-Barranco, Carlo La Vecchia, Antonio Agudo, Tilman Kühn, Marie-Christine Boutron-Ruault, Salvatore Panico, Sophia Harlid, Centre international de Recherche sur le Cancer (CIRC), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut Gustave Roussy (IGR), Mode de vie, génétique et santé : études intégratives et transgénérationnelles (U1018 (Équipe 9)), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut Gustave Roussy (IGR), and AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,Colorectal cancer ,Epidemiology ,[SDV]Life Sciences [q-bio] ,Gastroenterology ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Medicine ,Humans ,Helicobacter ,Prospective Studies ,Prospective cohort study ,11 Medical and Health Sciences ,biology ,Helicobacter pylori ,business.industry ,Cancer ,Odds ratio ,Middle Aged ,biology.organism_classification ,medicine.disease ,bacterial infections and mycoses ,digestive system diseases ,3. Good health ,European Prospective Investigation into Cancer and Nutrition ,Europe ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Case-Control Studies ,Cohort ,Antibody Formation ,Female ,business ,Colorectal Neoplasms - Abstract
Background: While Helicobacter pylori (H. pylori) is the major cause of gastric cancer, it has also been suggested to be involved in colorectal cancer development. However, prospective studies addressing H. pylori and colorectal cancer are sparse and inconclusive. We assessed the association of antibody responses to H. pylori proteins with colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Methods: We applied H. pylori multiplex serology to measure antibody responses to 13 H. pylori proteins in prediagnostic serum samples from 485 colorectal cancer cases and 485 matched controls nested within the EPIC study. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using multivariable conditional logistic regression to estimate the association of H. pylori overall and protein-specific seropositivity with odds of developing colorectal cancer. Results: Fifty-one percent of colorectal cancer cases were H. pylori seropositive compared with 44% of controls, resulting in an OR of 1.36 (95% CI, 1.00–1.85). Among the 13 individual H. pylori proteins, the association was driven mostly by seropositivity to Helicobacter cysteine-rich protein C (HcpC; OR: 1.66; 95% CI, 1.19–2.30) and Vacuolating cytotoxin A (VacA) (OR: 1.34; 95% CI, 0.99–1.82), the latter being nonstatistically significant only in the fully adjusted model. Conclusions: In this prospective multicenter European study, antibody responses to H. pylori proteins, specifically HcpC and VacA, were associated with an increased risk of developing colorectal cancer. Impact: Biological mechanisms for a potential causal role of H. pylori in colorectal carcinogenesis need to be elucidated, and subsequently whether H. pylori eradication may decrease colorectal cancer incidence.
- Published
- 2020
43. Predicted basal metabolic rate and cancer risk in the European Prospective Investigation into Cancer and Nutrition
- Author
-
Elisabete Weiderpass, Kim Overvad, Giovanna Masala, Guy Fagherazzi, Rudolf Kaaks, Daniel Redondo-Sánchez, Sabina Rinaldi, Ulrica Ericson, Dagfinn Aune, Pilar Amiano, Therese Haugdahl Nøst, Antonia Trichopoulou, Rosario Tumino, Paula Jakszyn, Neil Murphy, Elio Riboli, Tilman Kühn, Francesca Mancini, Heinz Freisling, Bas Bueno-de-Mesquita, Marie-Christine Boutron-Ruault, Maria Santucci de Magistris, Inge Huybrechts, Marc J. Gunter, Carlotta Sacerdote, Nathalie Kliemann, Christina C. Dahm, Vivian Viallon, Vittorio Krogh, Lena Maria Nilsson, Isabel Drake, Anne M. May, Heiner Boeing, Matthias B. Schulze, Carlo La Vecchia, Anne Tjønneland, Anna Karakatsani, Aurelio Barricarte Gurrea, Konstantinos K. Tsilidis, María Dolores Chirlaque, José Ramón Quirós, Centre international de Recherche sur le Cancer (CIRC), Université de Paris-Saclay [Villejuif], Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Deutsche Krebshilfe Cancer Research UK, CRUK: C8221/A19170, 14136, C570/A16491 Ligue Contre le Cancer Bundesministerium für Bildung und Forschung, BMBF Bundesministerium für Bildung und Forschung, BMBF Institut National de la Santé et de la Recherche Médicale, Inserm Kræftens Bekæmpelse, DCS Research Councils UK, RCUK Health and Medical Research Fund, HMRF: FIS Zorginstituut Nederland, ZIN PI13/01162, PI13/00061 World Cancer Research Fund, WCRF: ERC‐2009‐AdG 232997 Associazione Italiana per la Ricerca sul Cancro, AIRC National Research Council, NRC Ecumenical Project for International Cooperation, EPIC Institut National de la Santé et de la Recherche Médicale, Inserm European Commission, EU Centre International de Recherche sur le Cancer, CIRC Norway Deutsches Krebsforschungszentrum, DKFZ: DKFZ World Cancer Research Fund, WCRF Cancerfonden NordForsk Medical Research Council, MRC: MR/M012190/1, 1000143, The authors would like to thank the EPIC study participants and staff for their valuable contribution to this research. The authors would also like to thank Mr Bertrand Hemon for his support in preparing the databases and Dr Joseph Rothwell for his support in creating the figures. The coordination of EPIC is financially supported by the European Commission (DGSANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM, France), German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF, Germany), the Hellenic Health Foundation (Greece), Associazione Italiana per la Ricerca sul Cancro‐AIRC‐Italy and National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), ERC‐2009‐AdG 232997 and Nordforsk, Nordic Centre of Excellence Programme on Food, Nutrition and Health (Norway), Health Research Fund (FIS) of the Spanish Ministry of Health (FIS, PI13/00061 to Granada, PI13/01162 to EPIC‐Murcia), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra and the Catalan Institute of Oncology (Spain), Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden), Cancer Research UK (14136 to EPIC‐Norfolk, C570/A16491 and C8221/A19170 to EPIC‐Oxford), Medical Research Council (1000143 to EPIC‐Norfolk, MR/M012190/1 to EPIC‐Oxford, and United Kingdom).
- Subjects
Oncology ,Adult ,Male ,metabolic disorder ,Cancer Research ,medicine.medical_specialty ,obesity ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Neoplasms ,medicine ,Humans ,cancer ,1112 Oncology and Carcinogenesis ,Oncology & Carcinogenesis ,Prospective Studies ,Risk factor ,Càncer ,Nutrició ,Aged ,Cancer ,Nutrition ,Sex Characteristics ,business.industry ,Incidence (epidemiology) ,Incidence ,Hazard ratio ,Metabolic disorder ,Middle Aged ,medicine.disease ,Obesity ,3. Good health ,European Prospective Investigation into Cancer and Nutrition ,Europe ,Nutrition Assessment ,030220 oncology & carcinogenesis ,Basal metabolic rate ,basal metabolic rate ,Female ,Basal Metabolism ,business - Abstract
Emerging evidence suggests that a metabolic profile associated with obesity may be a more relevant risk factor for some cancers than adiposity per se. Basal metabolic rate (BMR) is an indicator of overall body metabolism and may be a proxy for the impact of a specific metabolic profile on cancer risk. Therefore, we investigated the association of predicted BMR with incidence of 13 obesity-related cancers in the European Prospective Investigation into Cancer and Nutrition (EPIC). BMR at baseline was calculated using the WHO/FAO/UNU equations and the relationships between BMR and cancer risk were investigated using multivariable Cox proportional hazards regression models. A total of 141,295 men and 317,613 women, with a mean follow-up of 14 years were included in the analysis. Overall, higher BMR was associated with a greater risk for most cancers that have been linked with obesity. However, among normal weight participants, higher BMR was associated with elevated risks of esophageal adenocarcinoma (hazard ratio per 1-standard deviation change in BMR [HR 1-SD]: 2.46; 95% CI 1.20; 5.03) and distal colon cancer (HR 1-SD: 1.33; 95% CI 1.001; 1.77) among men and with proximal colon (HR 1-SD: 1.16; 95% CI 1.01; 1.35), pancreatic (HR 1-SD: 1.37; 95% CI 1.13; 1.66), thyroid (HR 1-SD: 1.65; 95% CI 1.33; 2.05), postmenopausal breast (HR 1-SD: 1.17; 95% CI 1.11; 1.22) and endometrial (HR 1-SD: 1.20; 95% CI 1.03; 1.40) cancers in women. These results indicate that higher BMR may be an indicator of a metabolic phenotype associated with risk of certain cancer types, and may be a useful predictor of cancer risk independent of body fatness.
- Published
- 2020
44. Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort
- Author
-
Agnès Fournier, Eva Lundin, N. Charlotte Onland-Moret, Louise Hansen, Elisavet Valanou, Marina Kvaskoff, Leire Gil, Inger T. Gram, Rosario Tumino, Marc J. Gunter, Annika Idahl, Rudolf Kaaks, Noemi Bender, Eric J. Duell, María José Sánchez, Carlotta Sacerdote, Kristian Riesbeck, Sandra González Maldonado, Claudia Agnoli, Anne Tjønneland, Charlotte Le Cornet, Renée T. Fortner, Laure Dossus, Marie-Christine Boutron-Ruault, Elisabete Weiderpass, Antonia Trichopoulou, Amalia Mattiello, José Ramón Quirós, Aurelio Barricarte, Maria Dolores Chirlaque, Tim Waterboer, Eleni Peppa, Domenico Palli, Jenny Brändstedt, Kay-Tee Khaw, Aurora Perez-Cornago, Heiner Boeing, Umeå University, Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany, Danish Cancer Society Research Center, Copenhagen, Denmark, parent, Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Hellenic Health Foundation, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Epidemiology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, I-20133 Milano, Italy, University of Naples Federico II, Civile - M.P.Arezzo Hospital, Center for Cancer Prevention (CPO-Piemonte), Universiteit Utrecht, Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway, Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France. Electronic address: steliarova@iarc.fr., Catalan Institute of Oncology (ICO-IDIBELL), Hospitales Universitarios de Granada/Universidad de Granada, Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), CIBER de Epidemiología y Salud Pública (CIBERESP), IMIB-Arrixaca [Murcia, Spain], Universidad de Murcia, Public Health Institute of Navarra, Pamplona, Spain, and CIBER Epidemiología y Salud Pública (CIBERESP), IdiSNA, Navarra Institute for Health Research, Public Health Division of Gipuzkoa, Institute BIO Donostia-Health Department, Skane University Hospital [Lund], Department of Translational Medicine [Malmö, Sweden] (Clinical Microbiology), Lund University [Lund, Sweden], University of Cambridge [UK] (CAM), University of Oxford [Oxford], Ministerie van Volksgezondheid, Welzijn en Sport, VWS Deutsche Krebshilfe Cancer Research UK, CRUK: C8221/A19170, C570/A16491 VetenskapsrÃ¥det, VR Ministerie van Volksgezondheid, Welzijn en Sport, VWS Ligue Contre le Cancer Bundesministerium für Bildung und Forschung, BMBF Bundesministerium für Bildung und Forschung, BMBF Institut National de la Santé et de la Recherche Médicale, Inserm Kræftens Bekæmpelse, DCS CAN 2016/545 German Cancer Research Center, DKFZ National Research Council, NRC Cancer Research Foundation in Northern Sweden European Commission, EC Centre International de Recherche sur le Cancer, IARC RD06/0020 German Cancer Research Center, DKFZ Cancerfonden PI13/01162, PI13/00061 World Cancer Research Fund, WCRF: ERC-2009-AdG 232997 NordForsk Associazione Italiana per la Ricerca sul Cancro, AIRC Medical Research Council, MRC: MR/M012190/1, This work was supported by grants from The Cancer Research Foundation in Northern Sweden and The County Council of V?sterbotten, Sweden, and the German Cancer Research Center. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle G?n?rale de l'Education Nationale, Institut National de la Sant? et de la Recherche M?dicale (INSERM) (France), German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), the Hellenic Health Foundation (Greece), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands), ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway), Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia), Regional Governments of Andaluc?a, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain), Swedish Cancer Society, Swedish Research Council and County Councils of Sk?ne and V?sterbotten (Sweden), Cancer Research UK (14136 to EPIC-Norfolk, and C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom). Additional funding received from the Anna and Edwin Berger Foundation (K.R.), Malm? Hospital Cancer Foundation (K.R.), Cancerfonden (CAN 2016/545 to K.R.).
- Subjects
Oncology ,Cancer Research ,endocrine system diseases ,Càncer d'ovari ,Chlamydia trachomatis ,Mycoplasma genitalium ,Carcinoma, Ovarian Epithelial ,medicine.disease_cause ,Serology ,0302 clinical medicine ,Risk Factors ,Pelvic inflammatory disease ,Prospective Studies ,human papillomavirus ,Aged, 80 and over ,Ovarian Neoplasms ,Sexually transmitted diseases ,Human papillomavirus 16 ,Chlamydia ,VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801 ,biology ,Public Health, Global Health, Social Medicine and Epidemiology ,Middle Aged ,female genital diseases and pregnancy complications ,3. Good health ,Serous fluid ,ovarian cancer ,030220 oncology & carcinogenesis ,Female ,Malalties de transmissió sexual ,Adult ,Risk ,medicine.medical_specialty ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,03 medical and health sciences ,Ovarian cancer ,Internal medicine ,medicine ,Humans ,Neoplastic transformation ,Aged ,business.industry ,Papillomavirus Infections ,Chlamydia Infections ,biology.organism_classification ,medicine.disease ,herpes simplex virus ,Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi ,Relative risk ,Case-Control Studies ,VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801 ,business ,Biomarkers - Abstract
International audience; A substantial proportion of epithelial ovarian cancer (EOC) arises in the fallopian tube and other epithelia of the upper genital tract; these epithelia may incur damage and neoplastic transformation after sexually transmitted infections (STI) and pelvic inflammatory disease. We investigated the hypothesis that past STI infection, particularly Chlamydia trachomatis, is associated with higher EOC risk in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort including 791 cases and 1669 matched controls. Serum antibodies against C. trachomatis, Mycoplasma genitalium, herpes simplex virus type 2 (HSV-2) and human papillomavirus (HPV) 16, 18 and 45 were assessed using multiplex fluorescent bead-based serology. Conditional logistic regression was used to estimate relative risks (RR) and 95% confidence intervals (CI) comparing women with positive vs. negative serology. A total of 40% of the study population was seropositive to at least one STI. Positive serology to C. trachomatis Pgp3 antibodies was not associated with EOC risk overall, but with higher risk of the mucinous histotype (RR = 2.30 [95% CI = 1.22-4.32]). Positive serology for chlamydia heat shock protein 60 (cHSP60-1) was associated with higher risk of EOC overall (1.36 [1.13-1.64]) and with the serous subtype (1.44 [1.12-1.85]). None of the other evaluated STIs were associated with EOC risk overall; however, HSV-2 was associated with higher risk of endometrioid EOC (2.35 [1.24-4.43]). The findings of our study suggest a potential role of C. trachomatis in the carcinogenesis of serous and mucinous EOC, while HSV-2 might promote the development of endometrioid disease.
- Published
- 2020
45. Risk of cardiovascular diseases after breast cancer: an analysis on a cohort of 1.3 million women
- Author
-
Eva Pagano, Gianmauro Numico, Pierfrancesco Franco, S C Calabrese, E Ferracin, Carlotta Sacerdote, D Di Cuonzo, Fulvio Ricceri, Angelo d’Errico, and Alessandra Macciotta
- Subjects
Oncology ,medicine.medical_specialty ,Breast cancer ,business.industry ,Internal medicine ,Cohort ,Public Health, Environmental and Occupational Health ,Medicine ,business ,medicine.disease - Abstract
Background Breast cancer (BC) is the malignant tumor with the highest incidence in women in the world with an estimate of about 500,000 new cases per year in Europe. Guidelines for BC treatment include surgery followed by radiotherapy, hormonal therapy or chemotherapy. Several studies showed that BC treatment increases the risk of myocardial infarction (MI) while only few studies investigated the risk of stroke after BC. The aim of the present study was to assess the risk of MI and stroke in BC survivors, taking into account the possible influence of treatments. Methods Women included in the study are part of a longitudinal cohort including all residents in the Piedmont region linked to the 2011 census data and followed-up through administrative data on mortality, hospital admissions, drug prescriptions, and outpatient consultations. Validated algorithms to identify BC incident cases and their therapies as well as to identify MI and stroke were applied. The effect of BC on the risk of MI and stroke was tested using Cox models (adjusted for confounding variables) that allow to account for the competing risks. First, BC patients were compared to healthy women, then BC women that undertwent a specific therapy were compared with both healthy women and other BC patients. Results Women with BC showed an increased risk compared to healthy women for both MI (HR: 1.20; 95% CI: 1.05-1.38) and stroke (HR: 1.58; 95%CI: 1.38-1.82). Chemotherapy almost doubled the risk of MI, while radiotherapy did not seem to have a similar effect, even comparing with other BC patients. The high risk of stroke observed comparing BC (any therapy) with healthy women disappeared when comparing specific therapies among BC patients. Conclusions Chemotherapy increased the risk of MI in BC patients, while recent radiotherapy strategies had less impact, if any. Moreover, the mechanism for which BC patients have an increased risk of stroke seems not to be related to a late effect of therapies. Key messages Breast cancer women are at higher risk of developing cardio and cerebrovascular diseases and this should be taken into account when planning therapies and follow-up surveillance. Despite the increase in quality of the therapeutic approaches for breast cancer patients, chemotherapy increases the risk of myocardial infarction, while radiotherapy dangerousness recently decreased.
- Published
- 2019
46. Reproductive and lifestyle factors and circulating sRANKL and OPG concentrations in women:Results from the EPIC cohort
- Author
-
Elisabete Weiderpass, Inger T. Gram, Jiaxi Yang, Renée T. Fortner, Theron Johnson, Amalia Mattiello, Anna Karakatsani, Elissavet Valanou, Kim Overvad, Marc J. Gunter, Antonia Trichopoulou, Agnès Fournier, Dafina Petrova, Giovanna Masala, Marina Kvaskoff, Aurelio Barricarte, Rudolf Kaaks, Ruth C. Travis, Danja Sarink, Carla H. van Gils, Carmen Santiuste, Jenny Chang-Claude, Carlotta Sacerdote, Leila Lujan-Barroso, Claudia Agnoli, J. Ramón Quirós, Guri Skeie, Anja Olsen, Heiner Boeing, Sofia Christakoudi, Francesca Mancini, Anne Tjønneland, Laure Dossus, Pilar Amiano, and Rosario Tumino
- Subjects
0301 basic medicine ,musculoskeletal diseases ,medicine.medical_specialty ,Cross-sectional study ,Epidemiology ,medicine.medical_treatment ,Physiology ,Body Mass Index ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Osteoprotegerin ,medicine ,Humans ,Contraception Behavior ,Life Style ,Reproductive History ,11 Medical and Health Sciences ,business.industry ,Estrogen Replacement Therapy ,RANK Ligand ,Age Factors ,Middle Aged ,medicine.disease ,European Prospective Investigation into Cancer and Nutrition ,Postmenopause ,030104 developmental biology ,Cross-Sectional Studies ,Premenopause ,Oncology ,030220 oncology & carcinogenesis ,Cohort ,Female ,Hormone therapy ,business ,Body mass index ,Biomarkers - Abstract
Background: Except for a documented increase in osteoprotegerin (OPG) concentrations with older age, data on determinants of soluble Receptor Activator of Nuclear Factor κB (sRANKL) and OPG concentrations in women are limited. We evaluated reproductive and lifestyle factors as potential sources of variation in circulating sRANKL and OPG concentrations in pre- and postmenopausal women. Methods: This study includes 2,016 controls [n = 1,552 (76%) postmenopausal, n = 757 (38%) using postmenopausal hormone therapy (PMH)] from a breast cancer case–control study nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Serum sRANKL was measured using an ELISA and serum OPG using an electrochemiluminescent assay. Generalized linear models were used to evaluate associations between these analytes and reproductive and lifestyle factors. Results: Older age at blood collection was associated with lower sRANKL concentrations in postmenopausal women (Ptrend ≤ 0.03) and higher OPG concentrations in all women (Ptrend ≤ 0.01). Longer duration of oral contraceptive use among premenopausal women and postmenopausal PMH users was associated with higher OPG (Ptrend ≤ 0.04). In postmenopausal non-PMH users, sRANKL concentrations were lower with longer duration of oral contraceptive use and current (vs. never) smoking (P ≤ 0.01). sRANKL concentrations were higher among women with higher BMI (Ptrend ≤ 0.01). The evaluated factors accounted for 12% of the variation in sRANKL concentrations and 21% of the variation in OPG concentrations. Conclusions: Circulating sRANKL and OPG concentrations are minimally impacted by hormone-related factors in pre- and postmenopausal women. Impact: This study suggests circulating concentrations of sRANKL and OPG are unlikely to be strongly modified by hormone-related reproductive and lifestyle factors.
- Published
- 2019
47. microRNA profiles in urine by next-generation sequencing can stratify bladder cancer subtypes
- Author
-
Francesca Cordero, Giovanni Birolo, Federica Martina, Paolo Vineis, Marco Oderda, Paolo Gontero, Giuseppe Matullo, Cornelia Di Gaetano, Clara Viberti, Barbara Pardini, Alessio Naccarati, Maddalena Arigoni, Raffaele A. Calogero, and Carlotta Sacerdote
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Urinary system ,Malignancy ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Biomarker discovery ,Liquid biopsy ,Bladder cancer ,medicine.diagnostic_test ,liquid biopsy ,business.industry ,Area under the curve ,microRNA profiling ,Cancer ,urine biomarkers ,Cystoscopy ,medicine.disease ,030104 developmental biology ,030220 oncology & carcinogenesis ,bladder cancer ,next-generation sequencing ,business ,Research Paper - Abstract
Bladder cancer (BC) is the most frequent malignancy of the urinary tract with a high incidence in men and smokers. Currently, there are no non-invasive markers useful for BC diagnosis and subtypes classification that could overcome invasive procedures such as cystoscopy. Dysregulated miRNA profiles have been associated with numerous cancers, including BC. Cell-free miRNAs are abundantly present in a variety of biofluids including urine and make them promising candidates in cancer biomarker discovery. In the present study, the identification of miRNA fingerprints associated with different BC status was performed by next-generation sequencing on urine samples from 66 BC and 48 controls. Three signatures based on dysregulated miRNAs have been identified by regression models, assessing the power to discriminate different BC subtypes. Altered miRNAs according to invasiveness and grade were validated by qPCR on 112 cases and 65 controls (among which 46 cases and 16 controls were an independent group of subjects while the rest were replica samples). The area under the curve (AUC) computed including three miRNAs (miR-30a-5p, let-7c-5p and miR-486-5p) altered in all BC subtypes showed a significantly increased accuracy in the discrimination of cases and controls (AUC model = 0.70; p-value = 0.01). In conclusions, the non-invasive detection in urine of a selected number of miRNAs altered in different BC subtypes could lead to an accurate early diagnosis of cancer and stratification of patients.
- Published
- 2018
48. Lifetime and baseline alcohol intakes and risk of pancreatic cancer in the European Prospective Investigation into Cancer and Nutrition study
- Author
-
Androniki Naska, Kim Overvad, Kuanrong Li, Eric J. Duell, Domenico Palli, Giovanna Tagliabue, Christina Bamia, Ingegerd Johansson, Petra H.M. Peeters, Nicholas J. Wareham, Anne Tjønneland, Paul Brennan, Bas Bueno-de-Mesquita, Kathryn E. Bradbury, Antonia Trichopoulou, Miguel Rodríguez-Barranco, Guri Skeie, Marie-Christine Boutron-Ruault, Salvatore Panico, Franco Berrino, Rosario Tumino, Verena Katzke, Marc J. Gunter, Sabine Naudin, Elisabete Weiderpass Vainio, Pietro Ferrari, Inger T. Gram, Anne Laure Védié, Elio Riboli, Aurelio Barricarte, Miren Dorronsoro, Nada Assi, Tristan Jaouen, José Ramón Quirós, Rudolf Kaaks, Heiner Boeing, Maria Dolores Chirlaque, Malin Sund, Hanna Sternby, Carlotta Sacerdote, Vinciane Rebours, and Cecilie Kyrø
- Subjects
0301 basic medicine ,Cancer Research ,business.industry ,Hazard ratio ,Alcohol ,medicine.disease ,Confidence interval ,European Prospective Investigation into Cancer and Nutrition ,03 medical and health sciences ,chemistry.chemical_compound ,030104 developmental biology ,0302 clinical medicine ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Pancreatic cancer ,Medicine ,Smoking status ,business ,Prospective cohort study ,Wine intake ,Demography - Abstract
Recent evidence suggested a weak relationship between alcohol consumption and pancreatic cancer (PC) risk. In our study, the association between lifetime and baseline alcohol intakes and the risk of PC was evaluated, including the type of alcoholic beverages and potential interaction with smoking. Within the European Prospective Investigation into Cancer and Nutrition (EPIC) study, 1,283 incident PC (57% women) were diagnosed from 476,106 cancer-free participants, followed up for 14 years. Amounts of lifetime and baseline alcohol were estimated through lifestyle and dietary questionnaires, respectively. Cox proportional hazard models with age as primary time variable were used to estimate PC hazard ratios (HR) and their 95% confidence interval (CI). Alcohol intake was positively associated with PC risk in men. Associations were mainly driven by extreme alcohol levels, with HRs comparing heavy drinkers (>60 g/day) to the reference category (0.1-4.9 g/day) equal to 1.77 (95% CI: 1.06, 2.95) and 1.63 (95% CI: 1.16, 2.29) for lifetime and baseline alcohol, respectively. Baseline alcohol intakes from beer (>40 g/day) and spirits/liquors (>10 g/day) showed HRs equal to 1.58 (95% CI: 1.07, 2.34) and 1.41 (95% CI: 1.03, 1.94), respectively, compared to the reference category (0.1-2.9 g/day). In women, HR estimates did not reach statistically significance. The alcohol and PC risk association was not modified by smoking status. Findings from a large prospective study suggest that baseline and lifetime alcohol intakes were positively associated with PC risk, with more apparent risk estimates for beer and spirits/liquors than wine intake.
- Published
- 2018
49. Prospective evaluation of antibody response toStreptococcus gallolyticusand risk of colorectal cancer
- Author
-
Kathryn E. Bradbury, Carlo La Vecchia, Elisabete Weiderpass, Domenico Palli, Dagfinn Aune, Gianluca Severi, Eva Ardanaz, Michael Pawlita, Salvatore Panico, José María Huerta, H. Bas Bueno-de-Mesquita, María José Sánchez, Martina Willhauck-Fleckenstein, Anna Karakatsani, Kostas Tsilidis, Rosario Tumino, Franck Carbonnel, Marc J. Gunter, Angelika Michel, Carlotta Sacerdote, Mazda Jenab, Cecilie Kyrø, Heinz Freisling, Heiner Boeing, Claudia Agnoli, Rudolf Kaaks, Antonia Trichopoulou, Elio Riboli, Julia Butt, David J. Hughes, Tim Waterboer, Anne Tjønneland, Tilman Kühn, Catalina Bonet, Neil Murphy, and Marie-Christine Boutron-Ruault
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,biology ,Colorectal cancer ,business.industry ,Case-control study ,Cancer ,Odds ratio ,medicine.disease ,Gastroenterology ,Serology ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,biology.protein ,Streptococcus gallolyticus ,Antibody ,business ,Prospective cohort study - Abstract
The gut microbiome is increasingly implicated in colorectal cancer (CRC) development. A subgroup of patients diagnosed with CRC show high antibody responses to Streptococcus gallolyticus subspecies gallolyticus (SGG). However, it is unclear whether the association is also present pre-diagnostically. We assessed the association of antibody responses to SGG proteins in pre-diagnostic serum samples with CRC risk in a case-control study nested within a prospective cohort. Pre-diagnostic serum samples from 485 first incident CRC cases (mean time between blood draw and diagnosis 3.4 years) and 485 matched controls in the European Prospective Investigation into Nutrition and Cancer (EPIC) study were analyzed for antibody responses to 11 SGG proteins using multiplex serology. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using multivariable conditional logistic regression models. Antibody positivity for any of the 11 SGG proteins was significantly associated with CRC risk with 56% positive controls compared to 63% positive cases (OR: 1.36, 95% CI: 1.04-1.77). Positivity for two or more proteins of a previously identified SGG 6-marker panel with greater CRC-specificity was also observed among 9% of controls compared to 17% of CRC cases, corresponding to a significantly increased CRC risk (OR: 2.17, 95% CI: 1.44-3.27). In this prospective nested case-control study, we observed a positive association between antibody responses to SGG and CRC development in serum samples taken before evident disease onset. Further work is required to establish the possibly etiological significance of these observations and whether SGG serology may be applicable for CRC risk stratification.
- Published
- 2018
50. Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort
- Author
-
Petra H.M. Peeters, Anika Hüsing, Marina Kvaskoff, Hidemi S. Yamamoto, Eva Lundin, Carlotta Sacerdote, Elio Riboli, Renée T. Fortner, Louise Hansen, Elisabete Weiderpass, Heiner Boeing, Daniel W. Cramer, J. Ramón Quirós, Gianluca Severi, Kathryn L. Terry, Amalia Mattiello, Eric J. Duell, Rosario Tumino, Eva Ardanaz, Helena Schock, Titilayo Fashemi, Björn Nodin, Ruth C. Travis, Anne Tjønneland, Kim Overvad, Annika Idahl, Laure Dossus, Carmen Navarro, H B As Bueno-de-Mesquita, Carlo La Vecchia, Marie-Christine Boutron-Ruault, Allison F. Vitonis, Nerea Larrañaga, María José Sánchez, Domenico Palli, Marc J. Gunter, Karin Jirström, Antonia Trichopoulou, Charlotte Le Cornet, Mattias Johansson, Raina N. Fichorova, Kay-Tee Khaw, N. Charlotte Onland-Moret, Theron Johnson, Melissa A. Merritt, Sabina Sieri, Eleni-Maria Papatesta, and Rudolf Kaaks
- Subjects
0301 basic medicine ,Oncology ,endocrine system ,Cancer Research ,medicine.medical_specialty ,endocrine system diseases ,Context (language use) ,EPIC ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Ovarian cancer early detection ,business.industry ,Autoantibody ,Case-control study ,medicine.disease ,female genital diseases and pregnancy complications ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cohort ,Immunology ,business ,Ovarian cancer ,Cohort study - Abstract
CA125 is the best ovarian cancer early detection marker to date; however, sensitivity is limited and complementary markers are required to improve discrimination between ovarian cancer cases and no ...
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.